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ABSTRACT OF THE DISSERTATION
Defining the roles of outer membrane proteins and host cathelicidins in uropathogenic
Escherichia coli infection
by
Elizabeth Sarah Danka
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2015
Associate Professor David A. Hunstad, Chair

The Gram-negative bacterium uropathogenic Escherichia coli (UPEC) is the causative
agent of up to 85% of community-acquired urinary tract infections (UTIs). This thesis work
aimed to better define interactions between UPEC and host antimicrobial peptides (AMPs). The
bacterial outer membrane is constantly interacting with the external environment, and contains
many integral proteins with defined roles in pathogenesis. The E. coli outer membrane protein
OmpA is a highly conserved, integral beta-barrel membrane protein with four extracellular loops.
We found that the loops of OmpA individually influence binding and invasion of UPEC during
infection. Loop 2 appears to be essential for binding to the host epithelium. These effects are
seen in vitro as well as in a murine model of UTI, where the pathogenic cascade is severely
interrupted when loop 2 is absent. The loop 2 mutant forms very few intracellular bacterial
communities (IBCs, a hallmark of UPEC UTI) and fails to cause robust acute infection. These
phenotypes are not due to alterations in membrane permeability, growth, or the indispensable
adhesive virulence organelle termed type 1 pili.

x

AMPs are small proteins expressed by innate immune cells and epithelial cells, including
those of the urinary tract. Although we predicted that the murine cathelicidin, termed CRAMP,
would play an important role in urinary tract defense against UPEC, we instead found that
CRAMP-deficient mice exhibit attenuated UTIs. These mice have lower bladder bacterial loads
at all examined time points, fewer IBCs, less inflammation and inflammation-related bladder
damage, and resolve infection faster. Early differences in bacterial binding to wild-type and
mutant bladders are not attributable to modifications in bacterial adhesive factors, instead
pointing to altered host uroepithelium in CRAMP-deficient mice. Furthermore, cathelicidin does
not appear to be expressed within the urinary tract at concentrations necessary to cause bacterial
cell death in vitro. We conclude that cathelicidin is essential for normal maintenance of the
uroepithelium and for the promotion of innate immune responses to UPEC. We will continue to
examine this potential role for CRAMP as a driver of the immune response during UTI.
Finally, we were surprised to find that UPEC growth is augmented after exposure to sublethal concentrations of CRAMP, and UPEC specifically upregulate a defined set of genes in this
response. While these genes are also encoded by non-pathogenic E. coli, the same transcriptional
response is not observed. Most interestingly, the majority of these genes are involved in small
molecule transport or metabolism, implying that UPEC are actively sensing the peptide,
upregulating pathways that may allow for uptake of the AMP, and perhaps converting acquired
AMP into useful product. This model is consistent with the increased UPEC growth seen after
exposure to CRAMP, and suggests that UPEC are better adapted to strategically utilize
molecules in order to thrive in a limiting environment. Future experiments will characterize the
roles of these regulated genes in vitro after exposure of UPEC to other AMPs, and during
infection.

xi

CHAPTER ONE
INTRODUCTION TO THE DISSERTATION

Urinary Tract Infections
Urinary tract infections (UTIs) occur when bacteria grow within the lower urinary tract
(comprised of the urethra and bladder) or the upper urinary tract (comprised of paired ureters and
kidneys) [1]. The most common form of UTI is cystitis, or bladder infection, although infection
of one or both kidneys, termed pyelonephritis, can occur [1]. UTIs are most common in women,
occurring at an incidence of 3-13% [2, 3]. Over her lifetime, a woman’s risk of UTI is over 60%
[4]. Of the women that develop a UTI, 30-50% will have a second infection within 6 months [1].
While UTIs are rarely deadly in developed countries, these infections represent a significant
healthcare burden. In 2007, these infections resulted in nearly 11 million physician visits in the
United States, and UTI-associated costs approached $4 billion [5, 6]. Even though these
infections can be naturally cleared by the immune system, each year physicians write millions of
antibiotic prescriptions for UTI patients, which contribute to the current crisis of antibioticresistant bacteria [7]. A thorough understanding of the pathogenesis of UTI can direct the
development of alternative therapies to treat these infections.

Risk factors for UTI
The strongest risk factor for UTI is being female. This sex-specific susceptibility is due to
the shorter urethra in women, and to the highly colonized periurethral area [1]. Other important
risk factors for UTI among otherwise healthy adults include frequent sexual activity, recent
condom use, and recent spermicide use [1]. The link between multiple sexual encounters and
1

UTI is so strong that it is often referred to as “honeymoon cystitis.” Familial predisposition to
recurrent UTIs has been noted since the late 1970s [8-10]. The vast majority of genetic factors
that alter UTI risk affect the innate immune system [11]. For example, polymorphisms in
chemokines CCL2 and CCL5 as well as in the chemokine receptor CXCR1 have been shown to
increase UTI risk and risk of acute pyelonephritis [12, 13]. Decreased expression of the
transcription factor IRF3 has also been linked to increased risk of acute pyelonephritis [14].
Recent work has determined that TLR4 polymorphisms can have widely varying effects on the
development of cystitis and can increase or decrease risk of cystitis, recurrent cystitis, and
pyelonephritis [15, 16]. Other studies have suggested that blood group (with respect to P1
antigen and secretor status) can also increase risk of acute pyelonephritis [17-19].
Congenital abnormalities of the urinary tract, such as obstructions, ureteral duplication, or
other malformations can also result in a predisposition to UTI [20]. Significant vesicoureteral
reflux (VUR), or reflux of urine from the bladder into the kidneys, increases the chances of
developing pyelonephritis. Premature babies and uncircumcised males also have increased risk
for UTI [20]. In adults, diabetes, obesity, and vaginal infections have all been linked to increased
UTI risk [21, 22]. Catheter placement represents the largest risk factor for developing a UTI.
Reports since 1980 suggest that the incidence of UTI in male and female patients with urinary
catheters is between 1.1-6.5% [23]. Risk of UTI increases with prolonged catheter use; overall,
an indwelling catheter is thought to increase risk 4-fold [1].

Symptomology and diagnosis
As the severity of UTI can vary, patients can present with a range of symptoms. The most
common symptoms are urgency, increased frequency, pain while urinating, cloudy urine, and
2

suprapubic abdominal pain [1, 20]. Some patients also detect a foul odor from their urine.
Progression to pyelonephritis can result in renal abscess formation, and in rare cases, sepsis.
Patients with pyelonephritis may experience the symptoms of cystitis, in addition to fever,
nausea, vomiting, and back and flank pain [1]. A diagnosis of UTI is most commonly achieved
through culture of mid-stream urine (with >105 bacteria/mL), urine dipstick test for leukocyte
esterase, and leukocyturia. Many UTIs are diagnosed on the basis of symptoms alone, so as to
minimize the delay before starting treatment. Although uncomplicated UTIs are self-limiting and
can be cleared by the immune system in ~5 days, many physicians prescribe oral antibiotics to
help the patient resolve the infection more quickly [7, 24].

Asymptomatic bacteriuria
Asymptomatic bacteriuria (ASB) is diagnosed when a urine culture yields >105 CFU/mL
of a known uropathogen, but the patient does not present with symptoms of UTI. ASB has an
overall prevalence of 3.5% in women, although prevalence in teens is closer to 1% and increases
with age [25]. The prevalence of ASB has made correct diagnosis of UTI difficult, and new
criteria have recently been developed to better differentiate the two. PCR- and sequencing-based
methods are much more sensitive than culture-based methods, and detect a wide variety of flora
within the urine [26]. This has led to the concept of a urinary microbiome, although more work
needs to be done to distinguish bacteria that have truly colonized the bladder from contaminants.
The periurethral area and distal urethra are known to be colonized by bacteria, so it is likely that
some organisms detected by these very sensitive methods arise from this area and not the bladder
specifically [26]. Future research will delineate the effects of ASB on health and on the
development of UTI.
3

UPEC
Uropathogenic Escherichia coli (UPEC) represent the most common cause of
community-acquired UTI, accounting for up to 85% of cases [27]. Various species of Klebsiella,
Pseudomonas, Enterococcus, and Staphylococcus are also frequently isolated from ambulatory
patients [1, 27]. However, nosocomial infections are more commonly caused by strains other
than UPEC. Species such as Proteus mirabilis, Klebsiella pneumoniae, and Enterococcus are
each isolated in approximately one in ten nursing home patients with UTI, more than double the
incidence of these strains in ambulatory patients [27]. Up to 30% of catheter-associated UTIs are
caused by Enterococcus faecalis or E. faecium, although UPEC infections are also very common
[28].
UPEC and neonatal meningitis-causing E. coli (NMEC) are two classifications that are
included within the extraintestinal pathogenic E. coli pathotype (ExPEC) [29]. As the name
implies, most UPEC strains are thought to be strains that originated from the gut [30]. The
expression of certain virulence factors likely aids in the development of infection when these
bacteria are exposed to the urinary tract. UPEC strains isolated from patients have proven to be
highly genomically diverse [29, 31, 32]. While there are specific UPEC virulence factors, a set of
factors that can be used to define UPEC or potential uropathogens has not been specified [33].
Many factors can partially contribute to UPEC virulence, although there is much variation
among strains.

Murine Model of UTI
Method of infection
4

A murine model of UTI was created to investigate contributions of both host and
bacterial factors during infection. This simple and reliable method of inducing infection delivers
UPEC to the bladder via catheter, which is then removed [34]. Due to the technical difficulty of
catheterizing male mice, female mice have been used for the vast majority of UTI studies. Most
infection models inoculate the bladder with approximately 107 CFU of UPEC in a volume of 50
µL to ensure reliable infections [34, 35]. Larger volumes often result in VUR, but can be used to
force the development of pyelonephritis. If desired, control mice can be mock-infected with
sterile phosphate-buffered saline (PBS) and harvested in parallel to quantify changes in the
bladder due to catheterization and delivery of the inoculum.

Common downstream methodology to characterize UPEC infection
Urine can be collected to monitor the progress of the infection through the enumeration
of colony-forming units (CFU) of bacteria. The presence of immune and uroepithelial cells in the
urine can be examined by microscopy of urines spun onto slides and stained, or enumerated
using a hemacytometer. Bladder and kidney tissues are harvested after sacrifice and
homogenized in sterile PBS to determine bacterial load at various time points post-infection.
Cytokine expression in tissue homogenates can be quantified through antibody-based multiplex
assays or ELISA. Expression of the enzyme myeloperoxidase (MPO) within tissue homogenates
can be used as a proxy for neutrophil recruitment to the tissue [36]. Blood and serum can be
collected during infection or after sacrifice to screen for sepsis (via blood culture) or to measure
global cytokine expression.
Whole tissue studies can also provide information about the state of infection state within
the animal. Intracellular bacterial communities (IBCs) in the bladder (e.g., 6, 16, or 24 hours
5

post-infection [hpi]) can be quantified by bisecting the bladder after harvest and exploiting the
lacZ expression of UPEC to stain IBCs in situ within the tissue. We can also visualize IBC
structure and approximate the number of IBCs by infecting mice with GFP-expressing bacteria
and examining the bladder tissue by confocal microscopy at the desired time points. Nuclear
stains or host cell membrane stains help to localize UPEC within the tissue. Differences in the
size of IBCs can be quantified using 3D reconstruction techniques [37]. Additionally, we can fix
and stain whole tissues for histological analyses such as hematoxylin and eosin staining or
scoring of immune cell recruitment and inflammation. Unstained slides can be used for
immunofluorescence microscopy studies. Although these methods only provide a snapshot of
what was happening in the bladder at the time of harvest, different parts of the bladder can be
visualized at one time. To supplement histology and immunofluorescence microscopy, we
developed immunoblot assays to quantify uroplakins present in bladder homogenates; these were
used to approximate the amount of uroepithelial exfoliation that had occurred [37].

Effects of host genetics on development of UTI
Multiple groups have explored the effects of genetic background on development of UTI
[38-41]. The inbred mouse strains C57Bl/6 and C3H/HeN are commonly used to study acute and
chronic UTIs. There are many knock-out and conditional expression lines available in the
C57Bl/6 background, making these mice excellent tools to examine the contribution of host
factors to the development or resolution of UTI. In the C57Bl/6 background, UPEC infection is
often limited to an acute infection that is largely cleared from the bladder by 48 hpi [42]. These
mice rarely develop kidney infection, although quiescent bacteria do form reservoirs within the
deeper epithelium of the bladder [43]. C3H/HeN mice are commonly used to examine chronic
6

phenotypes, as 20-30% of these mice develop chronic cystitis after infection with 107 UPEC
[38]. Experiments using C3H/HeJ mice, which have a mutation in TLR4, have helped discern the
role of TLR4 in both host uroepithelial cells and immune cells [44, 45]. 80% of C3H/HeJ mice
go on to develop chronic infections [38]. Another C3H subtype, C3H/HeOuJ, develops chronic
cystitis in 90% of infected mice [38]. Meanwhile, C3H-related strains CBA/J and DBA/2J show
an intermediate phenotype, with 20-40% of these mice developing chronic cystitis [38].
Downstream studies can further elucidate factors that contribute to these differences, and will
contribute to the understanding of patient susceptibility to UTI.

UPEC Infections
Binding and invasion to the host cell epithelium
Upon introduction to the bladder, UPEC must first resist being washed from the urinary
tract by the flow of urine. Most UPEC strains accomplish this by binding to the surfaces of host
uroepithelial cells using the adhesive organelle type 1 pili (Figure 1) [46]. This binding requires
a specific interaction of the tip adhesin FimH with mannosylated proteins (uroplakins) on the
surfaces of superficial epithelial cells [47]. UPEC strains that do not express type 1 pili are
severely attenuated in the mouse model of cystitis [48, 49]. The interaction of FimH with
mannose has been shown to be greatly enhanced when the protein is bound to the chaperone
FimC and adopts an elongated conformation [50]. The expression of the fim operon is under the
regulation of an invertible switch element, which has been shown to be affected by a wide
variety of factors [51, 52].
Once bound to host uroepithelium, a subset of UEPC are internalized into the host cells
within a membrane-bound vacuole (Figure 1) [46]. This internalization is controlled by
7

microtubule destabilization and integrin-mediated interactions with actin filaments that cause
actin rearrangement and uptake of the bacteria into vacuoles [53-55]. An unknown percentage of
the bacteria-containing vacuoles re-fuse with the cell membrane, releasing the bacteria back into
the bladder lumen. This exocytosis is regulated by increases in intracellular cAMP
concentrations, which are triggered upon TLR4 activation by bacterial LPS [56, 57]. Therefore,
UPEC must escape into the cytoplasm from the vacuole to avoid being expelled. UPEC that
successfully invade the uroepithelium and escape into the cytoplasm are protected from
components of the innate immune system, the mechanical shear force of urine, and antibiotics.

Intracellular growth
The superficial facet cell cytoplasm provides a rich medium for UPEC growth. The
availability of nutrients allows division to occur more frequently, and results in many of the
bacteria becoming coccoid (Figure 1) [58]. These rapidly dividing bacteria form large, tightly
cohesive structures known as intracellular bacterial communities (IBCs; Figure 1) [59, 60]. Each
IBC may contain up to 105 bacteria, and can take up the majority of the cell’s cytoplasm [60].
Indeed, when viewed from the lumen, uroepithelial cells harboring mature IBCs bulge outward
[34, 59]. IBCs have similarities to biofilms, as polysaccharides, outer membrane vesicles, and
type 1 pili are highly expressed within the structure [49, 59, 60]. Mutations in genes (e.g., those
encoding pili, curli, flagella, antigen 43) with known roles in biofilm formation limit the ability
of UPEC to form IBCs and to propagate an acute infection [46, 49, 60]. After a yet undetermined
signal, UPEC will slow their division to create long filaments and flux out of the host cell
(Figure 1) [58]. These filaments are resistant to phagocytosis and killing by neutrophils [61-63].
This survival mechanism allows the filaments to infect neighboring epithelial cells to repeat the
8

cycle of infection. IBCs and filamentous bacteria are found in the urines of children and adults
with UTI [64, 65].

Clearance of UPEC
UTIs are usually self-limiting infections that can be cleared from an otherwise-healthy
host in 5 days. The exfoliation and shedding of infected uroepithelial cells represent one
mechanism by which UPEC are cleared from the bladder (Figure 1) [46]. Although exfoliation
can quickly rid the bladder of large numbers of bacteria, this mechanism also leaves the
underlying cells exposed and susceptible to infection by UPEC [46]. The expression of cytokines
from infected cells activates components of the innate immune system, largely neutrophils or
polymorphonuclear cells (PMNs), to respond to the infection [66]. While a few PMNs are
already present in the tissue, the majority of the response is due to circulating PMNs leaving
nearby vessels and localizing to IBC-containing cells (Figure 1) [66]. Although PMNs cannot
penetrate into healthy uroepithelial cells, PMNs can phagocytose the exposed bacteria once the
host cell membrane has been compromised. Leukocyturia in patients reflects the PMNs that have
responded to the infection being lost in the urine.
Two main pathologies develop within the bladder as an infection is cleared. The infection
of underlying host cells can lead to the development of small collections of UPEC within the
epithelium known as quiescent intracellular reservoirs (QIRs) [43]. Although thought to be
metabolically inactive, these collections can be triggered to reemerge and cause a new infection.
While antibiotics and intensive epithelial exfoliation have been shown to trigger reemergence of
bacteria from QIRs, the molecular mechanisms behind this activation are not well understood
[67]. Recent work has also been exploring the development of chronic infections within the
9

urinary tract. These infections are characterized by persistent bacterial titers >104 CFU/mL in the
urine, along with high levels of uroepithelial exfoliation, and high bladder titers at 2-4 weeks
post-infection [38]. Strong inflammatory responses during the early stages of infection are
predictive of chronic cystitis development, and mice that have experienced chronic cystitis are
more susceptible to a subsequent episode [38, 68]. However, the distinct differences in host or
bacterial physiology that lead to the development of QIRs instead of chronic infections and vice
versa are not known. Future studies can explore these differences, and determine if QIR
formation also occurs in patients that have cleared a UTI, or in patients that are susceptible to
recurrent cystitis.

Antimicrobial Peptides
Antimicrobial peptides (AMPs) are small, 12-100 amino acid sequences that are
produced by all kingdoms of life. Most of these peptides contain lysine and/or arginine residues,
which results in an overall positive charge. AMPs are also amphipathic, which promotes
interaction with bacterial membranes to cause cell death [69]. AMPs function as defensive
mechanisms for living organisms that range from bacteria, to insects, to vertebrates, and are
thought to represent one of the earliest branches of innate immunity [69]. Gram-positive and negative bacteria utilize these molecules, termed bacteriocins, for narrow (same species) or
broad-spectrum self-defense and competition within various environments [70]. In mammals,
AMPs are often part of the defense of epithelial surfaces, and are expressed by both epithelial
cells and innate immune cells [71]. In addition to activity against Gram-positive and -negative
bacteria, AMPs have been shown to be effective against viruses and fungi [69]. While expression
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of these peptides can be upregulated, constitutive expression provides a strong front line of
defense that potential pathogens must resist in order to establish infection [71-73].

Cathelicidins and other urinary tract AMPs
Within the urinary tract, the most highly-expressed AMPs are α- and β-defensins, RNase
7, hepcidin, and cathelicidin [71, 74-78]. While humans encode at least 30 defensins,
cathelicidins are not as diverse [79]. Humans and mice each express a single cathelicidin,
although other mammals encode multiple different cathelicidins (e.g., pigs, sheep, horses, and
cows) [80-82]. Cathelicidins share a four-exon, three-intron gene structure, with the mature
peptide encoded in exon 4 [82, 83]. Expression of the gene results in a pre-pro-peptide that is
cleaved once intracellularly to create a pro-peptide which must be secreted and cleaved again
extracellularly to form the mature peptide [82]. Conserved, signature patterns have been
identified within the pro-region of the peptide, but there is much variability within the amino
acid sequence of the mature peptide (Figure 2A) [82]. This sequence variability results in at least
three major classes of structures for the peptides: α-helical, hairpin-like, and more linear forms
containing proline- or tryptophan-rich sequences [82]. Human cathelicidin maintains an α-helical
structure (Figure 2B) [84]. Regardless of sequence and structure, cathelicidins are expressed by
many different cells types, including epithelial cells, neutrophils, monocytes, macrophages, and
B- and T-cells [73].
Recent work supports a role for cathelicidin in the defense of the urinary tract. Although
constitutively expressed, epithelial expression of cathelicidin can be upregulated in response to
bacterial infection. This has been demonstrated in culture using renal epithelial cells,
uroepithelial cells, and healthy human renal cortex sections [78]. LL-37 concentrations in the
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urines of patients with active UTI are higher than those of patients that have resolved an
infection or of control patients, supporting increased expression of the peptide during bacterial
infection [78, 85]. Furthermore, control samples had higher concentrations of LL-37 than
patients that had resolved an infection, suggesting that patients with low expression of
cathelicidin may have increased risk of UTI [85]. These findings, namely upregulation of an
AMP in response to bacterial infection and increased bacterial infection in AMP-deficient mice,
mirror previous work with various defensins [86-88]. It should be noted that while human βdefensin-1 is upregulated during infection, the concentration reached in the urine is too low to
directly kill potential pathogens [76]. Much of this work has focused on the expression and
activity of AMPs within the upper urinary tract. The effects of AMPs within the bladder, where
urine is stored for long periods of time, have been largely unexplored.

Alternative applications of AMPs
Interestingly, some AMPs and AMP derivatives have been tested for therapeutic
potential. The synthetic peptide omiganan pentahydrochloride mimics the bovine AMP indolicin
and is highly bactericidal and fungicidal [89]. Incorporation of this analogue into venous
catheters as a mechanism to prevent blood-stream infections has been pursued through phase III
clinical trials [90]. Multiple cecropin peptides isolated from insects have been shown to kill
Chlamydia trachomatis isolates [91]. Relevant to this work, human and bovine lactoferrins and
shorter synthetic lactoferrin derivatives have been shown to decrease bacterial titers in the
bladders and kidneys of mice infected with a pyelonephritis-derived UPEC isolate [92]. These
peptides were delivered to the mice orally 30 min after infection with 108 bacteria, and titers
were determined 24 hpi [92]. Together, these data indicate that natural and synthetic AMPs
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independently suppress bacterial infection, including within niches where they are not normally
expressed.
Sequence- or structural-based studies are often used to identify AMPs, and in vitro
studies are subsequently used to confirm antimicrobial activity. Downstream studies have
identified alternative functions for many cationic AMPs. In addition to antimicrobial roles, the
peptide hepcidin has been shown to regulate iron levels in multiple niches including the serum,
liver, intestine and macrophages [93, 94]. Hepcidin can directly bind to the iron transporter
ferroportin and limit iron export from cells [95, 96]. Both defensins and cathelicidins have been
shown to regulate components of the innate and adaptive immune systems in addition to
functioning as antimicrobials [97]. These peptides can induce and augment the expression of
cytokines, act as chemokines to enhance immune cell recruitment, and promote mast cell
degranulation [97]. Defensins and cathelicidins can stimulate angiogenesis and wound healing,
and defensin expression is important for proper sperm function in males [98, 99]. Cathelicidins
and defensins have even been shown to play roles in promoting invasion by cancer cells [98,
100-102]. Although these are but a few examples, AMPs undoubtedly mediate diverse and
complex roles in the innate immune system.

Summary and Prospectus
UTIs are very common bacterial infections that affect millions of people annually and
result in a significant burden on the healthcare system. As the vast majority of UTIs are caused
by UPEC, much work has been done to investigate the mechanisms of pathogenesis responsible
for these infections. A murine model of cystitis has greatly expanded our understanding of UPEC
infection and complements in vitro work with bacterial strains. The work described here aimed
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to better define the roles of specific factors expressed by the host and by the pathogen.
Specifically, we investigated the roles that UPEC outer membrane proteins play in promoting the
establishment of an infection within the urinary tract. The expression of AMPs in the urinary
tract by host uroepithelial cells and innate immune cells represents a first line of defense against
potential pathogens. Therefore, we investigated the effects of host cathelicidin on the
development of UPEC infection in vivo. We also surveyed the bacterial responses to sub-lethal
cathelicidin exposure in vitro. Taken together, these data allow us to profile the effects of
cathelicidin exposure on the host and on the pathogen during UPEC infection. Future
experiments will continue to define the roles of UPEC factors during infection.
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Tables and Figures

Figure 1: UPEC pathogenic cascade and IBC cycle. The major steps in the development of a
UTI are displayed as: attachment of UPEC to host epithelial cells (top center), invasion of UPEC
into the epithelial cells (top right), early IBC formation and recruitment of PMNs (bottom right),
development of a mature IBC (bottom center), bacterial filamentation and egress from the host
cell (top left), and exfoliation of IBC-containing epithelial cells (left center). Representative
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microscopy images are shown to support the information relayed in the schematic. (adapted from
Mulvey et al, 1998; Mysorekar et al, 2006; Rosen et al, 2007; Hunstad and Justice, 2010)
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Figure 2: Cathelicidin sequence comparison and LL-37 structure. (A) Alignments of the
mature peptide sequences for LL-37 (human), mCRAMP (mouse), rCRAMP (rat), CAP18
(rabbit), and RL-37 (Rhesus monkey) reveal much variability between species. Residues in red
are homologous to the LL-37 peptide. (B) Structure of the α-helical peptide LL-37 in micelles
[84]. DOI: 10.1074/jbc.M805533200
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CHAPTER TWO
EXTRACELLULAR LOOPS OF UPEC OUTER MEMBRANE PROTEIN A SPECIFICALLY
PROMOTE URINARY TRACT INFECTION

Abstract
The major outer membrane protein OmpA of uropathogenic E. coli (UPEC) does not
have a single, defined function, although it has been proposed to have many roles in both
pathogenic and non-pathogenic E. coli isolates. Here, we investigate the importance of the four
extracellular loops of OmpA with respect to the pathogenesis of UPEC in vitro and in vivo. We
find that UPEC cells expressing OmpA lacking loop 1 are unaffected in most assays, although
there is a mild impact on invasion into uroepithelial cells. More importantly, UPEC that only
express a mutant OmpA lacking loop 2 exhibit impaired binding and invasion in vitro, and are
cleared from the bladder more efficiently in a murine model of cystitis. Finally, the loop 2
mutant is dominant over the full-length protein in wild-type cells, and results in impaired binding
and invasion in vitro when cells co-express both proteins. These data are consistent with UPEC
OmpA acting as a binding cofactor during invasion of uroepithelial cells. Specifically,
extracellular loop 1 is dispensable for this interaction, while loop 2 is required. Although it is
unknown if these phenotypes are due to a direct interaction or due to secondary effects, future
experiments will define the binding partner(s) that exist on host uroepithelial cells.

Introduction
Outer membrane protein A (OmpA) is an abundantly expressed, integral outer membrane
protein (OMP) in E. coli and other Gram-negative bacteria [1, 2]. The ompA sequence is highly
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conserved, and expression of OmpA is tightly regulated during translation by mRNA structure
and the small RNA micA [1]. Full-length ompA mutants are viable, but complementation must be
carefully controlled, as overexpression of OmpA is lethal [3]. The ompA gene encodes a 35 kDa
protein with two major domains. The N-terminal domain of OmpA forms a β-barrel made of
eight, antiparallel, transmembrane β-sheets, including four extracellular loops and three short
periplasmic turn regions [1, 4, 5]. The extracellular loops of OmpA vary in length (7-17 aa), and
the sequences suggest that some loops may be more flexible than others. The C-terminal domain
of the protein extends into the periplasm and has been implicated in binding to peptidoglycan,
providing structural stability to the cell [1, 6, 7]. Many other roles have ben posited for OmpA in
E. coli. With respect to pathogenesis, OmpA has been shown to mediate serum resistance within
potential hosts, and Prasadarao and colleagues demonstrated that neonatal meningitis-causing E.
coli (NMEC) use OmpA to bind and invade cultured brain microvascular endothelial cells and to
cross the blood-brain barrier in mice [8-10]. Furthermore, expression of OmpA has been shown
to be critical for biofilm formation in some systems [11, 12]. Not all OmpA interactions benefit
the bacterium, though. OmpA is targeted by the phagocyte-produced enzyme neutrophil elastase,
is recognized by the immune system as a pathogen-associated molecular pattern (PAMP), and its
extracellular loops are important for binding of bacteriophage, bacteriocin, and attacin binding
[13-16].
Uropathogenic E. coli (UPEC) are the most common cause of cystitis (bacterial infection
of the urinary bladder) especially in women of child-bearing age [17]. Although uncommon,
bacteria from the bladder can also ascend up the ureters to cause a more severe infection in the
kidneys, known as pyelonephritis, or can disseminate into the bloodstream [17]. Clinical reports
estimate that 75-85% of all urinary tract infections (UTIs) are caused by UPEC [17, 18]. Cystitis
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is diagnosed by detection in the urine of bacteria (bacteriuria) and immune cells (pyuria),
particularly neutrophils [17]. Symptoms of cystitis include suprapubic abdominal pain, dysuria
(pain while urinating), and increased urgency [17, 19]. Many women visit their physician and are
prescribed antibiotics, even though the infection is self-limiting in many cases [19]. Up to 50%
of patients will have a second infection within six months of their original infection, and a small
percentage will develop chronic cystitis, characterized by ongoing symptoms and consistently
high levels of bacteria in the urine [17, 18, 20].
The UPEC infection cascade and important virulence factors have been detailed over the
past two decades using both in vitro methods and a murine model of cystitis. Upon introduction
to the bladder, type 1 pili on the surfaces of UPEC bind to mannosylated uroplakin proteins
decorating the luminal face of the uroepithelium [21-23]. Once bound, these bacteria can be
internalized into the superficial uroepithelial cells (facet cells), where they escape from an initial
Lamp1+ vacuole into the cytoplasm of the cell [24, 25]. The bacteria rapidly replicate in the
cytoplasm, forming a dense cluster of cells known as an intracellular bacterial community (IBC)
within 6-16 hours [26]. An IBC may contain as many as 105 UPEC cells, and can fill the
majority of the volume of the cell. This will often cause the facet cell to rupture, releasing
bacteria into the lumen of the bladder, where they can spread to naïve epithelial cells and repeat
the infection cycle [27]. UPEC contained within epithelial cells are protected from the
mechanical shear force of urine flow, innate immune components such as neutrophils and
antimicrobial peptides, and the action of antibiotics [27]. Many infected epithelial cells will be
exfoliated and shed in the urine as a means of clearing the infection, and phagocytes will attack
and kill bacterial cells that have emerged from epithelial cells [27]. Some bacterial cells will
form quiescent clusters deeper within bladder tissue, and can emerge weeks to months later to
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cause a new infection [25, 28]. A more thorough understanding of the mechanism that allows
UPEC to enter the uroepithelial cell and gain access to its cytoplasm may help define new
therapies that can prevent establishment of infection, and also protect against repeated
pathogenic cycles and recurrent infections.
Previously, UPEC OmpA was shown to be important for chronic infection in a murine
model of cystitis in C3H/HeN mice [3]. In those studies, binding, invasion, and acute bladder
titers were similar between wild-type and OmpA mutant bacteria [3]. However, OmpA mutant
bacteria subsequently formed only sparse and rudimentary IBCs by confocal microscopy [3].
Further, relative to the starting inoculum, wild-type UPEC highly upregulated ompA expression
while in the bladder [3]. This may be due in part to the fact that the inoculum consists of bacteria
in stationary phase, and ompA has been shown to be downregulated during stationary phase [29].
Here, we present data demonstrating that ompA mutant bacteria cause less robust infection in
C57Bl/6 mice. We sought to define the interactions of OmpA with the host during infection, and
to identify specific regions of the protein that are most important in these interactions.
We hypothesized that the extracellular loops represent a way for UPEC to directly
interact with the surrounding environment, and may be responsible for some of the phenotypes
observed in an OmpA mutant. Here, we present data characterizing the effects of two of the
extracellular loops of OmpA. We found that OmpA loop mutants had distinct phenotypes during
infection. Although loop 1 was largely dispensable during infection, loop 2 mutant bacteria
showed severely limited binding and invasion in vitro, and were quickly cleared from the bladder
in vivo without progressing through the IBC cycle. These data indicate that OmpA may function
as a co-factor during binding to the uroepithelium, and that loop 2 is mediating this interaction.
Future experiments will identify a binding partner or partners, and will investigate if loop 2 is
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directly interacting with these partners, or is indirectly influencing the binding of UPEC to the
uroepithelium.

Materials and Methods
Bacterial strains and cloning
The cystitis-derived UPEC strain UTI89 was inoculated from frozen stock directly into LuriaBertani broth (LB) for all experiments [26]. Chloramphenicol or kanamycin was added at 100
µg/mL where indicated. A UTI89 ompA::cat strain was previously created by lambda red
mutagenesis, and the chloramphenicol marker was excised with Flp recombinase to yield the
UTI89 ΔompA strain used in all experiments [3, 30]. The entire ompA gene, including a 60 bp
region upstream thought to include the promoter, was cloned into the low-copy number plasmid
pACYC184. This plasmid was used to complement the ompA mutant strain. This plasmid was
further mutated to create and express the individual loop mutants used in the present
experiments, based on mutants previously created by Ralf Koebnik [31]. Briefly, the majority of
the amino acids composing each surface loop were deleted and replaced with 1-2 amino acid (aa)
linkers. This was accomplished by using complementary forward and reverse internal loop KO
primers containing approximately 4 aa before the deletion, and 11 aa after the deleted region that
correspond to the matching full-length plasmid template (Table 1). These primers were used with
a forward or reverse OmpA primer that contained a restriction enzyme site to create two products
for each mutant (Table 1). These products were amplified a second time with the OmpA forward
and reverse primers using the sewing method of PCR to create a final product with a single loop
mutation. These products were sequenced, and clones without unintended mutations were
screened for protein expression by SDS-PAGE gel. UTI89fimH::kan (kind gift from S. Hultgren)
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lacks the type 1 pilus tip adhesin FimH and does not produce pili. UTI89 surA::kan lacks the
periplasmic chaperone SurA and is deficient in many major outer membrane proteins, including
OmpA [32]. The loop 2 KO plasmid was re-derived and transformed into UTI89 and
the ompA mutant to create a second clone. UTI89 was also transformed with a plasmid encoding
an HA-labelled OmpA lacking loop 2. UTI89, UTI89 ΔompA, and the loop mutants were also
transformed with a GFP-containing plasmid for confocal microscopy studies.

Mouse infections
Age-matched, 8-10 week old female C57Bl/6 mice (Jackson Laboratories) were infected by
transurethral catheterization with approximately 107 colony-forming units (CFU) of UPEC in 50
µL of phosphate-buffered saline (PBS) as previously described [22]. Bladders and kidneys were
harvested using sterile technique after the infection was allowed to develop for the indicated
intervals, homogenized in PBS, serially diluted, and plated on LB agar (with antibiotics when
appropriate) to determine CFU per organ. Remaining homogenates were stored at -80˚C for use
in downstream applications.

Immunoblotting
Lysed whole cells, cell supernatants, cell fractions, or mouse bladder lysates were separated by
SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes, and probed with
antibodies to detect bacterial and murine proteins. A polyclonal rabbit antibody was generated
using UTI89 OmpA. The antibody was mixed 1:1 with UTI89 ΔompA cell lysate for 30 min on
ice and centrifuged at 14,000 × g for 10 min. The supernatant was used at 1:10-25,000 for
immunoblotting with minimal background. HA-tagged proteins were detected with an anti-HA
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primary antibody (1:1000, Zymed). A primary antibody for GroEL was used as a cytoplasmic
marker (1:40,000; Sigma), and sera from mice that had been inoculated with SurA was used as a
periplasmic marker (1:5000). The FimH protein was detected using sera from rabbits that had
been inoculated with the FimH protein (1:5000). A primary antibody specific to the murine
mitochondrial marker CoxIV was used as a loading control in bladder lysates (1:2000; Cell
Signaling). Anti-rabbit and anti-mouse alkaline phosphatase-tagged secondary antibodies were
used at 1:2000-2500 (Sigma). Blots were developed with Tropix CDP-STAR (Applied
Biosystems).

Cell fractionation
Overnight cultures of the indicated strains were sub-cultured into fresh LB at 1:100 and grown
under shaking conditions at 37°C to an OD600 = 0.8. Cultures were centrifuged at 5000 × g for 20
min and the resulting pellets were weighed and frozen overnight. Thawed pellets were
resuspended in 10mM Tris pH 8.0 with 100 μg/mL of RNase and DNase (4mL/g of pellet). Cells
were lysed twice in a Stansted Cell Pressure Homogenizer, and residual whole cells were
removed by centrifugation at 2000 × g for 15 min. The resulting supernatant was ultracentrifuged
at 82500 × g for 80 min to separate the soluble fraction from the pellet of the cell membranes.
The soluble fraction was decanted and saved at -20°C for future analysis. The membranecontaining pellet was resuspended in 50mM Tris pH 8.0 with 1% sarkosyl and ultracentrifuged at
82500 × g for 80 min to separate the inner and outer membranes. The soluble inner membrane
fraction was saved at -20°C, and the pellet containing the outer membrane was fully resuspended
in 10mM Tris pH 8.0 before being stored at -20°C.
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Transmission electron microscopy (TEM)
For negative-stained samples, overnight static cultures were pelleted, fixed in 1% glutaraldehyde,
and adsorbed to flow-discharged formvar/carbon-coated copper grids for 2 min. Grids were
washed with water, stained for 1 min with 1% aqueous uranyl acetate (Ted Pella, Redding, CA),
and air-dried. Immunolabelled and negative-stained samples were adsorbed to formvar/carboncoated nickel grids for 10 min, washed in PBS, and blocked with 1% fetal bovine serum (FBS)
for 20 min. Anti-FimH antibody (1:200) was applied for 30 min before grids were washed with
1% FBS and incubated with goat anti-rabbit secondary antibody conjugated to 18 nm colloidal
gold (1:10; Jackson ImmunoResearch, Laboratories, Inc., West Grove, PA) for 30 min. Grids
were washed with PBS, fixed in 1% glutaraldehyde for 10 min, and washed with dH2O before
being stained with uranyl acetate and air dried. Samples were viewed on a JEOL 1200EX
transmission electron microscope (JEOL USA, Peabody, MA).

Bacterial growth curves
Overnight cultures grown in LB, with antibiotics when appropriate for plasmid maintenance,
were sub-cultured 1:100 into fresh LB and grown under shaking conditions to an OD600 = 1.
These cultures were diluted 1:5000 into fresh media, plated in triplicate, and grown at 37°C. The
optical density was read every 40 min for 16 h in a temperature-controlled microplate reader
(Synergy 2, Biotek). The experiment was repeated at least three times for each strain.

Novobiocin susceptibility assay
Overnight, shaking cultures grown in LB broth were sub-cultured 1:100 in LB and grown to an
OD600 = 1. These cultures were diluted 1:10 with PBS before a sterile cotton swab was dipped
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into each culture and spread evenly across a single LB agar plate. The moisture was allowed to
absorb for 5 min, and then two discs impregnated with novobiocin (30 ug/disc, Sensi-Disc, BD
BBL) were placed on each plate, and the plates were incubated at 37°C overnight. The next
morning, the diameter of the zone of inhibition around each disc was measured. The experiment
was repeated three times.

Confocal microscopy
Mice were infected as usual with GFP-expressing strains [33]. After 16 h, bladders were
harvested, splayed, and fixed with 2.5% paraformaldehyde in PBS for 1 h. Bladders were
washed, permeabilized with 0.1% Triton X-100, and stained with the nuclear stain Syto 61
(1:1000 in PBS; Life Technologies). Bladders were washed three times in PBS and mounted
with antifade reagent (ProLong Gold, Life Technologies) before imaging on an inverted confocal
microscope (LSM510, Zeiss).

IBC enumeration by lacZ staining
Mice were infected with the indicated strains for 16 h, before the mice were sacrificed, and the
bladders were harvested, bisected, stretched, and gently washed twice with PBS. Bladders were
fixed for 1 h at 4°C (0.2% glutaraldehyde, 50 mM EGTA, 100 mM MgCl2 in PBS, washed three
times (2mM MgCl2, 0.01% deoxycholic acid sodium salt, 0.02% IGEPAL CA-630 in PBS), and
stained (1 mg/mL X-gal, 114 mM potassium ferrocyanide, 97mM potassium ferricyanide in
wash buffer) for 6 h at 30°C. After staining, tissues were washed three times with PBS and
stored at 4C until IBCs were counted under a dissecting microscope.
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Hemagglutination assays
Static 20 mL overnight cultures of indicated strains grown in LB were diluted to an OD540 = 1
with LB broth. Cells were concentrated 10-fold in PBS, and duplicate cultures were prepared
with 2% mannose in PBS. Concentrated cells were serially diluted in an equal volume of PBS or
PBS with 2% mannose in 96-well V-bottom plates (Costar). Guinea pig red blood cells
(Colorado Serum Company) were washed 2-3 times with sterile PBS and resuspended to an
OD640 = 2.0. An equal volume of diluted red blood cells was added to each well of the plates.
The plates were gently tapped to ensure mixing and were covered with sealing tape. The last well
in which hemagglutination occurred was determined visually after overnight incubation at 4°C
(this is the HA titer). The experiment was repeated three times.

In vitro binding and invasion assays
Human bladder carcinoma cells (5637 cells; ATCC HTB-9) were maintained in RPMI with 10%
fetal bovine serum (Sigma) in a humidified incubator at 37°C with 5% CO2. Triplicate wells of
confluent 5637 cells were prepared for each bacterial strain in 24-well tissue culture plates
(TPP). Before infection, existing medium was aspirated, cells were washed once with sterile
PBS, and 1 mL of fresh medium was added to each well. Overnight static cultures of the
indicated bacterial strains were centrifuged and resuspended in sterile PBS to OD600 = 1. Ten
microliters of the desired bacterial suspension was added to each well. Plates were spun at 325 ×
g for 3 min at room temperature and returned to the incubator. Binding and input plates were
removed from the incubator after 30 min. Supernatants were removed from the binding wells,
and cells were washed five times with PBS before lysis (PBS with 0.1% Triton X-100) at room
temperature for 15 min. Input wells were not washed before lysis with 10 µL of 10% Triton X38

100. Each well was scraped and examined under the microscope to ensure that all cells were
released. Lysates were serially diluted and plated on LB agar plates to enumerate CFU. Invasion
plates were removed from the incubator after 60 min and wells were washed once with PBS.
Gentamicin (10 mg/mL in medium) was added to each well and the plate was returned to the
incubator for 90 min. After gentamicin treatment, wells were washed three times with PBS
before lysis, scraping, dilution, and plating as above. LB agar plates were incubated overnight at
37°C, and colonies were enumerated the following day.

Results
UTI89 ΔompA is less virulent in a murine model of cystitis.
Previous work has established that UTI89 ΔompA cannot cause chronic infections in
C3H/HeN mice, unlike the parent strain UTI89. However, the virulence of UTI89 ΔompA in the
C57Bl/6 mouse, a strain that has a more robust immune response and many available genetic
tools, was unknown. We found that UTI89 ΔompA was cleared from the bladder faster than wildtype UTI89, and that bacterial loads of UTI89 ΔompA were significantly lower by 24 hpi
(Figure 1). Kidney infections are not prominent in C57Bl/6 mice, a strain that does not exhibit
significant vesicoureteral reflux; we did not find any difference in the (low) frequency of kidney
infection between UTI89 and UTI89 ΔompA (data not shown).

Creation of extracellular OmpA loop mutants.
We hypothesized that one or more of the extracellular loops of OmpA could be necessary
for interacting with the host environment during infection, and that we could identify this
interaction by creating individual loop mutants. Each extracellular loop of UPEC OmpA is a 1239

14 amino acid sequence that connects two of the transmembrane domains that comprise the βbarrel of OmpA. We created mutants that have each loop replaced by a 1-2 amino acid linker,
while the rest of the OmpA protein (i.e., the barrel and the periplasmic domain) is unchanged
[31]. Low-copy plasmids encoding the loop mutant proteins are then used to complement UTI89
ΔompA. We refer to each loop mutant strain as LP n KO. By immunoblot with an OmpAspecific antibody, each loop mutant strain expresses its OmpA variant at levels similar to that of
wild-type OmpA in UTI89 (Figure 2A). To ensure that the loop mutant proteins localize to the
outer membrane, we fractionated cultures into outer membrane, inner membrane, and soluble
fractions. The vast majority of each protein variant was detected in the outer membrane fraction
(Figure 2B). We conclude that the loop mutant proteins are stable and are expressed at levels
similar to that of wild-type in the outer membrane.

Mutation of loops does not affect growth rate or outer membrane permeability.
We next investigated if the mutant proteins had deleterious effects on the cells.
Transmission electron microscopy (TEM) did not reveal any differences in the physical
appearance of the bacterial strains (Figure 3A). We compared the growth of the loop mutant
strains to UTI89 and UTI89 ΔompA in rich media and found no differences (Figure 3B). The
small lag in growth of the loop mutants is likely due to chloramphenicol (included in the media
to maintain the plasmid), as this lag also observed in cells carrying the empty vector (Figure
3B). Novobiocin, an antibiotic that cannot permeate the outer membrane of healthy Gramnegative cells, was used to determine if the loop mutant proteins affected permeability of the
outer membrane. Novobiocin disc diffusion assays demonstrated no significant differences in
outer membrane permeability between the loop mutants and UTI89 or UTI89 ΔompA (Figure
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3C). UTI89 surA::kan does not express the periplasmic chaperone SurA, which is responsible
for correct insertion of many OMPs, and serves as a positive control for increased outer
membrane permeability (Figure 3C).

Mutation of OmpA does not affect the expression of type 1 pili.
It is possible that mutation of OmpA or individual extracellular loops alters the
expression of the major adhesive organelle involved in UPEC binding to epithelial cells, namely
type 1 pili. However, when negative-stained cells were examined by TEM, pili were observed on
UTI89, ΔompA, LP 1 KO, and LP 2 KO cells (Figure 4A). Immunogold labeling using an
antibody specific to FimH confirmed that the pili decorating the cells of all four strains were type
1 pili (Figure 4A). The negative control UTI89 fimH::kan exhibited severely stunted pili
(Figure 4A). An immunoblot of whole cells further confirmed equivalent expression of FimH
across wild-type, ΔompA, LP 1 KO, and LP 2 KO strains (Figure 4B). Finally, hemagglutination
(HA) assays were used to confirm that these pili function as expected. Minimal variation was
observed in the HA titers of LP 1 KO and LP 2 KO cells (Figure 4C).

Deletion of loop 2 limits virulence in a mouse model of cystitis.
To investigate the effects of loop mutation in the context of in vivo infection, we used the
loop mutant strains in an established mouse model of cystitis and quantified bladder titers 24 hpi.
While LP 1 KO titers were equivalent to those of UTI89 ΔompA, the LP 2 KO bacteria were
almost completely cleared from the bladder by 24 hpi (Figure 5A). As detailed above, the
intracellular bacterial community (IBC) is an important step in the propagation of cystitis. By
confocal microscopy, we found that UTI89, UTI89 ΔompA, and LP 1 KO cells were all able to
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form mature IBCs by 16 hpi (Figure 5B). However, no IBCs were observed in the bladders of
mice that had been infected with LP 2 KO. This block in the infection cascade likely accounts for
the deficient titers observed with LP 2 KO 24 hpi. We next quantified numbers of IBCs in the
bladders of mice using a lacZ-based staining method. The confocal data provided an excellent
snapshot of what was happening in the bladders, as bladders infected with LP 2 KO bacteria
harbored significantly fewer IBCs than the other three strains (Figure 5C). Furthermore, mice
infected with ΔompA also harbored significantly fewer IBCs than UTI89-infected mice, which
likely accounts for the difference in bacterial titer at 24 hpi (Figure 5C).

Loop 2 is required for host cell binding and internalization.
To identify if the loss of loop 2 affects UPEC binding to of invasion of the uroepithelium,
we employed in vitro binding and invasion assays with cultured 5637 bladder epithelial cells.
Binding and invasion in the ompA mutant were equivalent to wild-type UTI89 (Figure 6A, B).
The LP 1 KO strain showed a small, non-significant decrease in binding, but a significant
decrease in invasion (Figure 6A, B). Meanwhile, LP 2 KO cells bound and invaded uroepithelial
cells at a significantly lower rate than wild-type or ΔompA cells (Figure 6A, B). A second,
independent clone of the LP 2 KO displayed the same phenotype (“new LP 2 KO” in Figure 6A,
B).
We further discovered that this is a dominant effect. The LP 2 KO plasmid (with or
without an HA tag) was transformed into wild-type UTI89, and the resulting strains were used
for binding and invasion assays. Cells expressing both wild-type and mutant forms of OmpA
exhibited impaired binding and invasion into 5637 cells (Figure 6A, B). Importantly, we
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confirmed that both the native and OmpA variant proteins were expressed at approximately
equal levels (Figure 6C).

Discussion
The major outer membrane protein OmpA has been shown to be important in the
development of chronic cystitis in C3H/HeN model hosts [3]. Here, we demonstrate that OmpA
is required for high-titer acute cystitis in C57Bl/6 mice. We hypothesized that the extracellular
loops of OmpA may be driving this phenotype, and created individual loop mutants that allowed
us to explore the roles of these structures during infection. This work focuses on the impacts of
extracellular loops 1 and 2 during in vitro and in vivo infection.
Although the expression of OmpA proteins with mutations in the extracellular loops did
not affect cell shape, growth, permeability, or type 1 pili expression, we observed that mice
infected with LP 2 KO bacteria had significantly lower bladder titers in C57Bl/6 mice 24 hpi
when compared to wild-type bacteria. Further, this strain was unable to form mature IBCs, which
resulted in significantly fewer IBCs 16 hpi. In vitro binding and invasion of uroepithelial cells by
LP 2 KO strains was significantly worse than both wild-type and ompA mutant cells. Binding to
host cells was not affected by the LP 1 KO, although invasion was modestly impacted, which
may account for the lower numbers of IBCs observed 16 hpi. Surprisingly, LP 2 KO OmpA
proteins exerted a dominant effect over the wild-type protein, as UTI89 cells expressing both
native and LP 2 KO OmpA also exhibited sharply limited binding and invasion.
Together, these data indicate that UPEC OmpA may directly interact with a molecule on
or in uroepithelial cells, and that LP 2 is necessary for promoting this interaction. Our studies
suggest that this interaction could be necessary for binding, internalization, or for preventing the
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expulsion of bacteria-containing vacuoles. Work in other infectious E. coli systems hints at
potential mechanisms to investigate. The role of OmpA in neonatal meningitis-causing E. coli
(NMEC) has been extensively studied within the context of binding to human microvascular
brain endothelial cells (HBMECs). In this system, NMEC OmpA can interact with the protein
Ecgp (also known as gp96, Grp94, or HSP90B1) on the surfaces of HBMECs to promote
internalization [9, 34, 35]. Although Ecgp contains a KDEL endoplasmic reticulum-localization
sequence, this protein appears to be expressed in the cell membrane [35, 36]. Further, Prasadarao
and colleagues have also utilized OmpA LP KO strains, and found that NMEC bacteria with
mutant loop 1 or loop 2 are severely attenuated in a meningitis model [37, 38].
To determine if Ecgp is important for binding and invasion during UPEC cystitis, future
experiments will examine the expression and localization of Ecgp in 5637 human bladder
epithelial cells before and after exposure to UPEC, and will determine if there are differences in
expression after exposure to full-length or loop mutant bacteria. Similar experiments can also be
conducted in the murine model of cystitis to examine expression levels and localization of Ecgp
before and after infection with wild-type and ompA mutant UPEC. Furthermore, confocal
microscopy studies with cultured cells or in the murine host can be used to examine
colocalization of UPEC and Ecgp. Additionally, several Ecgp blocking antibodies have been
identified, and it may be possible to test these as a therapeutic to impair the infectious cycle that
occurs during acute UTI, and to prevent the development of chronic cystitis [34]. These
experiments will help determine if Ecgp is important for promoting binding and invasion of
bacteria into host cells, a critical step in the development of acute UTI.
More broadly, we can use purified native OmpA protein and our OmpA antibody in
immunoprecipitation and Far Western experiments to probe host cell lysates or fractions for
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potential binding partners and co-factors. Structural modeling studies have identified multiple
putative binding pockets within the extracellular loops of OmpA [39, 40]. When a variety of
sugars are modeled against these binding pockets, chitobiose shows the strongest affinity for
binding [36, 40]. This is of particular interest, as chitobiose has also been shown to be important
for the interaction of the type 1 pili adhesin FimH with glycoproteins on the surface of the
bladder [41]. It is possible that OmpA and type 1 pili function cooperatively during UPEC
infection. A similar cooperative interaction is important for NMEC invasion into brain
microvascular endothelial cells, where binding of both FimH and OmpA results in an increase in
intracellular Ca2+ levels, which promotes the actin rearrangement necessary for bacterial invasion
[42-44]. Future studies will determine if type 1 pili and OmpA work together to facilitate binding
in UPEC pathogenesis.
An alternative explanation is that OmpA forms a homodimer to promote binding and
invasion, and that mutation of loop 2 disrupts this dimerization. Alternatively, loop 2 may be
required for OmpA to interact with a separate outer membrane protein, and this interaction may
enhance binding to the host cell. Preliminary studies to determine if there are alterations in outer
membrane proteins other than OmpA when the loop mutants are expressed did not identify any
changes (data not shown). In these models, binding would be driven by type 1 pili alone when
OmpA is mutated, leading to decreased binding to the host in vivo, although this decrease is
harder to detect in vitro, potentially due to limited expression of uroplakins on 5637 cells (data
not shown).
Finally, we can also utilize the UTI89 strain that also expresses both native and LP 2 KO
forms of OmpA in our mouse model of UTI to see if the dominant in vitro binding and invasion
defects are also evident during in vivo infection. These experiments can help us identify which in
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vitro phenotypes are most important for UPEC infection, and lend direction to future in vivo
studies. We have demonstrated that the extracellular loops of UPEC OmpA promote binding of
bacterial cells to the host to enhance infection. The future experiments outlined here will dissect
the specific roles of the loops during infection to further define how OmpA promotes UPEC
pathogenesis during cystitis. We hope that this information will help direct the development of
new methods for treating UTI.
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Tables and Figures
Table 1: Primers used to make UPEC OmpA extracellular loop mutants
Primer name

Sequence (5’ to 3’)*

LP1SDM_4-10B-F

CTGGTCCCAGTACTCTCGCGAAAACCAACTGGGCGCTGGTGCTTTTGGTGGTTAC

LP1SDM_4-10-R

CAGTTGGTTTTCGCGAGAGTACTGGGACCAGCCCAGTTTAGCACCAGTGTAC

LP2SDM_5-10B-F

GGTCGTATGCCTAGGAAAGCTCAGGGCGTTCAGCTGACCGCTAAACTGGG

LP2SDM_5-10B-R

CGCCCTGAGCTTTCCTAGGCATACGACCTAACCAGTCATAACCCATTTC

OmpA Xba1-F

CGTGTCTAGATTTCCTTGCGGAGGCTTGTCTGAAGCGGTTTC

OmpA HindIII-R

ACCCAAGCTTAACTTAAGCCTGCGGCTGAGTTACAACGTC

* Membrane/non-surface exposed loops in red, surface exposed loops that are not deleted
are bold, connectors replacing surface exposed loops underlined, matching spots in primer
design green
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Figure 1: OmpA is required to cause robust acute infection in C57Bl/6 mice. C57Bl/6 mice
were transurethrally infected with approximately 107 bacteria, either UTI89 (circles) or UTI89
ΔompA (squares). Bladder titers (colony-forming units, CFU) are shown for the indicated time
points (hours or weeks post infection). Each point represents a single mouse; horizontal bar
indicates the geometric mean. Significance, as determined by Mann-Whitney U test, is denoted
by asterisks; *** p < 0.0001.
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Figure 2: Individual OmpA loop mutants express and localize correctly. (A) Immunoblot
showing expression of OmpA in UTI89, UTI89 ΔompA (ΔompA), UTI89 ΔompA/LP 1 KO (LP 1
KO), and UTI89 ΔompA/LP 2 KO (LP 2 KO) cells. The cytoplasmic protein GroEL is used as a
loading control. (B) Representative immunoblots showing expression of the OmpA, periplasmic
SurA, and cytoplasmic GroEL in whole bacterial cells, outer membrane fractions, and soluble
fractions (cytoplasm and periplasm). U = UTI89, A = UTI89 ΔompA, 1 = LP 1 KO, 2 = LP 2
KO.
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Figure 3: Expression of loop mutant OmpA does not cause overt phenotypic differences.
(A) Overnight cultures of UTI89, ΔompA, LP 1 KO, and LP 2 KO do not show any differences
in overall morphology, as assessed by TEM. Representative pictures are shown. Scale bar
represents 500 nm. (B) Growth of wild-type and mutant strains in LB media. pACYC is the
empty vector. Lower growth in the strains carrying a plasmid is likely due to the inclusion of
chloramphenicol in the media for plasmid maintenance. A representative plot is shown. (C)
Mutant strains do not exhibit increased membrane permeability, as tested by a novobiocin disc
diffusion assay.
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Figure 4: Pili expression is not disrupted in OmpA loop mutants. (A) Immuno-gold TEM
using a primary antibody directed against FimH tip adhesin. Secondary antibody is conjugated to
18nm gold particle. Representative images are shown. Scale bar represents 500 nm. (B)
Immunoblot for the type 1 pilus tip adhesin FimH shows approximately equivalent levels
between strains. (C) Hemagglutination titers are modestly lower in bacteria expressing loop
mutants. SurA mutant and FimH mutant bacteria are included as controls. Mean and standard
deviation are shown. * p < 0.05; *** p < 0.0005; **** p < 0.001.
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Figure 5: OmpA loop 2 mutant UPEC are severely attenuated in vivo. (A) Bladder titers 24
hpi with wild-type or mutant bacteria in C57Bl/6 mice. Mice were infected with approximately
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107 UTI89 (circles), ΔompA (squares), LP 1 KO (diamonds), or LP 2 KO (diamonds) bacteria (n
= 9-10 mice/strain). Geometric mean is indicated by the horizontal line. (B) Confocal
microscopy to examine IBC formation 16 hpi in C57Bl/6 mice. DNA is stained red, and UTI89,
LP 1 KO, and LP 2 KO UPEC express GFP. Representative images are shown. (C) Enumeration
of IBCs in the bladders of C57Bl/6 mice 16 hpi as determined by lacZ stain (n = 11-13
mice/strain). Geometric mean is indicated by the horizontal line; dashed line indicates the limit
of detection. * p < 0.05; ** p < 0.005; *** p < 0.001; **** p < 0.0001.
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Figure 6: Loop 2 mutant UPEC display severe binding and invasion defects. (A) Binding to
human bladder uroepithelial cells, displayed as percent bound of input. FimH mutant bacteria are
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included as a negative control. (B) Invasion into host cells, displayed as percent of bound.
Average and standard deviation are shown in (A) and (B). * p < 0.05; ** p < 0.005; *** p <
0.001; **** p < 0.0001. (C) UTI89 cells transformed with LP 2 mutant-expressing plasmids
express both native and variant forms of OmpA, as determined by immunoblot with anti-OmpA
polyclonal antibody. The cytoplasmic protein GroEL is used as a loading control. Representative
blot is shown.
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Abstract
Cathelicidin is a proposed defender of the urinary tract via its antimicrobial properties,
but its activity has not been delineated in a dedicated cystitis model. Female C57Bl/6 mice, wildtype or deficient in CRAMP (ortholog of the sole human cathelicidin, LL-37), were infected
transurethrally with the cystitis-derived uropathogenic Escherichia coli (UPEC) strain UTI89.
Infection course was evaluated by bladder titers, intracellular bacterial community (IBC)
quantification, and histology; immune responses and resolution were characterized through
cytokine profiling, microscopy, and quantitation of epithelial recovery from exfoliation.
CRAMP-deficient mice exhibited significantly lower bladder bacterial loads and fewer IBCs
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during acute cystitis. Through differences in bacterial titers were evident as early as 1 hour post
infection, CRAMP-deficient mice showed no baseline alterations in immune activation,
uroepithelial structure, apical expression of uroplakins (which serve as bacterial receptors), or
intracellular bacterial growth rate. CRAMP-deficient hosts demonstrated less intense cytokine
responses, diminished neutrophil infiltration, and accelerated uroepithelial recovery. Mice
lacking the antimicrobial peptide CRAMP suffered less severe infection than wild-type mice in a
well-establish model of cystitis. Though CRAMP exhibits in vitro antibacterial activity against
UPEC, it may enhance UPEC infection in the bladder by promoting epithelial receptivity and
local inflammation.

Introduction
Urinary tract infections (UTIs) are common worldwide, predominantly affecting young,
premenopausal women. Over 80% of UTIs are caused by uropathogenic E. coli (UPEC), among
which many strains have acquired significant antibiotic resistance [1]. A thorough understanding
of both host and bacterial factors affecting the progression of UTIs is necessary to devise new
treatment methods. Complicating this effort, UPEC comprise an array of strains that, by virtue of
different genetic attributes and virulence factors, are adapted to colonization and virulence in
distinct niches within and outside the urinary tract [2]. For example, the cystitis-derived UPEC
strain UTI89 attaches via type 1 pili to mannosylated uroplakins on the luminal surface of
bladder epithelial cells and is internalized [3, 4]. Intracellular organisms, protected from immune
effectors and antibiotic therapies, replicate into biofilm-like structures termed intracellular
bacterial communities (IBCs) [5, 6]. Exfoliation of the superficial epithelium is one host strategy
to eliminate invasive bacteria, while a cytokine response recruits phagocytes (predominantly
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neutrophils and macrophages) to the infected bladder [3, 7-10]. Host strain-dependent attributes
specify additional influences on the progress and outcomes of experimental infection. In healthy
C57Bl/6 mice, UPEC undergo multiple IBC cycles within the first 24 h, but pathogen control
and diminishing bacterial titer are evident by 48 h post-infection (hpi) [11]. In other susceptible
host strains (e.g., C3H/HeN), a dose-dependent proportion of infected animals maintains hightiter chronic cystitis for weeks following inoculation [12].
While exfoliation and urine flow represent mechanical defenses that protect the bladder,
molecules including lysozyme, lipocalin, lactoferrin, and antimicrobial peptides also make the
luminal environment less hospitable for pathogens [13]. Antimicrobial peptides (AMPs)
comprise a diverse group of 12-50 amino acid chains produced by a wide variety of organisms.
In humans, the chief classes of AMPs are cathelicidins and defensins; both have been implicated
in defense of epithelial surfaces against infectious agents [14]. Humans and mice each express a
single cathelicidin, termed LL-37 in humans and cathelin-related antimicrobial peptide
(CRAMP) in mice [14, 15]. Though their antimicrobial domains vary in primary sequence, both
LL-37 and CRAMP form amphipathic α-helices with demonstrated activity against Grampositive and -negative bacteria, fungi, and viruses [14]. Cathelicidin is constitutively expressed at
low levels by epithelial cells in many tissues, including the urogenital tract, skin, lungs, and gut;
pathogen recognition can rapidly induce local production of the peptide [15-18]. Beyond its
antimicrobial properties, cathelicidin can recruit immune cells to sites of infection and stimulate
production of pro-inflammatory cytokines [14, 19]. Recruited neutrophils can also produce
cathelicidin to aid in controlling infection [15, 20].
Uroepithelial expression of cathelicidin has been described as an important innate
defense mechanism in the urinary tract. Higher cathelicidin levels are detected in urine during
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human UTI, while post-infection levels fall below those of controls, suggesting that patients with
naturally lower levels of cathelicidin may be more susceptible to UTI [17]. Chromek and
colleagues examined UTI in CRAMP-deficient mice on a 129/SvJ genetic background using a
UPEC strain, CFT073, isolated from the blood of a patient with pyelonephritis [16]. These
authors observed more severe infections in CRAMP-deficient mice, evidenced by augments
bacterial binding to renal proximal tubule cells and higher kidney bacterial loads 48 hpi [16].
To further specify the role of cathelicidin during the most common form of human UTI,
cystitis, we employed the cystitis-derived UPEC isolate UTI89 and CRAMP-deficient C57Bl/6
mice. Although CRAMP effectively limited UPEC growth in vitro, its role during UTI was
revealed as more complex than previously appreciated. Contrary to expectation, we found that
CRAMP-deficient mice demonstrated lower bacterial loads at multiple time points and recovered
more quickly from cystitis. CRAMP-deficient mice exhibited an attenuated immune response to
infection and less tissue damage, correlating with accelerated epithelial restoration. Our data
indicate that CRAMP may confer benefits to both host and pathogen in distinct ways within the
urinary tract.

Materials and Methods
Bacterial strains and culture
For infections, the cystitis-derived UPEC isolate UTI89 [21] was inoculated into Luria-Bertani
broth (LB; 20 mL) directly from frozen stock and grown statically at 37°C for 16 h. Overnight
cultures were centrifuged at 5000 × g for 10 min, resuspended in sterile phosphate-buffered
saline (PBS) to OD600nm 1.0, and diluted 1:1 in PBS for inoculation.
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In vitro CRAMP resistance assay
CRAMP (mCRAMP, Anaspec, Fremont, CA) was resuspended in water to a final concentration
of 2 mg/mL. Aliquots were stored at -80°C until use. Bacteria were prepared as described above.
50 µl of bacterial suspension was added to 150 µl of sterile PBS with varying concentrations of
CRAMP in a 96-well plate, briefly mixed, and incubated at 37°C for 2 h. Treated cultures were
serially diluted and plated on LB agar to determine survival. Each concentration of CRAMP was
tested in triplicate, and the experiment was repeated three times.

Mice and infections
Female mice aged 8-10 weeks were used for all experiments; animal procedures were approved
in advance by the Animal Studies Committee at Washington University. Homozygous CRAMPdeficient mice in a C57BL/6 background (kind gift of R. Gallo [22]) were bred on site. Mice
were genotyped with PCR on tail DNA with primers specific to the third and fourth exons of the
Cnlp gene [23]. C57Bl/6J mice (bred on site and purchased from Jackson Laboratories, Bar
Harbor, ME) were used as comparators. Cystitis was induced by transurethral inoculation of 50
μL of bacterial suspension in PBS (~107 CFU) as previously described [3].

Organ and urine bacterial titers
Urine collected from mice 1 hpi was serially diluted and plated to LB agar. Bladders and kidneys
were harvested sterilely at specific time points (1, 6, 16, 24, 48 hpi, or 2 weeks post-infection
[wpi]), homogenized in sterile PBS (Bullet Blender, Next Advance, Averill Park, NY), and
plated to LB agar. Remaining homogenates were stored at -80C for use in uroplakin
immunoblotting and soluble analyses as described below.
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Confocal microscopy and IBC volume determination
Mice were infected with UTI89/pcomGFP [24] and bladders harvested at 16 hpi. Bladders were
bisected and stretched with fine forceps and mounting pins. Bladder halves were fixed in 2.5%
paraformaldehyde, permeabilized with Triton X-100, and stained with Syto 61 (1:1000, Life
Technologies, Grand Island, NY). Bladder halves were imaged using a Zeiss LSM510 inverted
confocal microscope; Z-stacks of individual IBCs were collected and volumes quantified using
Volocity 6.3 software (PerkinElmer, Shelton, CT).

IBC enumeration
Bladders were harvested 16 hpi, bisected, stretched, and gently washed twice with PBS, then
fixed for 1 h at 4°C (0.2% glutaraldehyde, 50 mM EGTA, 100 mM MgCl 2 in PBS) and stained
as previously described until IBCs could be clearly visualized [25]. After staining, tissues were
washed three times with PBS. Stained tissues were stored at 4C in PBS until IBCs were counted
under a dissecting microscope [25].

In vivo binding and invasion assays
Bladders were harvested 1 hpi, partially bisected, and washed three times with 500 μL PBS with
gentle rocking; washes were plated to LB agar to enumerate lumenal bacteria. Washed bladders
were incubated in 100 µg/mL gentamicin at 37°C for 90 min; this gentamicin wash was plated to
confirm death of extracellular bacteria. Bladders were then homogenized in sterile PBS and
plated to enumerate intracellular bacteria.
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Electron microscopy of CRAMP-treated cultures
Overnight bacterial cultures were pelleted, resuspended to OD600 = 1.0, and treated with 10
µg/mL CRAMP or PBS for 1 h at 37°C. Cultures were fixed (1% glutaraldehyde) before bacteria
were adsorbed to glow-discharged formvar/carbon-coated copper grids for 2 min. Grids were
washed in water and stained for 1 min with 1% aqueous uranyl acetate (Ted Pella Inc., Redding,
CA). Air-dried samples were viewed on a JEOL 1200EX transmission electron microscope
(JEOL USA, Peabody, MA).

Immunoblotting
Bladder homogenates were thawed, vortexed, and separated on 12% SDS-PAGE gels. Proteins
were transferred to PVDF membranes and blocked in 2% powdered milk + 2% BSA in blocking
buffer (0.5% Tween-20, 0.5M NaCl, 0.01M Tris base; pH 8.2). Membranes were incubated with
either rabbit anti-uroplakin IIIa (UPIIIa; 1:5000, sc-33570, Santa Cruz Biotechnology, Dallas,
TX) or goat anti-uroplakin Ia (UPIa; 1:250, sc-15173, Santa Cruz Biotechnology), and the
control rabbit anti-CoxIV (1:2000, #4844, Cell Signaling Technology, Danvers, MA). Alkaline
phosphatase-conjugated anti-rabbit IgG (1:2500, Sigma, A3812) or anti-goat IgG (1:2000,
Sigma, A4187) was used as secondary antibody. Blots were incubated with Tropix CDP-STAR
(Life Technologies) and exposed to film. Band densities were quantified using ImageJ, and
uroplakin levels were normalized to the loading control CoxIV. All homogenates (3 uninfected
mice/strain, 5 infected mice/strain/time point) were run adjacently on three separate gels and
blots, with independent quantification.

cAMP quantification
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Bladders were harvested sterilely 30 min post-infection, everted (with two pairs of fine forceps,
one securing the superior end and the other everting the tissue from the cut inferior end), and
incubated in 0.1 M HCl for 30 min at room temperature (RT). Lysates were cleared by
centrifugation at 20,000 × g for 10 min and stored at -20°C, then acetylated and used in the
cAMP Enzyme Immunoassay Kit (Sigma, CA201) according to manufacturer’s instructions.
Comparator C57Bl/6 mice were administered 10 mg/kg forskolin (Sigma) intraperitoneally plus
100 μM forskolin transurethrally [26], or DMSO vehicle control 30 min before processing.

Tissue histology
The bladder and left kidney of two (C57Bl/6) or three (CRAMP-deficient) mice were harvested
and fixed in methacarn (6:3:1 solution of methanol:chloroform:glacial acetic acid). Bladders and
kidneys were bisected and set in 2% agar. Agar blocks were paraffin embedded, and 5-μm
sections were stained with hematoxylin and eosin, then imaged using an Olympus DP25 camera
and BX40 light microscope.

Immunofluorescence microscopy
Unstained sections from uninfected C57Bl/6 and CRAMP-deficient bladders were deparaffinized
in mixed xylenes, rehydrated in isopropanol, washed in water, then boiled 30 min in 10 mM
sodium citrate. Sections were blocked for 1 h in PBS with 1% BSA and 0.3% Triton X-100 at
RT, and incubated with rabbit anti-UPIIIa (1:100) overnight at 4°C. AlexaFluor 488-conjugated
goat anti-rabbit IgG (1:500, Life Technologies) and Syto 61 (1:10,000) were added for 1 h at RT
before mounting and visualization.
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Cytokine analysis
Cytokines in bladder homogenates were quantified using a 23-plex magnetic bead cytokine array
(Bio-Plex Pro, Mouse Group I; Bio-Rad, Hercules, CA). Homogenates were thawed on ice and
cleared by centrifugation at 20,000 × g for 10 min. Individual samples (3 uninfected mice/strain,
5 infected mice/strain/time point) were assayed in duplicate, and data were analyzed per the
manufacturer’s instructions.

Tissue myeloperoxidase assay
Myeloperoxidase (MPO) activity was quantified as a measure of neutrophils present in bladder
tissue [27]. Cleared lysates from bladder homogenates were analyzed with the Fluoro MPO kit
(Cell Technology, Mountain View, CA) per the manufacturer’s instructions.

Bacterial killing by murine bone marrow-derived neutrophils
Bone marrow from C57Bl/6 and CRAMP-deficient mice was isolated in parallel; each sample
was placed in PBS containing 0.1% bovine serum albumin (BSA; Sigma, St. Louis, MO) and 1%
glucose (termed PBS-BG) before centrifugation at 100 × g for 10 min at 4°C. The pellet was
resuspended in 45% Percoll and layered on top of a gradient comprised of 81%, 62%, 55% and
50% Percoll layers. Gradients were centrifuged at 600 × g for 30 min at 4°C without brake.
Neutrophils were collected from the interface between the 81% and 62% layers and washed once
with PBS-BG, and the red cells were lysed. The neutrophils were washed again with PBS-BG
and resuspended in RPMI to 107 neutrophils/mL. Neutrophils were incubated with bacteria at a
multiplicity of infection of 10 for 1 h in a tissue culture incubator (37˚C, 5% CO2), before lysis
with Triton X-100 (final concentration 0.1%). Lysates were serially diluted and plated to
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enumerate CFU, expressed as a percentage of input bacteria. The experiment was repeated 3
times, with 5 samples per treatment (RPMI, C57Bl/6 or CRAMP-deficient) at 0 and 60 min.

Statistical analysis
All data were analyzed using the Mann-Whitney U test in GraphPad Prism software. P values <
0.05 were considered significant.

Results
CRAMP-deficient mice display less severe cystitis.
We confirmed the in vitro antimicrobial properties of CRAMP against the cystitisderived UPEC strain UTI89 (Figure 1). We therefore expected CRAMP-deficient mice to
display more extensive infection in the urinary tract. Instead, CRAMP-deficient mice exhibited
significantly lower bladder bacterial loads as early as 1 hpi and at all time points through 48 hpi
(p<0.005 at 1, 6, and 48 hpi, p<0.05 at 16 and 24 hpi; Figure 2A). Kidney infection was
infrequently observed in either host strain (data not shown). Wild-type C57Bl/6 mice rarely
progress to chronic high-titer cystitis [12], and similarly, CRAMP-deficient bladders did not
harbor elevated bacterial loads 2 wpi (Figure 2B).

Intracellular growth and IBC formation are unaffected in the absence of CRAMP.
The IBC represents a key phenotypic stage in the development of murine cystitis [5, 6,
28, 29]. Thus, we asked whether defective IBC formation in CRAMP-deficient mice might
correlate with the lower bladder titers observed in these hosts. Confocal microscopy revealed
early and mature IBCs, as well as filamentous forms, in C57Bl/6 and CRAMP-deficient mice
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(Figure 3A). Neutrophils properly located infected epithelial cells in both strains of mice
(Figure 3A, right column). Quantification of IBC volumes did not reveal differences (Figure
3B), but CRAMP-deficient bladders bore significantly fewer IBCs than did wild-type mice
(p=0.002; Figure 3C). Together, these data indicate that while the IBC pathway is intact in
CRAMP-deficient mice, diminished IBC numbers point to an early alteration in the infectious
process (e.g., impaired initiation of infection, accelerated clearance of bacteria, increased
exfoliation) in these hosts.

Epithelial binding and invasion are diminished in CRAMP-deficient mice.
Given that bladder bacterial loads differed as early as 1 hpi, we investigated binding,
invasion, and other processes occurring within this interval. Using in vivo binding and invasion
assays, we recovered significantly fewer bacteria from both the luminal and intracellular
compartments 1 hpi in CRAMP-deficient mice (p<0.001 and p<0.05, respectively; Figure 4A),
implicating bacterial binding and invasion in the defective pathogenesis observed in these hosts.
Corroborating this finding, CRAMP-deficient mice liberated significantly more bacteria in the
urine 1 hpi (p<0.05; Figure 4B).
Because type 1 pili represent the primary determinant of UPEC binding to bladder
epithelium, we tested whether CRAMP might represent a stimulus for bacterial expression of
these organelles. However, no alteration in piliation was observed by electron microscopy upon
CRAMP exposure in vitro (84.8% vs 78.2%; Figure 4C). Bladder UPIIIa content (by
immunoblot of tissue homogenates) was also equivalent between wild-type and CRAMPdeficient mice 1 hpi, indicating that accelerated uroepithelial exfoliation does not underlie
decreased bacterial loads in CRAMP-deficient bladders (Figure 4D).
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Abraham and colleagues have shown that TLR4-dependent surges in epithelial cell
cAMP result in expulsion of internalized UPEC [26, 30, 31]. In addition, cathelicidin may bind
to and mask recognition of bacterial lipopolysaccharide (LPS), thereby down-regulating TLR4dependent immune signaling [32]. Consequently, we hypothesized that in CRAMP-deficient
mice, TLR4 hyperactivation due to unmasked LPS may drive increased epithelial expulsion of
internalized bacteria. However, cAMP activation in superficial epithelium in response to UTI89
infection was equivalent in wild-type and CRAMP-deficient mice (Figure 4E).

CRAMP deficiency does not impart inherent epithelial changes.
In further considering attenuated UPEC binding and invasion in CRAMP-deficient mice,
we reasoned that these hosts might show baseline differences in epithelial structure or surface
receptors (e.g., uroplakins). By immunoblot, UPIa and UPIIIa were equivalently expressed in
bladder homogenates from the two mouse strains; this was corroborated by immunofluorescence
microscopy for UPIIIa of uninfected bladder sections (Figure 5A). By histology, uninfected
bladders of wild-type and CRAMP-deficient mice were similar in size and in tissue structure and
organization (Figure 5B and C).
Cathelicidin expression can stimulate cytokine release from epithelial cells and promote
immune cell recruitment to infected tissues [19, 33]. To investigate whether CRAMP influences
soluble and cellular immune constituents in the bladder environment at baseline, we compared
expression of 23 cytokines in uninfected C57Bl/6 and CRAMP-deficient bladders, finding no
significant differences; six representative cytokines relevant to host response in cystitis are
shown (Figure 5D; complete data in Table 1). We also found no difference in bladder neutrophil
content (as measured by myeloperoxidase [MPO] activity) in the two uninfected host strains
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(Figure 5E). These data indicate that UPEC pathogenicity in the CRAMP-deficient host is not
influenced by pre-infection alterations in the resting immunologic state of the bladder.

CRAMP-deficient mice show attenuated inflammatory responses to infection.
We next investigated whether CRAMP deficiency altered the inflammatory response to
UPEC introduction into the bladder. By histology, luminal bacteria and areas of epithelial
exfoliation were evident in both host strains by 6 hpi. Bladders from both hosts displayed mild
edema and inflammatory cellular infiltrates (Figure 6A and B). While histologic differences at
this time point were modest, analysis of bladder homogenates 6 hpi revealed significantly higher
levels of 16 inflammatory cytokines in wild-type compared with CRAMP-deficient mice
(representative cytokines shown in Figure 6C; complete data in Table 1). As inflammation and
associated tissue damage may promote sustained UPEC infection [2, 11, 12], we repeated these
analyses 24 hpi; at this subsequent interval, bladders of CRAMP-deficient mice displayed
epithelial restoration and minimal edema, while wild-type bladders remained notably edematous,
with widespread epithelial exfoliation (Figure 6A and B). Meanwhile, tissue cytokines remained
generally higher in wild-type mice 24 hpi, though these differences did not retain statistical
significance (Figure 6D and Table 1). Similarly, bladder MPO content was significantly higher
in CRAMP-deficient hosts 6 hpi, but this difference had resolved by 24 hpi (p=0.016; Figure 6E
and F, respectively).
These contrasts in inflammatory response were also reflected in recovery of the
superficial epithelium. Though bladder uroplakin content at baseline and 1 hpi was equivalent
between host strains, (Figure 4D), significantly more exfoliation was evident 6 and 24 hpi in
wild-type mice (p=0.0317; Figure 6G). More striking, by 48 hpi, infected CRAMP-deficient
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mice had restored the superficial epithelium fully, while wild-type bladder UPIIIa levels
remained low, about one third of baseline (p=0.0089; Figure 6G). In combination, these data
suggest significant alterations in the immune response to UPEC cystitis in CRAMP-deficient
mice.

Discussion
Cathelicidin antimicrobial peptides have been implicated in defense of multiple epithelial
surfaces, including the skin, lungs, and urinary tract. Within the murine urinary tract, the
expression and protective capacity of cathelicidin have been described in relation to kidney
infection in 129/SvJ mice inoculated with 108 CFU of UPEC strain CFT073 [16]. Here, we
employed an established murine cystitis model, notably different from prior studies in host
strain, bacterial strain, infectious dose, and the organ of focus. Our findings in this model system
suggest that CRAMP exerts a complex influence on the progression and outcome of infection.
Though in vitro assays showed antimicrobial activity of CRAMP against UTI89,
CRAMP was not essential for uroepithelial defense in our in vivo cystitis model. Instead, as
indicated by significantly lower IBC numbers and bladder bacterial loads throughout infection,
hosts lacking CRAMP resolved infections more efficiently. Diminished IBC formation in
CRAMP-deficient hosts results from very early alterations in pathogenesis, specifically in
epithelial binding and invasion by UPEC; we found no differences in several molecular
determinants of these processes. Of note, cathelicidin has also been shown to enhance the
bactericidal capacity of human and murine neutrophils, by stimulating ROS production in
response to bacterial components and by augmenting bacterial engulfment. Specifically, bone
marrow-derived neutrophils from CRAMP-deficient 129/SvJ mice showed diminished killing of
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Gram-negative and -positive bacteria compared with wild-type neutrophils, and cathelicidin may
alter gene expression in neutrophils [34, 35]. In contrast, we found normal UPEC-killing ability
in bone marrow-derived neutrophils from CRAMP-deficient C57Bl/6 mice (Figure 7). In total,
our data instead indicate important activities for cathelicidin during UTI that are independent of
its direct antimicrobial activity and support of phagocyte killing. Future studies of cathelicidin in
epithelial defense should account for these multiple biological activities that occur during hostpathogen interactions, and should examine both epithelial and hematopoietic sources of the
peptide.
Consonant with recent transcriptional profiling data [36, 37] and other prior studies (e.g.,
[7, 38]), we observed a sharp pro-inflammatory cytokine response in infected wild-type C57Bl/6
mice by 6 hpi, with subsequent resolution. However, CRAMP-deficient hosts exhibited
significantly reduced pro-inflammatory cytokine expression, edema, and neutrophil influx by 6
hpi (Figure 6 and Table 1). Our findings support a model in which CRAMP participates in
activation and development of the host immune response to UPEC within the bladder, a response
that helps to control but may also facilitate UPEC infection [2]. Of note, a similar function for
cathelicidin has been demonstrated in studies with cultured human lung epithelial cells and with
human and murine peripheral monocytes [39, 40]. Consistent with an immunostimulatory role,
cathelicidin concentrations during human UTI are on the order of other immunomodulators but
well below concentrations necessary for bactericidal activity [16, 17] (Figure 1). While the
bactericidal activity of AMPs may be impaired in high-salt conditions, it is unknown how such
conditions (as may occur in urine) may influence its immunostimulatory properties. During
experimental cystitis, absence of CRAMP may dampen inflammatory cytokine responses and
exfoliation, processes that in wild-type hosts produce the significant epithelial damage that offers
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UEPC access to naïve cells in deeper uroepithelial layers [41]. Though bladder instillation of
concentrated cathelicidin can elicit edema and leukocytic infiltrates, enhanced IBC formation in
wild-type mice may also drive augmented inflammation [42]. Indeed, multiple studies indicate
that the degree of intracellular invasion and IBC formation predicts the intensity of inflammatory
response in the bladder, and that increased inflammation in turn facilitates persistence of UPEC
infection [2, 11, 12]. Thus, the development and outcome of uroepithelial infection depend on
ongoing interplay between invasive bacterial populations and the soluble and cellular immune
components of the host milieu.
Finally, cathelicidin is among multiple AMPs that could influence the progression of
UTIs. For example, α-defensins produced by infiltrating neutrophils, as well as renally-expressed
β-defensins, function to kill uropathogens and promote innate responses in infected tissue [43].
Uroepithelial expression of RNase 7 also increases during infection to yield urinary
concentrations inhibitory to uropathogens [44, 45]. Additionally, AMPs have been shown to
signal to other types of epithelial cells through surface receptors of upon internalization [39, 46].
Beyond potential signaling roles in host epithelial or hematopoietic cells, cathelicidin and other
AMPs, might also elicit transcriptional programs (e.g., envelope stress responses) in bacteria.
Cross-talk and/or redundancy likely occur among urinary AMPs and would complicate the
development of a complete model detailing the effects of an individual AMP on the course of
UTI. Our data also do not exclude the possibility that CRAMP-deficient mice might have
alterations in intracellular events that follow bacterial internalization. However, the field
presently lacks detailed molecular and cell-biological knowledge of these events, including a
mechanism for presumed UPEC escape from the endocytic vacuole into the epithelial cell
cytoplasm. Further exploration of potential influences of cathelicidin on UTI pathogenesis and
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accompanying immune responses may reveal avenues for modulating these host responses in
order to mitigate progression, chronic infection, and recurrence.
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Tables and Figures

Figure 1: CRAMP has antimicrobial activity against UPEC strain UTI89 in vitro. Dosedependent inhibition of bacterial viability is seen after 2 h treatment with CRAMP. Survival is
shown as a percentage of input bacteria after 2 h. The mean and standard error are shown for
each treatment concentration.
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Figure 2: CRAMP-deficient mice have significantly lower bladder bacterial loads. (A)
Bladder bacterial loads in wild-type C57Bl/6 mice (filled circles) were significantly higher than
in CRAMP-deficient mice (open circles) at 1, 6, 16, 24, and 48 hpi (*p<0.05, **p<0.005). Bar
represents the geometric mean. (B) C57Bl/6 and CRAMP-deficient mice show equivalent and
minimal bladder bacterial loads at 2 wpi. Each point represents a single mouse.
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Figure 3: Intracellular bacterial growth is similar between host strains, although wild-type
mice have more IBCs. (A) Early and mature IBCs can be found in the bladder epithelial cells of
both C57Bl/6 and CRAMP-deficient mice after infection with GFP-expressing UTI89.
Filamentous bacteria were identified in both host strains of mice, as well as neutrophils that
localize to IBC-bearing epithelial cells. DNA (host cell and bacterial) is stained red.
Representative pictures are shown. (B) IBC volumes were equivalent between the two host
strains, as quantified by Volocity software (all IBCs from 3 C57Bl/6 and 4 CRAMP-deficient
mice). (C) IBC numbers, measured by lacZ staining, were significantly higher in wild-type mice
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(***p<0.001; n = 13-15 mice per strain). Bars in (B) and (C) represent the geometric mean. Each
point represents a single mouse.

81

Figure 4: Epithelial binding and invasion is less efficient in CRAMP-deficient mice. (A)
Bacterial titers in the luminal and intracellular (gentamicin-protected) compartments at 1 hpi
were both significantly lower in CRAMP-deficient mice (*p<0.05, ***p<0.001; n = 5
mice/strain/experiment). (B) CRAMP-deficient mice liberate increased bacterial CFU in the
urine at 1 hpi (*p<0.05). Dashed line represents the limit of detection and bars represent the
geometric mean in (A) and (B). (C) Proportion of bacteria, either untreated or after 1 h exposure
to 10 µg/mL CRAMP, that were piliated as determined by electron microscopy (n =
100/condition x 5 separate experiments). (D) Densitometric quantification by immunoblot of
UPIIIa in 1 hpi bladder homogenates as a measure of epithelial exfoliation showed no difference
between host strains. Mitochondrial enzyme CoxIV was used to normalize the amount of protein
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in each sample. (E) cAMP expression in the bladder uroepithelium of C57Bl/6 and CRAMPdeficient mice at 30 min post-infection (n = 6-7 mice/strain). Negative and positive controls,
respectively (white bars), included vehicle-only (DMSO) and forskolin-treated C57Bl/6 bladders
(n = 2 mice/treatment). Mean and SEM are indicated in (C), (D), and (E).
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Figure 5: Uninfected mice do not have inherent differences in the uroepithelium. (A)
Densitometric analysis of immunoblots for UPIa and UPIIIa in uninfected bladder homogenates
showed no significant differences (UPIa, p=0.1354; UPIIIA, p=0.1). Mitochondrial enzyme
CoxIV was used to normalize the amount of protein in each sample. Mean and SEM are
indicated. At right are representative fluorescence images of uninfected bladders sections (UPIIIa
shown in green, nuclei shown in red; scale bar, 20 µm). (B and C) Sections of uninfected
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C57Bl/6 (B) and CRAMP-deficient (C) bladders were stained with hematoxylin and eosin
(H&E) for morphological analysis. Whole bladders are shown on the left (scale bar, 400 µm),
and magnified epithelial views are shown on the right (scale bar, 100 µm). Representative
images are shown. (D) Cytokine profiles of uninfected bladder homogenates from C57Bl/6 and
CRAMP-deficient mice. (E) Myeloperoxidase (MPO) activity, a surrogate for tissue neutrophil
content, in uninfected whole bladder homogenates from the two host strains (n = 6 C57Bl/6
mice, 11 CRAMP-deficient mice). Mean and SEM are indicated in (D) and (E).
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Figure 6: Bladder from CRAMP-deficient mice recover faster after infection with UPEC.
Sections of C57Bl/6 (A) and CRAMP-deficient bladders (B) 6 and 24 hpi were stained with
H&E for morphological analysis. Whole bladder sections (left panels; scale bar, 400 µm) show
substantially increased edema in wild-type mice at both time points. Acute cystitis is evident in
both host strains 6 hpi (right panels; scale bar, 40 µm). However, at 24hpi, the infected wild-type
bladder remains edematous and completely exfoliated, while CRAMP-deficient bladders reflect
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resolved inflammatory changes and recovery of the superficial epithelial layer. (C) Expression of
six representative cytokines is significantly lower in CRAMP-deficient bladder homogenates 6
hpi (*p<0.05, **p<0.01). (D) At 24 hpi, only GM-CSF was significantly lower in CRAMPdeficient mice, among 23 cytokines measured (*p=0.032; data not shown). Whole bladder MPO
activity is significantly lower in CRAMP-deficient mice 6 hpi (E); this difference was no longer
significant 24 hpi (F). (G) Densitometric analysis of bladder UPIIIa expression indicates more
rapid epithelial recovery in CRAMP-deficient mice (white bars) than in wild-type mice (black
bars) (*p<0.05, **p<0.01). Mean and SEM are indicated in (C-G).

87

Table 1: Pro- and anti-inflammatory cytokine levels in bladder homogenatesa

IL-1α
IL-1β

Uninf
C57Bl/6
15.87 ± 1.49
85.81 ± 9.25

Uninf
CRAMP
15.26 ± 1.51
87.83 ± 6.63

6 hpi C57Bl/6

6 hpi CRAMP

35.86 ± 3.54
320.22
±
48.96*
59.24 ± 5.04
6.50 ± 0.68
OOR
114.53
±
11.24*
193.73
±
41.93*
OOR

35.87 ± 3.54
162.16
±
15.13*
43.92 ± 5.81
5.77 ± 0.56
OOR
78.4 ± 5.01*

IL-2
IL-3
IL-4
IL-5

32.94 ± 1.08
4.31 ± 0.30
OOR
57.34 ± 3.22

31.76 ± 4.06
4.77 ± 0.53
OOR
55.06 ± 4.23

IL-6

4.46 ± 0.15

3.82 ± 0.45

IL-9

OOR

OOR

IL-10
IL-12 (p40)
IL-12 (p70)

30.25 ± 0.83
16.15 ± 2.58
39.77 ± 0.39

27.87 ± 1.44
13.32 ± 0.59
45.24 ± 3.11

66.27 ±5.39*
34.78 ± 2.57*
126.99
±
7.44**
273.04
±
21.37*
184.03
±
20.69*
1154.64
±
121.65*
438.81
±
43.91*

44.00 ± 2.18*
21.42 ± 2.17*
86.61 ± 5.82**

IL-13

97.86 ± 7.22

93.61 ± 8.81

IL-17

27.07 ± 1.28

24.58 ± 2.02

Eotaxin

275.12 ± 16.93

208.22 ± 27.24

Granulocyte
colonystimulating factor
(G-CSF)
Granulocytemacrophage
colonystimulating factor
(GM-CSF)
IFN-γ
KC

239.52 ± 44.07

202.82 ± 15.22

60.91 ± 4.47

64.26 ± 4.38

209.11
20.97**

±

OOR
7.03 ± 0.25

OOR
6.72 ± 1.06

Monocyte
chemotactic
protein (MCP)-1

86.46 ± 9.75

72.97 ± 5.46

Macrophage
inflammatory
protein (MIP)-1α

12.45 ± 0.53

MIP-1β
RANTES
TNF-α

20.03 ± 1.50
15.15 ± 4.97
OOR

a

24
hpi
C57Bl/6
37.08 ± 6.35
241.46 ± 43.61

24
hpi
CRAMP
37.08 ± 6.35
142.45 ± 28.28

83.83 ± 8.98
12.96 ± 5.05
OOR
56.76 ± 9.28

69.798 ± 9.91
5.27
OOR
46.275 ± 8.23

46.23 ± 13.68*

50.9 ± 18.34

51.1 ± 18.05

OOR

773.84
±
145.23
60.53 ± 8.18
44.04 ± 13.10
92.06 ± 16.27

695.72
±
247.94
36.22 ± 5.82
27.39 ± 4.51
53.59 ± 6.20

167.49
±
14.03*
87.78 ± 6.68*

253.24 ± 30.77

237.06 ± 44.87

116.05 ± 15.28

62.07 ± 16.17

692.26
53.71*
222.45
23.94*

±

OOR

OOR

±

403.2 ± 177.21

184.96

120.7 ± 4.43**

115.04
21.47**

±

57.09 ± 9.84**

21.23 ± 1.21**
621.79
±
72.74**
1519.02
±
324.44**

14.78 ± 1.36**
174.44
±
28.89**
355.96
±
78.53**

36.76 ± 13.13
208.04 ± 53.41

30.82 ± 7.97
180.25 ± 73.03

230.77 ± 53.36

129.63 ± 40.49

16.07 ± 1.00

59.15 ± 8.80*

30.06 ± 5.08*

40.66 ± 6.11

24.862 ± 4.07

20.59 ± 1.14
15.17 ± 4.02
OOR

68.93 ± 8.69*
176.45 ± 40.02
OOR

39.56 ± 5.34*
79.17 ± 25.75
OOR

43.02 ± 6.61
101.84 ± 13.50
OOR

31.05 ± 3.66
51.462 ± 8.40
OOR

values shown represent mean ± SEM for all samples, bolded pairs indicate significant

differences (C57Bl/6 vs CRAMP); *p < 0.05; **p < 0.01; OOR = out of range (low)
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Figure 7: UPEC killing by CRAMP-deficient neutrophils is equivalent to wild-type. UPEC
were incubated with RPMI (media control) or bone marrow-derived neutrophils from C57Bl/6 or
CRAMP-deficient mice for 1 h, before the neutrophils were lysed and the lysates were plated to
determine percent survival relative to input. There is no difference in UPEC recovery after
exposure to wild-type vs CRAMP-deficient neutrophils (p=0.1524). Mean and standard error are
shown for each treatment.
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CHAPTER FOUR
RNA SEQUENCING REVEALS UPEC-SPECIFIC PATHWAY REGULATION
AFTER SUB-LETHAL EXPOSURE TO CATHELICIDIN

Abstract
Antimicrobial peptides (AMPs) are important for defense of many epithelial surfaces,
including the skin, respiratory system, gut, and urinary tract. The AMP cathelicidin is produced
by epithelial cells and innate immune cells within the urinary tract at low levels; published data
support possible in vivo roles both in limiting infection and in promoting inflammation. In order
to examine the effects of cathelicidin on uropathogenic E. coli (UPEC) in vitro, UPEC were
treated at various points in growth with increasing concentrations of cathelicidin and plated to
quantify survival. Surprisingly, UPEC in mid-log phase reproducibly increased in number
relative to an untreated control after a 1 h treatment with 1 µg/mL cathelicidin. In contrast, the
laboratory E. coli strain MG1655 exhibited decreased survival after the same treatment. This
may indicate that UPEC have specifically adapted to better resist cathelicidin. When treated with
higher concentrations of cathelicidin, UPEC survival decreased in a dose-dependent manner.
RNA sequencing was employed to interrogate UPEC global transcriptional responses to
treatment with the murine cathelicidin CRAMP at concentrations of 1 or 3 µg/mL. A limited
number of genes were significantly upregulated after 1 µg/mL CRAMP treatment and
approximately half of these upregulated genes are involved in metabolism. Interestingly, another
subset of upregulated genes encodes known small molecule and peptide transporters. Upon
exposure to 3 µg/mL CRAMP, almost one fifth of the UPEC genome was differentially
regulated, including all of the genes upregulated after exposure to 1 µg/mL CRAMP. These data
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suggest that sensing of cathelicidins in the environment may prompt UPEC to upregulate genes
that allow for uptake and subsequent breakdown of these peptides. This could function as a
defense mechanism, and/or to simultaneously promote growth in a nutrient-limited environment.
Current experiments are elucidating mechanisms through which cathelicidin interacts with the
cell to induce these alterations in gene expression.

Introduction
Urinary tract infections (UTIs) are infections of the bladder (cystitis) and sometimes the
kidneys (pyelonephritis) that most commonly affect otherwise healthy women of child-bearing
age. More than half of women will experience at least one UTI in their lifetime, and up to 40%
of infected women will have recurrent UTIs within 6 months that are not eliminated through the
use of antibiotics [1-3]. Due to the high incidence of these infections (approximately 11 million
in 2007), there is significant burden on the healthcare system, amounting to upwards of $4
billion per year in the United States [3]. The most common cause of UTI is uropathogenic E. coli
(UPEC), which can account for up to 85% of all UTIs [2]. Although the majority of these
infections will be naturally cleared from the body in 3-4 days, antibiotics are often prescribed to
help clear these infections, contributing to the epidemic of antibiotic resistance [4, 5]. Much
work has been done to elucidate the important interactions that occur between UPEC and the
host during the establishment of infection, but a clearer understanding of the bacterial responses
to the host environment may help drive the creation of new antimicrobials.
The majority of UTIs are thought to originate from seeding of extraintestinal pathogenic
E. coli (ExPEC), originating from the natural gut microbiota, into the urinary tract [6-8].
Behavioral, genetic, and anatomical factors in the host contribute to the incidence of UTI and to
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the progression from cystitis to pyelonephritis [3]. While there are a number of bacterial factors
that also influence whether or not a UTI develops, there is not a set of virulence factors that
“defines” UPEC, as UTI-causing strains are genomically diverse [8-10]. Genes that have been
identified as important include adhesive fimbriae (type 1, S and P pili), iron acquisition
molecules (yersiniabactin, aerobactin, enterobactin, among others), and toxins (cytotoxic
necrotizing factor 1, hemolysin) [11-13]. The identification of other mechanisms that specifically
promote UPEC infections would help with the design of treatments that would not harm
important gut flora. A murine model of cystitis has aided in the discovery of a UPEC infection
cycle, while subsequent clinical studies have confirmed the occurrence of key points in the
cascade in affected children and adults [14-18].
The urinary tract features a variety of defenses to protect against uropathogens. These
include mechanical defenses, such as urine flow and exfoliation of the bladder epithelium, and
limitation of critical nutrients through the expression of molecules such as lactoferrin and
lipocalin [19]. Most importantly, the innate immune system is comprised of molecules and cells
that can quickly and broadly eliminate potential pathogens. Within the urinary tract, the
important cellular components include phagocytes such as polymorphonuclear cells (PMNs;
neutrophils) and macrophages, mast cells, natural killer cells, and γδ T-cells [20-22]. In addition
to the molecules that comprise the complement system, antimicrobial peptides (AMPs) are
produced by innate immune cells and epithelial cells. These peptides have demonstrated
antimicrobial activity against a range of pathogens. The most prevalent AMPs in the urinary tract
are cathelicidin, α- and β-defensins, hepcidin, and RNase 7 [23-26]. Previous work has shown
that many of these peptides are constitutively expressed within the urinary tract and are upregulated in response to bacteria. Therefore, to successfully cause a robust infection, potential
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pathogens must be able to evade the killing effects of these molecules as soon as they enter the
urinary tract.
Many AMP defense mechanisms have been described in both Gram-negative and Grampositive bacteria. These mechanisms range from outer membrane protein modifications that alter
the surface charge of the bacteria, to the expression of efflux pumps and proteases, and the
expression and release of proteins that can sequester or break down AMPs [27]. While UPEC
encode many of the proteins important for these defenses, it is unclear which of these
mechanisms are most important for survival within the urinary tract. Furthermore, it is likely that
there are additional resistance mechanisms that have not yet been discovered. We hypothesized
that UPEC may have specific AMP resistance mechanisms that permit them to cause infections
in the host, and that we could discover these mechanisms by examining the genes that are
upregulated in response to AMP exposure. Of the multiple AMPs expressed in the urinary tract,
we chose to focus first on cathelicidin, as both humans and mice encode a single cathelicidin
(LL-37 and cathelin-related antimicrobial peptide or CRAMP, respectively) [28, 29].
Here, we created an in vitro assay that would allow us to ascertain mechanisms used by
UPEC use to resist the killing effects of AMPs, and to approximate the effects that sub-lethal
exposure to AMPs has on bacteria in the urinary tract. Briefly, pathogenic or non-pathogenic E.
coli were grown to mid-log phase, treated with murine cathelicidin, and then RNA was isolated
for RNA sequencing and transcriptomic analysis. While UPEC actually showed augmented
growth in the presence of a low concentration of CRAMP, non-pathogenic cells were killed by
the same concentration, indicating that there may be response mechanisms that are specifically
encoded by uropathogens. RNA sequencing revealed that a limited number of UPEC genes were
differentially regulated when cells were treated with 1 µg/mL of cathelicidin. These expression
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patterns suggested that uropathogens may selectively up-regulate genes that enable the cells to
take up AMPs, increase TCA cycle output, and utilize the peptides as a source of nutrient amino
acids. Together, these responses would promote growth in the otherwise limiting environment of
the urinary tract.
The results shown here may support another mechanism in which UPEC utilize
uncommon yet available resources in the urinary tract to quickly amplify in number and establish
infection. Future experiments will directly test the use of cathelicidin by UPEC as a nutrient
source, and will elucidate the specific roles of the identified genes through in vitro and in vivo
experiments. We hope that this work will illuminate the biological processes that occur when
UPEC are introduced into the urinary tract, and will direct the development of new methods for
inhibiting the growth of UPEC during infection.

Materials and Methods
Bacterial strains and culture
The prototypic cystitis isolate UTI89 and the laboratory-adapted K12 E. coli strain MG1655
were cultured directly from frozen stocks for experiments [30, 31]. Cultures were grown in 20
mL static cultures overnight at 37°C unless otherwise indicated.

CRAMP survival of stationary phase cultures
UTI89 and MG1655 were grown in LB Miller broth overnight, pelleted, and resuspended to an
OD600 = 1 in sterile phosphate-buffered saline (PBS). In triplicate wells of a 96-well plate, 50 µL
of resuspended bacteria were mixed with 150 µL sterile PBS, along with freshly thawed CRAMP
to yield the indicated final concentrations. The plate was briefly shaken before static incubation
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at 37°C for 2 h. Cultures were serially diluted in sterile PBS and plated on LB agar to determine
survival. The experiment was repeated three times, and significance was determined by Student’s
t test.

AMP treatment during growth
CRAMP or LL-37 (Anaspec, Fremont, CA) was resuspended in sterile water and 2 mg/mL
aliquots were stored at -80˚C until needed. Overnight cultures were centrifuged and resuspended
in PBS to an OD600 = 1. The resuspended culture was used to subculture fresh LB Luria 1:10,
and the cultures were grown statically at 37°C until the OD600 reached 0.5. At this point, aliquots
were removed, centrifuged, and the pellets resuspended in a volume of PBS twice that of the
original aliquot (1:1 final dilution). Freshly thawed AMP was added to the desired final
concentration (after 1:10 dilution in sterile water, if necessary), and the samples were incubated
at 37°C for 1 h before serial dilution in PBS and plating to determine CFU. An untreated sample
was prepared in parallel to the treated samples for each strain. The experiment was repeated at
least three times.

RNA isolation and sequencing
RNA was isolated from CRAMP-treated cultures of UTI89 and MG1655 immediately after
incubation at 37°C using a QIAgen RNeasy Mini Kit, according to the manufacturer’s
instructions. Samples were stored at -80°C. Sets of five samples (UTI89 untreated, UTI89 with 1
µg/mL CRAMP, UTI89 with 3 µg/mL CRAMP, MG1655 untreated, MG1655 with 1 µg/mL
CRAMP) were prepared on three separate days. Samples were submitted to the Genome
Technology Access Center for ribosomal RNA depletion (Ribo-Zero rRNA Removal Kit,
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Illumina), reverse transcription, and sequencing. The samples were sequenced using a single lane
of a Solexa sequencer, and reads were aligned to either the UTI89 genome or the MG1655
genome. Read data from individual genes were used for comparisons and downstream
applications.

Molecular biology
Electrocompetent cultures of UTI89/pKM208 expressing λ Red recombinase were transformed
with linear PCR products that contained 20-30 bases of homology to the target gene on either
side of a chloramphenicol resistance marker [32]. The primers used to prepare these PCR
products are listed in Table 2. Correct insertion of the chloramphenicol cassette into the gene of
interest was confirmed in individual colonies using flanking primers, or a primer that recognizes
the middle of the chloramphenicol cassette (primers listed in Table 3). A single colony with
PCR-confirmed allelic replacement was selected for each gene of interest and used for further
characterization.

Growth curves
Overnight shaking cultures of the desired strains in LB Miller were sub-cultured at 1:100 in fresh
LB Miller broth and grown to an OD600 = 1. These cultures were diluted 1:10,000 in fresh media,
and 200 μL was transferred to each well of a 96-well plate, with five wells per strain. The
cultures were grown at 37°C with shaking in a Synergy 2 microplate reader (BioTek, Winooski,
VT), and the OD600 of each well was read every 30 min. The experiment was repeated three
times, and a representative plot is shown.
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Results
UTI89 and MG1655 are susceptible to CRAMP-mediated killing.
The bactericidal effects of cathelicidin have been touted in many models of disease and
infection. We first confirmed that the cystitis-derived UPEC isolate UTI89 and the laboratoryadapted K12 E. coli strain MG1655 were both susceptible to killing in vitro by the murine
cathelicidin CRAMP. The strains were similarly susceptible to killing at doses <10 µg/mL,
although MG1655 was significantly more susceptible to killing at both 20 and 50 µg/mL doses
(**** p < 0.0001; Figure 1).

UTI89 cells grow in response to low-dose CRAMP treatment.
Upon introduction into the urinary tract, bacteria are promptly exposed to sub-lethal
concentrations of AMPs. To determine if E. coli are able to sense and respond to the presence of
AMPs in their environment, we measured changes in growth rate after treatment with
cathelicidin. We hypothesized that if bacteria respond by activating AMP resistance
mechanisms, we would not observe an increase in cell death relative to untreated cells. For these
experiments, bacteria were grown in low-salt LB Luria in order to more closely replicate the
environment of the urinary tract. When cultures of UTI89 in early to mid-log phase were treated
with a 1 µg/mL of CRAMP for 1 h at 37°C, increased growth was observed, relative to an
untreated sample studied in parallel (Figure 2A). Of note, cells at this point in growth were not
fully resistant to the killing effects of CRAMP, as treatment with a higher dose of CRAMP (5
µg/mL) did result in cell death (Figure 2A).
We also aimed to identify any UPEC-specific mechanisms important for resistance to
AMPs. Thus, we studied the laboratory-adapted K12 E. coli strain MG1655 in parallel growth
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and treatment experiments. In contrast to UTI89, MG1655 cells were susceptible to killing by 1
µg/mL of CRAMP at all examined points in growth; this susceptibility decreased as the cultures
approached mid-log phase (Figure 2B). However, MG1655 cells were more susceptible to
killing by 5 µg/mL of CRAMP at later points in growth than UTI89 (Figure 2B). When these
experiments were repeated with the human cathelicidin LL-37, there was not an increase in
growth with 1 µg/mL treatment; UTI89 and MG1655 were equally susceptible to killing at the 1
and 5 µg/mL doses (Figure 2C).

A subset of UTI89 genes are significantly differentially regulated in response to CRAMP.
A global approach was used to investigate the genetic changes that underlie the increased
growth observed in UTI89 cultures treated with 1 µg/mL of CRAMP. We prepared RNA from
untreated samples, as well as samples treated with 1 or 3 µg/mL of CRAMP, and analyzed the
transcriptional profile of these samples by RNA sequencing. An aliquot was removed from each
of the treated samples before RNA isolation in order to confirm that the survival phenotypes
were consistent with our preliminary experiments (Figure 3A). A treatment of 3 µg CRAMP/mL
was used in these experiments to ensure that the cultures contained mostly live cells. Using a
False Discovery Ratio (FDR) cut-off of 0.05 and a p-value < 0.05, we identified 12 genes that
were significantly differentially regulated when UTI89 was exposed to 1 µg/mL of CRAMP
(Table 1). Of the 12 identified genes, six have roles in metabolism, five are identified as
transporters, and one is a hypothetical protein of unknown function (Figure 3B and Table 1)
[33]. Three different operons had two genes represented in this set: the dppABCDF operon,
which encodes an inner membrane dipeptide transporter; the UTI89 homolog of the
arnBCADTEF operon in MG1655 (annotated as yfbG and yfbH in UTI89), which encodes a
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group of transferases; and the malK-lamB-malM operon, encoding an inner membrane maltose
transport system [33].
We also treated cells with 3 µg/mL of CRAMP and performed a similar analysis. Using
the same stringent analysis criteria, 942 genes were significantly differentially regulated under
these treatment conditions (data not shown), representing almost one fifth of the UPEC genome
[34]. All 12 genes that were differentially regulated at 1 µg/mL were also differentially regulated
at 3 µg/mL. The expression of all but two genes (aceA and gatY) was more highly upregulated
after treatment with 3 µg/mL CRAMP (data not shown). It is important to note that in the
samples submitted for RNA sequencing analysis, treatment with 3 µg/mL CRAMP resulted in
measurable cell death relative to untreated samples (66% survival; Figure 3A). It is likely that
some of the measured changes in gene regulation are associated with lysed or dead cells in the
samples.

MG1655 genes are not significantly differentially regulated in response to 1 µg/mL CRAMP.
Cultures of MG1655 treated with 1 µg/mL of CRAMP exhibited decreased survival in
relation to an untreated control (83% survival; Figure 3A). Even though some bacterial cell
death was observed at this dose, analysis of RNA sequencing data using the same stringent
criteria as before did not reveal any significantly differentially regulated genes in MG1655.

Mutants do not have altered growth or CRAMP resistance phenotypes.
In order to determine if any of the identified genes have critical roles in normal bacterial
cell growth, we created in-frame allelic replacements in UTI89 for each of the 12 genes
differentially regulated upon 1 µg/mL CRAMP exposure. We were able to isolate mutants for
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each gene, indicating that none of these genes are essential. Mutants for two genes (aceA and
lamB) had previously been generated (unpublished data). We did not identify any defects during
growth in rich medium as compared to wild-type UTI89 (Figure 4A). To characterize the ability
to respond to sub-lethal concentrations of CRAMP, we tested all of the mutants in our CRAMP
survival assay. Preliminary results indicate that single-gene mutants are not more susceptible to
killing by 1 µg/mL CRAMP, although further experiments are needed to confirm these
phenotypes (Figure 4B).

Discussion
Cathelicidin antimicrobial peptides have been shown to be exhibit activity against a wide
range of microorganisms. Here, in relation to urinary tract defense, we sought to identify
mechanisms by which UPEC (in contrast with non-pathogenic E. coli strains) can respond to the
presence of cathelicidins in the environment. We confirmed that both the cystitis strain UTI89
and the laboratory strain MG1655 are susceptible to killing in vitro by the murine cathelicidin
CRAMP, and were then surprised to find that UPEC in mid-log phase showed increased growth
after treatment with a sub-lethal concentration of CRAMP (Figure 1, 2A). Non-pathogenic E.
coli did not display this growth phenotype after exposure to sub-lethal CRAMP (Figure 2B).
We were interested to determine if there are UPEC-specific mechanisms that promote
survival and growth in an environment with AMPs. We employed unbiased RNA sequencing
(transcriptomic analysis) to identify genes that are differentially regulated after cathelicidin
treatment. This analysis yielded 12 differentially regulated genes in UPEC after treatment with 1
µg/mL of CRAMP, and nearly 1000 genes after treatment with 3 µg/mL of CRAMP (Table 1).
The majority of these 12 genes do not represent previously annotated AMP resistance
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mechanisms, and instead encode membrane-localized small molecule and peptide transporters, as
well as metabolic enzymes [33]. None of these genes are essential for survival, as in-frame
deletion mutants were all viable and exhibited normal growth in rich medium (Figure 4A).
Furthermore, all 12 of these genes are encoded by both UTI89 and MG1655 [33].
The genes dppB, dppC, and oppC encode inner-membrane transporters that function to
transport peptides from the periplasm into the cytoplasm. DppB and DppC are two of the three
subunits that make up the DppABC dipeptide transporter [35]. The gene encoding the other
subunit, dppA, is one of the top 50 genes expressed in pyelonephritis isolate CFT073 when
grown in human urine in vitro and has also been identified as highly expressed in many clinical
UPEC isolates [36, 37]. OppC is one of three components that make up the OppABC
oligopeptide transporter, and the oppA gene is also highly expressed in E. coli isolates from
patients with active UTI [37-39]. It is particularly interesting that both dpp and opp genes were
identified in our screen as mutants in dppA and oppA have been shown to promote cystitis in the
murine model of infection [40]. These proteins had been shown to be highly upregulated during
growth in human urine [40]. It was further shown that gluconeogenesis and the TCA cycle are
required for in vivo UPEC infection [40]. It is possible that the opp and dpp operons are
important for regulating the uptake of peptides that can be fed into these metabolic cycles.
Finally, the genes lamB and malK occur in an operon along with the gene malM, and encode
maltose transporters within the outer and inner membranes, respectively [38, 39, 41].
The other seven genes (aceA, fumC, gatY, glcD, ydcW, yfbG, and yfbH) encode
cytoplasmic proteins. All but yfbH have well-defined functions, although yfbH likely functions in
the same pathway as yfbG. YfbG (known as ArnA in MG1655) has a well-defined role in
resistance to the cationic AMP polymyxin [42]. This protein forms the sugar nucleotide UDP-L106

Ara40, which is eventually incorporated into Lipid A where it mediates polymyxin resistance in
E. coli and Salmonella typhimurium [42, 43]. We can use mass spectrometry analysis to
determine if this Lipid A modification occurs in UTI89 after exposure to CRAMP, and the yfbG
mutant can be used in a murine model of cystitis to explore the effects of Lipid A modification
on establishment of UTI.
The genes aceA, fumC, gatY, glcD, and ydcW encode enzymes that function in
metabolism, some in the TCA cycle and others in intermediate metabolism. Within the TCA
cycle, fumC encodes fumarate hydratase, which reversibly converts (S)-malate to water and
fumarate, while gatY encodes fructose-1,6-bisphophate aldolase, which catalyzes the
condensation of dihydroxyacetone phosphate and glyceraldehyde 3-phosphate [44-47]. Of note,
fumC is co-transcribed with fumA, a gene shown to be downregulated by UPEC in vivo relative
to expression in growth in human urine in vitro [37]. Furthermore, gatY has been termed as a
UPEC-specific gene because it was encoded by 8 sequenced UPEC strains, but was not found in
a set of fecal/commensal isolates; however, this gene is encoded by MG1655 [31, 48]. The
ydcW-encoded γ-aminobutyraldehyde dehydrogenase is involved in choline and putrescine
degradation; glcD encodes a glycolate oxidase subunit that helps with small carbon compound
degradation; and the isocitrate lyase AceA functions in the glyoxylate bypass pathway [49-55].
Although these genes represent distinct metabolic pathways, the recurring theme of increased
metabolic activity is consistent with the growth phenotype that was identified in the preliminary
experiments. Together, these expression patterns support a model in which UPEC are actively
upregulating genes that allow for the uptake and subsequent breakdown of CRAMP, potentially
to use as a source of amino acids. This detection of CRAMP could be triggering the changes that
occur and which may help prime the bacteria to survive in the urinary tract.
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No significantly differentially regulated genes were identified when the treated and
untreated MG1655 transcriptomes results were compared using stringent criteria. However,
variation among the three untreated MG1655 samples may affect the sensitivity to changes in
gene expression. Indeed, if we eliminate one outlying untreated MG1655 from the analysis, a
single gene (thrL) is significantly upregulated upon CRAMP exposure, based on the p-value
alone. This gene encodes a 21 aa peptide that controls expression of the thrLABC operon, an
operon encoding four of the five threonine biosynthesis enzymes [33, 56, 57]. As MG1655 cells
are dying at this treatment dose, the upregulation of thrL may represent a limited and futile stress
response to slow the metabolism of the cells as a mechanism of waiting for conditions to
improve. It should be noted that the FDR ratios for all genes identified in the MG1655 analysis
are fairly high, and therefore confirmatory qRT-PCR should be done before moving forward
with additional experiments. Future experiments could use genetic tools to manipulate the
expression of the differentially regulated UTI89 genes within MG1655 cells before treatment
with sub-lethal CRAMP. It is possible that the pathways can function in both cell types to
mediate the growth phenotype, but that MG1655 cells normally are unable to detect the CRAMP,
or to activate the adaptive pathways.
Finally, the RNA sequencing results for both strains were initially aligned to the
published MG1655 genome before the different treatment groups were compared. Analysis of
the data generated by this alignment indicated that close to 90% of the genes were differentially
regulated in UTI89 in response to CRAMP. The sequencing data were re-aligned to the cognate
genomes for the analysis presented here. However, our initial results underline the importance of
using robust reference genomes for analysis of sequencing data, and how there can be vast
differences among strains within the same species. UTI89 and MG1655 are very divergent
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strains, and MG1655 may not be the best model strain to use in representing non-pathogenic
strain E. coli. We have access to a collection that contains strains from acute UTI, recurrent
infections, asymptomatic bacteriuria, and pyelonephritis. It would be interesting to repeat these
studies with a more closely related non-pathogenic strain, other UPEC strains (both cystitis- and
pyelonephritis-causing strains), or fecal isolates.
Together, though our results do not identify UPEC-specific genes that are important for
responding to cathelicidin in the environment, our data do reveal a distinct UPEC gene
expression response to cathelicidin. It is possible that downstream post-translational
modifications further affect this transcriptional response [58]. Future experiments will explore
whether cathelicidin AMPs can serve as a source of amino acids for rapidly growing bacteria in
culture, especially under conditions in which other nutrients are limited or absent. This work can
be expanded to determine if UPEC can also sense and utilize other cationic AMPs. We will also
work to ascertain the role of each differentially-regulated gene in the growth phenotype. We can
test our mutants in an in vivo model of UTI to determine if the identified genes have direct
effects on pathogenesis. AMP-deficient strains of mice have been created, which would allow us
to determine the extent to which cathelicidin influences the phenotypes. The individual mutants
will be used in these experiments, but it may also be necessary to look at full operon mutants,
and to test these strains under more limiting conditions. We can also examine a strain that is
mutant for all of the transporters to determine if uptake of the AMP is necessary for the growth
phenotype. Completion of this work will provide insight into the mechanisms utilized by UPEC
to persist in the hostile environment of the urinary tract, and may inspire the creation of new
antimicrobials that can be used to treat UTI.
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Figure 1: The murine cathelicidin CRAMP is effective against UTI89 and MG1655 in vitro.
Overnight cultures of UTI89 (green) and MG1655 (blue) are susceptible to killing by CRAMP in
a dose-dependent manner. Average percent survival at each concentration is shown (± SEM);
**** p < 0.0001. Each concentration was tested in triplicate, and the experiment was repeated
three times.
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Figure 2: UPEC treated with 1 µg/mL CRAMP have increased growth relative to untreated
samples. Hourly aliquots of samples grown in LB Luria were treated with CRAMP and plated to
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determine survival. UTI89 (A) and MG1655 (B) were untreated (0) or treated with 1 or 5 µg/mL
CRAMP. Average percent survival with SEM is shown. The experiment was repeated three
times. (C) UTI89 and MG1655 grown to OD600 = 0.5 in LB Luria and treated with LL-37 (1 or 5
µg/mL) or untreated (0). Average percent survival with SEM is shown. The experiment was
repeated three times.
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Figure 3: Samples prepared for RNAseq have expected survival profiles and reveal three
categories of differentially regulated genes. (A) Survival after treatment was determined by
plating an aliquot of the sample before RNA was isolated for RNA sequencing. The average of
the three sets of treatments, along with the SEM, is shown. (B) Schematic representation of the
major functional groups of the differentially regulated genes from 1 µg/mL-treated UTI89
samples. Genes encoding inner and outer membrane transporters are shown in purple (42%),
genes encoding proteins involved in metabolism are shown in teal (50%), and one gene of
unknown function is shown in blue (8%).
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Table 1: Differentially regulated genes in UTI89 treated with 1 µg/mL CRAMP
Gene name
aceA
dppB

Putative functiona
isocitrate lyase
dipeptide transporter permease B

P value
3.67E-06
2.44E-06

FDR
0.015033
0.002994

log FC
0.30387
0.33431

dppC
fumC
gatY
glcD
lamB
malK

dipeptide transporter permease C
fumarate hydratase
fructose-1,6-bisphosphate aldolase
glycolate oxidase subunit
maltoporin
maltose ABC transporter
ATP-binding protein

7.71E-06
7.31E-05
1.11E-06
1.38E-04
7.58E-06
1.48E-04

0.005681
0.026907
0.002994
0.045472
0.005681
0.045472

0.35681
0.35309
0.97178
0.37146
0.40872
0.33396

oligopeptide transport system permease
2.18E-05
γ-aminobutyraldehyde dehydrogenase
2.98E-05
bifunctional
UDP-glucuronic
acid 1.94E-05
decarboxylase/UDP-4-amino-4-deoxy-Larabinose formyltransferase
yfbH
hypothetical protein
2.31E-06
a
Putative function identified in the E. coli database Ecocyc[33]

0.011487
0.013726
0.011487

0.36851
0.3368
0.36143

0.002994

0.43178

oppC
ydcW
yfbG

115

Table 2: Primers used to create single gene mutants in UTI89
Primer
Primer sequence (5’-3’)#
name
TATGTTGCAGTTTATTCTCCGACGTTTGGGACTCGTGTGTAGGCTGGAGCTGCTTC
dppB-F
TTACTTCTTATGACGAATACGCGGGTTCACCATATGAATATCCTCCTTAG
dppB-R
ATGTCACAGGTTACTGAAAATAAAGTGATTAGCGGTGTAGGCTGGAGCTGCTTC
dppC-F
TTACTGCTTCAGTTTGGGATCGAGCGCGTCACATATGAATATCCTCCTTAG
dppC-R
TGAGGAGCAGGCCATGAATACAGTACGCAGCGAAAAGTGTAGGCTGGAGCTGCTTC
fumC-F
TTTCATACTGCCGACCATCTGTTCTGGCCGTACATATGAATATCCTCCTTAG
fumC-R
ATGTACGTGGTATCGACAAAGCAGATGCTGGTGTAGGCTGGAGCTGCTTC
gatY-F
TTATGCCCTGCCCTCGCAGCCACAATCGGCAATCACTTTCATATGAATATCCTCCTTAG
gatY-R
ATGAGCATCTTGTACGAAGAGCGTCTTGATGTGTAGGCTGGAGCTGCTTC
glcD-F
TCAGAAACGCTCCAGTTCAGGAAAAGGTAACATATGAATATCCTCCTTAG
glcD-R
GTGGAGGATTTAAGCCATCTCCTGATGACGCATAGTGTGTAGGCTGGAGCTGCTTC
malK-F
TTAAACGCCCGGCTCCTTATGCAGTCGACGACATGCCATATGAATATCCTCCTTAG
malK-R
ATGATGTTAAGTAAGAAAAACAGCGAGACGGTGTAGGCTGGAGCTGCTTC
oppC-F
TTAACGATCTTTCGGGTCGAGGGCATCACGCAACATATGAATATCCTCCTTAG
oppC-R
ATGCAACATAAGTTACTGATTAACGGAGAACGTGTAGGCTGGAGCTGCTTC
ydcW-F
TTAATGTTTAACCATGACGTGGCGGACGACAGTGTACATATGAATATCCTCCTTAG
ydcW-R
ACCGTCGTTTTTGCCTACCACGATATGGGATGCGTGTAGGCTGGAGCTGCTTC
yfbG-F
TGGTTTATCCGTAAGATCAACGGTGCGCAGGAAGAACATATGAATATCCTCCTTAG
yfbG-R
AAAGTCGGCTTACGCATTGATGTCGATACCTTTCGTGTGTAGGCTGGAGCTGCTTC
yfbH-F
AATTTGTTGGCAACCCAGCCAGCCTTCACGTCATATGAATATCCTCCTTAG
yfbH-R
#
Homology to chloramphenicol cassette is bolded
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Table 3: Primers used to confirm allelic replacement (flanking primers)
Forward primer (5’-3’)

Reverse primer (5’-3’)

dppB

AATACAGACACGCAGTTCCA

AAATAGTGCCAGAACTCCTGTA

Expected
product if no
insert (bp)
1156

dppC

ATGATTATCCTCGTCAACTTGC

CCGAAATGCACCGATAATTTAT

1038

fumC

TACATGGCACGAAAGACCAA

ACAATGTGCAGCACCGTTAT

1597

gatY

GCCTTTCATTCCTGGATTGATT

CTTTATGCCGGGCAATTAAC

1027

glcD

GCTTAATAACTGTTCACAGAAGC

TTTATCGCTAATCGCCTGATTC

1637

malK

TACATGACCTCGGTTTAGTTCA

CTATCTCCTGAGTCATTGCTT

1350

oppC

GATGTGCTATATGCGGTTATC

AATCTTTCACGTTCAGCAGTG

1049

ydcW

GAAGGCGACAATGGTCAATAA

CAGTACGCAAGATCATCTCAT

1493

yfbG

TTGTTCAGCAAGTTATCCGTC

ATGCTTACTCAAGATTTCCAGC

2112

yfbH

GATATGCAGGAAACCATCGAC

GCAGGCAATAAATGCGAAGAG

1009

pCAT

GCGGCATCAGCACCTTGTCG

CGACAAGGTGCTGATGCCGC

N/A
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Figure 4: Single mutants have normal growth in rich media, and do not display altered
CRAMP susceptibility. (A) Single-gene disruptions of the twelve identified genes were created
in the UTI89 background. Growth in LB Miller was determined by measuring the OD600 of
cultures every 30 min for 10 h. A representative plot is shown. The experiment was repeated
three times. (B) Sub-cultured samples of MG1655, UTI89, or the single mutants were treated
with 0 or 1 µg/mL CRAMP in triplicate and plated to determine survival. This experiment has
been done once. Average survival and SEM are shown for each strain.
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CHAPTER FIVE
CONCLUDING REMARKS AND FUTURE DIRECTIONS

The overarching goal of this work was to expand our knowledge of host-pathogen
interactions within the context of urinary tract infections. We chose to focus on components of
the uropathogenic Escherichia coli (UPEC) outer membrane and on a host peptide (cathelicidin)
produced by the innate immune system. The UPEC OmpA protein is highly represented in the
outer membrane and evolutionarily conserved, but is not essential for the bacterium. We find that
the extracellular loops of OmpA play specific roles in fostering infection in the urinary tract.
Other outer membrane proteins, as well as outer membrane vesicles, may also influence the
progression of UPEC infection. Work with human and murine cathelicidin has demonstrated that
this peptide regulates the uroepithelium and promotes the innate immune response, more
prominently than in its function as an antimicrobial. Furthermore, UPEC are specifically able to
respond to the presence of cathelicidins, adaptation which may encourage the establishment of
infection. This work has uncovered many interesting findings, and has unveiled exciting new
directions for the UPEC field.

Extracellular loops of UPEC OmpA enhance binding to the uroepithelium
The OmpA protein is highly expressed in the outer membrane of E. coli, but its
expression is also tightly regulated [1]. The protein is composed of an N-terminal β-barrel, with
eight transmembrane domains that form four extracellular loops and three short periplasmic
turns, as well as a large C-terminal periplasmic domain with peptidoglycan-binding properties [1,
2]. The conservation of OmpA throughout E. coli species suggests that the protein may play
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roles in many settings. This idea is supported by data showing that OmpA is active in
conjugation, biofilm formation, as an adhesin, and as an immune evasin, but also has roles in
bacteriocin binding and immune recognition [1, 3]. Of note, OmpA is also required for
propagation of chronic infection in the urinary tract of C3H/HeN mice [4]. We sought to
investigate the role of OmpA in a model of acute bladder infection in C57Bl/6 mice, and to
characterize the functions of the extracellular loops during infection.
When matched groups of C57Bl/6 mice were infected with UTI89 and UTI89ΔompA, the
OmpA mutant strain yielded significantly lower bladder titers 24 hpi. To determine if the
extracellular loops of OmpA are affecting this phenotype, we created individual loop mutants
and complemented the full-length ompA knock-out (KO) with these plasmids. The loop mutant
proteins all localize to the outer membrane and do not affect growth, permeability, or type 1 pili
expression. However, we find that a LP 2 KO is attenuated in our murine model of infection, and
results in a level of infection similar to that of the full-length mutant. The LP 2 KO cannot forms
IBCs, and binding and invasion assays with human bladder epithelial cells (HBECs) indicate that
the LP 2 KO binds and invades significantly worse than UTI89 or the ompA mutant. Most
interestingly, the LP 2 KO phenotype is dominant over native OmpA, as a UTI89 strain
simultaneously expressing the LP 2 KO phenocopies the LP 2 KO. The defect was not
attributable to the presence of the complementing plasmid, as UTI89/pACYC184 did not have
altered binding or invasion (Figure 1A, B). Further, episomal expression of the LP 1 mutant in
UTI89 does not alter the binding and invasion (Figure 1A, B). We do not yet have conclusive
evidence explaining why the LP 2 KO phenotype is even more notable than that of the fulllength mutant. Global approaches, such as proteomics of the outer membrane, could help to
determine if other proteins are affected in the mutant strains.
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Work in other infection models has identified a specific binding partner of OmpA on the
surface of host cells and has established that the loops of OmpA can individually affect the
function of the protein. OmpA was shown to bind specifically to a glycoprotein known as Ecgp
expressed by human brain microvascular endothelial cells (HBMECs) [5]. After the initial
binding of type 1 pili bind to the surface of the cells, OmpA binds to Ecgp and promotes
bacterial cell invasion [6, 7]. Similarly, outer membrane vesicles from adherent-invasive E. coli
that contain OmpA have been shown to interact with Ecgp on the surface of ileal epithelial cells
and promote invasion of the bacteria [8]. We will determine if Ecgp is expressed in HBECs and
in mouse bladder tissue. Immunohistochemistry in human bladder cancer tissue suggests that this
protein is indeed expressed in bladder uroepithelium [9]. Prasadarao et al showed that after
initial binding to NMEC to HBMECs, nitric oxide production triggers increased expression of in
HBMECs, further facilitating uptake of the bacteria [10]. Knowing this, we will also use
confocal microscopy and cellular fractionation to determine if the localization of Ecgp
expression in HBECs is altered upon interaction with UPEC. We will use the individual loop
mutants to explore the effects of loop mutation on Ecgp interaction. However, Ecgp may not
interact with OmpA in this system; therefore, we will use parallel approaches with purified
OmpA protein to identify other host cell molecules that can directly interact with OmpA.
Preliminary work with individual loop 3 and 4 OmpA knock-outs suggests that these
loops also contribute to in vivo phenotypes. Both of these strains yielded significantly lower
bladder titers 24 hpi in the murine model of cystitis. The LP 3 KO is recovered at levels similar
to the LP 2 KO, while the majority of mice have cleared the LP 4 KO from the bladder at 24 hpi
(titers < 104) (Figure 2A). However, mature IBCs can be detected by confocal microscopy 16
hpi in the bladders of mice infected with either of these strains (Figure 2B). This was
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particularly surprising, as enumeration of IBCs by lacZ stain indicates that very few IBCs are
found in the bladders of mice infected with the LP 4 KO (Figure 2C). The difference in numbers
of IBCs found in LP 4 KO-infected bladders is not statistically significant, but a low number of
mice have been examined thus far. Mice infected with the LP 3 KO demonstrate IBC formation
approximately the same as both ΔompA-infected mice or LP 1 KO-infected mice (Figure 2C and
data not shown). In a binding and invasion assay with UTI89 complemented with the LP 3 KO
and LP 4 KO plasmids, both UTI89/LP 3 KO and UTI89/LP 4 KO bound less avidly than
UTI89, but only UTI89/LP 4 KO bound less well than the plasmid control (Figure 3A).
UTI89/LP 3 KO invaded as well as the parent strains, while UTI89/LP 4 KO actually invaded
better than the parent strains (Figure 3B). When considered together, the binding defect in the
LP 3 KO likely accounts for the lower titers observed in the bladders of mice 24 hpi.
As there is not a strict relationship among ability to form IBCs, rate of IBC formation,
and bladder titers 24 hpi, further experiments should explore the differences in these loop
mutants. OmpA has previously been shown to play a role in resisting the killing effects of
complement [11]. Differences in the ability of loop mutant cells to resist the innate immune
system while exposed in the lumen of the bladder (e.g., during the fluxing and reinfection stages
of the IBC cycle) could account for the inability of LP 4 KO bacteria to cause a robust infection.
Experiments that quantify the susceptibility of these strains to killing after exposure to serum can
help clarify if complement resistance is indeed critical for propagation of infection during
cystitis. Additionally, a number of experiments, such as the growth, fractionation, and pili
expression assays done with the other loop mutants, must first be completed in order to ensure
that the mutations do not result in a confounding phenotype. Interestingly, the LP 4 KO has
slightly decreased outer membrane permeability, relative to the wild-type and OmpA mutant
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strains (Figure 4). The diminished binding likely contributes to the lower bladder titers and lack
of IBC formation with LP 4 KO bacteria, but decreased membrane permeability could affect
nutrient acquisition and growth.
Finally, it would also be interesting to compare the sequences of OmpA proteins that
have been isolated from various niches within the urinary tract, including the urines of patients
with cystitis or pyelonephritis, the blood of sepsis patients, and commensal fecal strains. These
data could give us further clues about the roles that OmpA extracellular loops play in promoting
infection within one or more of these niches, which would be used to inform our future studies.
To our knowledge, this idea has not been examined in E. coli, let alone in UPEC, although
studies in Pasteurella indicate that the loops can vary in a host-specific manner [12]. We have
also begun to compile a library of mutants that contain two or more loop knock-outs.
Downstream studies with these strains may help elucidate whether interactions involving
multiple specific loops are required for normal function of OmpA in this system. We plan to
continue our work revealing the roles that the individual loops of OmpA play during UPEC UTI.

Involvement of other outer membrane proteins during infection
OmpA is one example of an outer membrane protein that can allow UPEC to interact
with the host milieu during infection. The outer membrane protease OmpT is potentially another
mechanism through which UPEC can modulate the extracellular environment and promote
infection by resisting the killing effects of AMPs. OmpT is composed of ten antiparallel β-sheets
that form five long, extracellular loops and four short periplasmic turns [13]. The protein
recognizes specific sequences of charged residues and cleaves between them [14]. The amino
acid sequence must include two consecutive basic residues: two lysines, two arginines, or a
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lysine with an arginine, with flexibility outside of the cleavage site. Enterohemorrhagic E. coli
(EHEC) and enteropathogenic E. coli (EPEC) can cleave the α-helical antimicrobial peptides
C18G and LL-37 in an OmpT-dependent manner [15]. ompT mutants in these strains have
decreased peptide resistance in vitro, likely due to the inactivity of the protease [15]. In addition
to the proteolytic cleavage of AMPs, OmpT has been reported to modulate outer membrane
vesicle (OMV) biogenesis in the EHEC strain EDL933 through an unknown mechanism [16].
OMVs isolated from ompT mutant EHEC have different lipid and protein profiles when
compared to wild-type OMVs, which may indicate that OmpT plays a role in the regulation of
bacterial molecules that are packaged in OMVs [16]. The proteins included or excluded from
those OMVs could also be affecting the AMP resistance phenotype.
E. coli OmpT was first suggested as a putative virulence factor in 1992 when Lundrigan
and Webb identified OmpT in over 50% of E. coli clinical isolates, including 73-76% of
genitourinary and urine isolates [17]. Later, ompT was found in 83-94% of UTI isolates,
including first, second, and recurrent UTIs, as wells pyelonephritis strains [18]. A similar study
in Japan examined the expression of multiple factors in cystitis and pyelonephritis-derived E.
coli isolates and found that ompT was encoded in over 90% of cystitis and pyelonephritis
isolates, nearly double the prevalence of the gene in stool isolates [19]. OmpT is expressed in the
outer membrane of our prototypical cystitis isolate UTI89. This gene is not essential as a knockout strain did not display a growth defect (data not shown). Proteolytic cleavage of cationic
peptides isolated from the urine, mostly thought to be α- and β-defensins, can be mediated by
OmpT in E. coli K1 strains, but had not been investigated in UPEC [20, 21]. Therefore, we
sought to determine the effects of UPEC OmpT on cathelicidin resistance in vitro and on the
progression of infection in vivo.
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To determine if the OmpT encoded by UTI89 has proteolytic activity against cationic
AMPs, live bacterial cells were incubated with biotin-labelled CRAMP or LL-37 for up to an
hour in PBS. At designated time points, the samples were centrifuged to pellet the bacterial cells,
and the supernatant was run on 15% SDS-PAGE gels. The AMPs were detected by immunoblot.
The positive control EHEC strain EDL933 cleaves the 4 kDa AMP, resulting in a band ~2 kDA
in size. The intensity of this band increases over time (Figure 5). Similarly, UTI89 can also
cleave cationic AMPs, but this is dependent on expression of OmpT as UTI89 ompT::cat does
not cleave these peptides (Figure 5). We find that UTI89 OmpT is equally active against LL-37
and CRAMP in vitro (Figure 5 and data not shown). We were therefore surprised to find that the
OmpT mutant was not more susceptible to killing by CRAMP when exposed to varying
concentrations of this peptide in vitro. Specifically, UTI89 ompT::cat was equivalently
susceptible to killing by CRAMP as UTI89 at concentrations ranging from 1 to 20 µg/mL
(Figure 6). A recently published paper also found that OmpT in the pyelonephritis-derived strain
CFT073 can cleave LL-37 in vitro [22]. The mutation of ompT in CFT073 also did not affect LL37 resistance in vitro [22].
Based on our in vitro results, we were curious if OmpT activity affects virulence in our
murine model of UTI. We infected C3H/HeN mice with either UTI89 or UTI89 ompT::cat. We
quantified bladder and kidney titers 1, 6, and 24 hpi, as well as 2 wpi, but did not find any
significant differences in the bacterial load in these organs (Figure 7). Preliminary results in
C57Bl/6 also do not indicate a difference in bladder bacterial load 24 hpi (data not shown).
These data indicate that although OmpT can function to cleave AMPs such as CRAMP and LL37 in vitro, this mechanism is not critical for bacterial survival within the murine urinary tract.
As suggested by the data presented in Chapter 3, the cathelicidin in the urinary tract may not be
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sufficiently high to cause bacterial killing; it is possible that OmpT would be more important for
propagating infection if the concentration of AMPs in the urinary tract were higher.
Additionally, it is likely that the context in which OmpT is expressed is also important.
He et al recently demonstrated that CFT073 ompT::kan causes limited infection in C567Bl/6
mice at 12 hpi [23]. This strain is also more susceptible to protamine and cannot bind or invade
5637 cells as well as the parent strain or a complemented mutant even though type 1 pili
expression is not altered [23]. It is important to note that a 10-fold higher inoculum dose was
used for these infections. While these data are interesting, we believe that our data provide a
more accurate representation of the reality of AMP resistance within the urinary tract. We have
shown that outer membrane proteins (e.g., OmpT) can have demonstrated roles in vitro, but these
roles do not necessarily translate to valid functions during infection. It is likely that many other
UPEC outer membrane proteins will have minimal effects in vivo, even if an in vitro function
can be demonstrated. These data provide a valuable lesson in studying both in vitro functions of
proteins as well as the effects within the context of a whole animal infection.

Outer membrane vesicles and infection
As the outer membrane is a dynamic interface that is important for the promotion of
infection, we hypothesized that outer membrane vesicles could also be involved in UPEC
infection of the urinary tract. Outer membrane vesicles (OMVs) are small (10-200 nm) vesicles
that are formed when portions of the outer membrane pinch off and are liberated from Gramnegative bacteria [24, 25]. The precise molecular mechanism behind this process is not well
understood, but weakened connections between the outer membrane and peptidoglycan likely
contribute to OMV release [25]. In the context of infection, OMVs can aid the bacteria by
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delivering toxins to host cells, increasing the reach of antimicrobial resistance mechanisms (like
proteases), and by functioning as decoys [26]. However, these structures also display PAMPs
such as OmpA, LPS, and pili, which can alert the host to the presence of the bacterium. We
believe that isolated OMVs might therefore function as an excellent natural vaccine, if an
immunizing response is in fact generated in the bladder. To explore that idea further, we first
needed to understand the role of OMVs during UTI.
We began by creating UTI89 mutants that had disruptions in genes that have been shown
to increase or decrease OMV production. Genes were selected based on previous transposonmediated studies in DH5α E. coli [27, 28]. Mutations in degP, degS, ompR, and yieM should
result in hyper-vesiculating strains, while mutations in pepP and glnA should result in hypovesiculating strains [27]. To confirm the vesiculation phenotypes, we isolated OMVs from
overnight cultures by removing whole cells through centrifugation and filtration, and then
concentrating OMVs from the supernatant through ultra-centrifugation (Figure 8A). As some
loose contaminants (e.g., pilus fragments) could be identified by electron microscopy, we further
purified some samples using a density gradient (Figure 8B, C). Silver-stained SDS-PAGE gels
allowed us to compare the protein profiles of the isolated OMVs, and we were able to
approximate changes in OMV production in vesiculation mutants by performing densitometric
analyses of major proteins (Figure 8D). We created two hypervesiculating mutants and a
hypovesiculating mutant in UTI89 by mutating previously identified genes [27]. When we
isolated the OMVs from cultures of the same size, we found that the mutant strains did have
altered OMV production (Figure 8D).
A recent summer student characterized the effects of degS mutation on in vitro and in
vivo infection [29]. The DegS protein is an inner membrane protein that functions to degrade
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incorrectly folded proteins in the periplasm [30-32]. UTI89 degS::cat has a minor growth defect,
but pili production and outer membrane integrity are not compromised [29]. This mutant does
produce significantly more OMVs, and there are pronounced differences in the protein content of
OMVs from wild-type and degS mutant bacteria (Figure 3 from Bradley and Danka reproduced
as Figure 9) [29]. The increased OMV production is likely due to an accumulation of misfolded
proteins within the periplasm. In this instance, production of OMVs would be functioning to rid
the cells of unwanted proteins. These proteins are packaged into the OMVs, and are not observed
as corresponding to bands in wild-type OMVs when compared by silver-stained gel.
Complementation of the mutant in trans fully restores wild-type phenotypes [29]. When used in
a mouse model of UTI, the degS mutant reaches significantly lower bacterial titers in the bladder
24 hpi even though early and mature IBCs can be identified through confocal microscopy
(Figures 6 and 7 from Bradley and Danka adapted as Figure 10A, B) [29]. Most interesting,
when compared in an in vitro binding and invasion assay with 5637 human bladder endothelial
cells, invasion by the mutant is significantly lower than by the wild-type strain (Figure 8 from
Bradley and Danka modified as Figure 11) [29]. The mechanism behind this reduced invasion
phenotype is currently unknown. Future experiments will explore the pathways that may be
affected by degS mutation or OMV overproduction. However, it is important to note that deletion
of this protein altered the number of OMVs produced as well as the composition of those OMVs.
With DegS as an example, we conclude that hypo- or hyper-vesiculating mutations are
altering more than just the quantity of OMVs produced such that it is difficult to separate the
contribution of OMV quantity from other effects of the mutated gene. Thus, future experiments
will employ add-backs of purified OMVs, either alone or in combination with UPEC, to
specifically address the role of OMVs during the development of UTI.
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We performed preliminary experiments to examine how long OMVs (and the proteins
contained within them) would remain in the bladders of mice. OMVs were delivered to the
bladders of mice transurethrally at time 0 and again after 3 h. The mice were sacrificed at 3, 6 or
24 h after inoculation. Urine was collected prior to inoculation, prior to sacrifice, and at time
points between delivery and sacrifice. Immunoblots specific to the FimH adhesin of type 1 pili,
OmpA, and the cytoplasmic chaperone protein GroEL (which is often present in our OMV
preparations) were used to probe for bacterial protein presence in the bladder. We were surprised
to find that GroEL can be detected in the tissue homogenates up to 24 h after inoculation (data
not shown). We did not detect OmpA or FimH within the tissues. As GroEL primarily functions
as a chaperone, its ability to bind a wide range of proteins may facilitate its persistence in the
bladder. Immunoblotting of the collected urines did not detect any of these proteins, which was
not surprising as the OMVs would be highly diluted within the urine. While these experiments
certainly need to be repeated, the data suggest that some OMV-associated proteins may remain
in the bladder for a period of time after delivery. Future experiments will specifically determine
how long OMVs can remain in the bladder, whether the presence of OMVs triggers an innate
immune response (perhaps preparing the host for subsequent infection), and if an adaptive
immune response can be elicited by OMVs.

CRAMP modulates epithelial receptivity and immune function during UTI
The human and murine cathelicidins LL-37 and CRAMP (respectively) have long been
thought to be important for proper defense of the urinary tract [33-35]. Multiple groups have
shown that these peptides can be found in the urines of child and adult patients with UTI, and
that the expression of these peptides increases after bacterial exposure [36, 37]. However,
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previous studies with UPEC strains left many unanswered questions. Using CRAMP-deficient
mice in the C57Bl/6 background, we began to characterize the role of CRAMP in the
development of, and subsequent response to, cystitis. We first confirmed the antimicrobial
effects of CRAMP against UTI89 using multiple concentrations of CRAMP in an in vitro assay
before characterizing the course of infection in wild-type and CRAMP-deficient mice [38].
When CRAMP-deficient mice are infected with UTI89, the bladder bacterial titers are
significantly lower than those of infected wild-type C57Bl/6 mice at all examined acute time
points (1 hpi-48 hpi) [38]. Although IBCs are formed in CRAMP-deficient mice, significantly
fewer occur in the bladders of these mice. In vivo binding and invasion assays determined that
CRAMP-deficient mice have significantly fewer bacteria bound in the lumen of the bladder, and
the urines of these mice contain more bacteria [38]. However, the binding defect does not appear
to be due to changes in the piliation state of the bacteria [38]. Uninfected CRAMP-deficient mice
do not seem to have changes in uroplakin quantity or localization, or in the immune state of the
bladder, as determined by a bead-based 23-plex cytokine array and by quantification of
myeloperoxidase (MPO; used to approximate neutrophil presence) in uninfected bladder
homogenates [38]. Additionally, there does not seem to be increased cAMP in the bladders of
CRAMP-deficient mice immediately after infection, which would lead to internalized bacteria
being expelled at a higher rate [38]. We conclude from this data that CRAMP is essential for
normal maintenance of the bladder uroepithelium, and that changes in the uroepithelium result in
decreased bacterial binding to the bladders of CRAMP-deficient mice.
As CRAMP is also though to stimulate the innate immune response, we quantified
cytokine levels and neutrophil influx in the bladders of wild-type and CRAMP-deficient mice 6
and 24 hpi. We found significantly higher expression of 16 of the 23 measured cytokines, and
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higher levels of MPO, in the bladders of wild-type mice 6 hpi [38]. Visual inspection of H&Estained bladder sections supported a more robust immune response in wild-type mice 6 hpi. By
24 hpi, the bladders of CRAMP-deficient mice exhibited very little remaining edema, and had
mostly restored their uroepithelial cells [38]. These data suggest that CRAMP is important for
amplifying the immune response early during infection. Furthermore, the bladder histology
demonstrates the detrimental and long-lasting effects of bladder tissue damage caused by a
robust immune response, and the amount of time needed to recover from such a serious insult.
We quantified uroplakin expression within the bladder at multiple time points in order to
examine recovery of the uroepithelium. We found that CRAMP-deficient mice fully restored
their epithelium by 48 hpi, while wild-type mice still displayed persistent exfoliation at this time
point [38]. Taken together, our data support a role for CRAMP in maintaining the normal
uroepithelial surface and in the promotion of an immune response, but do not support a
prominent antimicrobial function for CRAMP in the urinary tract.
We began to address whether CRAMP is playing an important role as a driver of the
immune response in this system by comparing the cytokine content of bladders with more similar
bacterial loads. Although low numbers of mice were used in these comparisons – due to the
disparity in bladder titers – we generally found that wild-type mice had higher cytokine loads
than CRAMP-deficient mice 6 hpi (data not shown). We believe that such a comparison could be
informative, but many more infections would be needed to obtain significant numbers of mice
with similar bladder titers. Of note, recent literature suggests that the “other” functions of many
AMPs may be more important than their antimicrobial activities. For example, the peptide
hepcidin was originally described as an antimicrobial peptide but has since been shown to
regulate iron by limiting export of iron through ferroportin [39, 40].
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It is still unknown why binding is disrupted in the CRAMP-deficient host. We were
unable to overcome the block in the establishment of infection by using a higher inoculum (data
not shown). However, with two other UPEC strains, CFT073 or NU14, or with UTI89 fimH::kan
cells, levels of infection were more similar between wild-type and CRAMP-deficient mice (data
not shown). These data suggested that the specific interaction between type 1 pili and the bladder
uroepithelium may be disrupted, but that other mechanisms of infection are intact. In an attempt
to determine if the uroplakin proteins are expressed on the luminal membrane of mutant host
cells, wild-type and mutant bladders were examined by scanning electron microscopy (SEM).
The bladders of C57Bl/6 mice have uroepithelial cells with defined cell borders and a wrinkled
surface (Figure 12A, B). We were surprised to find that the bladders of CRAMP-deficient mice
appeared to bear a coating of an unidentified substance (Figure 12C). This apparent coating
obscured the borders between cells as well as the wrinkled appearance of the surface of the cells
(Figure 12C). Where epithelial cells have been naturally or mechanically exfoliated, smaller
cells with less-defined shapes can be seen underneath the epithelial layers (Figure 12D).
However, this coating did not seem very thick and appeared to have been disrupted during
processing of the tissue in several places. The epithelial cells underneath the coating have a
wrinkled appearance, similar to that observed in wild-type bladders (Figure 12E, F). These data
suggest a physical disruption in binding could account for the lower levels of infection seen in
CRAMP-deficient mice.
Currently, the make-up of the coating seen on the surface of the bladders of CRAMPdeficient mice is unknown. It is possible that the charged nature of cathelicidin prevents another
charged substance from interacting with and coating the surface of uroepithelial cells. Some
groups have shown that cathelicidin can be internalized and affect gene expression; in this
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system, cathelicidin might be downregulating the expression of a molecule that would otherwise
coat the surface of the bladder. Regardless of the mechanism, we suspect that CRAMP
expression is important for maintaining normal uroepithelial expression in the bladder. Future
experiments will confirm this intriguing finding, then focus on identifying the composition of the
coating on the uroepithelial cells, and describing the mechanism through which cathelicidin
regulates the presence of this coating.

RNA sequencing reveals specific upregulation of genes after UPEC exposure to CRAMP
Cathelicidins are constitutively expressed at low levels by the epithelial cells that line
many organs in the body [33]. It is therefore likely that bacteria are routinely exposed to sublethal concentrations of these AMPs before, during, and after causing a robust infection. Data
from other fields suggest that many AMPs can be playing alternative roles within the body at
concentrations below those required to kill bacteria [41-43]. While this idea opens new fields of
research into the regulation of host systems, it is unknown how these low concentrations of
AMPs affect potentially pathogenic bacteria. We sought to determine if UPEC can recognize the
presence of sub-lethal cathelicidin in their environment, and if they generate a response to the
peptide upon detection. While we expected that the bacteria to upregulate pathways that would
function as defense against the AMPs, we instead found that the bacteria increase expression of
peptide transporters and genes involved in metabolism.
We initially found that UTI89, but not MG1655, can grow in response to 1 µg/mL
cathelicidin when treated in early- to mid-log phase. The bacteria used in these experiments were
grown in media with lower salt concentrations (0.5 g/L NaCl vs 10 g/L NaCl) to mimic the
limiting environment of the urinary tract. Untreated and treated samples of UTI89 and MG1655
139

were prepared for RNA sequencing to analyze the global effects of CRAMP treatment.
Alignment of the resulting reads to the respective genomes demonstrated that there was excellent
coverage, and that the samples could be grouped by treatment (data not shown). Our results
indicated that UTI89 cells treated with 1 µg/mL CRAMP differentially regulated twelve genes.
Of these genes, five represented membrane-associated peptide or small molecule transporters, six
were involved in a metabolic pathway, and one is a hypothetical protein of unknown function.
We hypothesize that this indicates that UTI89 are indeed able to detect the presence of CRAMP
in their environment and then upregulate pathways to take up this peptide, and potentially break
it down for use as individual amino acids. UTI89 cells that had been treated with 3 µg/mL
CRAMP experienced increased cell death relative to the 1 µg/mL treatment, and this was
reflected in the differential regulation of nearly 1000 genes. It is likely that this massive response
represents a chaotic final attempt to prevent cell death. MG1655 cells did not generate a specific
response to CRAMP exposure.
We were able to create individual mutants in UTI89 for each of the identified genes using
linear recombination. Neighboring genes and nearby proteins within operons were not disrupted.
When the mutants were tested using our CRAMP-exposure experiment, we did not observe any
changes in CRAMP resistance and growth of these mutants. Although this will need to be
repeated, this result may indicate that there are redundant pathways that prevent a single mutant
from displaying a strong phenotype in this assay. Future experiments will treat cultures of UTI89
with labeled CRAMP, and analyze these cultures by mass spectrometry at various points posttreatment to specifically address whether CRAMP is taken up and/or degraded by UPEC. We
will also test our single mutants in our murine model of cystitis to determine if the genes play a
role in resistance to CRAMP upon introduction to the urinary tract, and if this affects the
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establishment of an infection. We may also need to develop other methods in order to thoroughly
assess the role of each gene in responding to CRAMP treatment.
Finally, these results might be connected to our earlier findings that less robust infections
occur in CRAMP-deficient mice. In these mice, the bacteria would not be exposed to sub-lethal
concentrations of CRAMP, which may function as a signal or as an alternative food source, and
may not increase their growth rate as rapidly as bacteria that are exposed to CRAMP. This
proportionally limited growth rate could in turn exacerbate the binding defect in these mice,
leading to much lower rates of infection. Future experiments will treat bacteria with low doses of
CRAMP before using these bacteria to infect mice, and will address the direct effects of CRAMP
on bacteria during infection.

Concluding remarks
The work presented here demonstrates that there are unique interactions occurring
between previously described UPEC factors and host immune factors during urinary tract
infection. Our findings did not necessarily mirror prior work from other fields and infection
models, and we therefore expand the breadth of knowledge of UPEC pathogenesis and the innate
immune system. New techniques were designed to study these interactions, and future
experiments can further augment the conclusions drawn from these data. We hope that these
studies will complement other studies that are investigating new UPEC virulence factors, the
innate and adaptive immune response to infection, changes in the uroepithelium during infection,
and more. Although much of this work addresses the mechanisms behind the basic biology that
occurs during UPEC infection, we believe that this work can help direct the development of new
clinical therapeutics. For example, as OmpA is highly conserved, we envision the design of
141

small-molecule therapeutics that block the specific UPEC OmpA loop-host receptor interaction
and could be used to treat UTIs. This is but one potential opportunity for downstream application
of the work presented in this dissertation.
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Tables and Figures

Figure 1: Binding and invasion of UTI89 are unaffected by empty vector or OmpA LP 1
KO expression. (A) Binding of UTI89, UTI89/pACYC184 (empty vector), or UTI89/pLP 1 KO
to 5637 cells was assessed in vitro. (B) Invasion into 5637 cells is shown as a percentage of the
bound bacterial cells. For binding and invasion at least three wells/bacterial strain were used for
each experiment, and the experiment was repeated three times. Mean and SEM are graphed for
each strain.
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Figure 2: UTI89 ΔompA/pLP 3 KO and UTI89 ΔompA/pLP 4 KO cause less severe
infections. (A) Bladder titers of C57Bl/6 mice 24 hpi after inoculation with the indicated strains.
Geometric mean is indicated by the horizontal bar and the limit of detection is shown by the
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dashed line. n = 9-10 mice/strain. (B) IBC structure in the bladders of mice inoculated with
UTI89 ΔompA/pLP 3 KO or UTI89 ΔompA/pLP 4 KO. Nuclei are stained red, bacteria are
expressing GFP. Representative images are shown. (C) Enumeration of IBCs 16 hpi as
determined by lacZ staining of bacteria within the bladder. n = 5-13 mice/strain. * p < 0.05, ** p
< 0.01, *** p < 0.0005
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Figure 3: Binding and invasion of UTI89/pLP 3 KO and UTI89/pLP 4 KO. (A) Binding of
UTI89 fimH::kan, UTI89, UTI89/pACYC184 (empty vector), UTI89/pLP 3 KO, or UTI89/pLP
4 KO to 5637 cells was assessed in vitro. (B) Invasion into 5637 cells is shown as a percentage
of the bound bacterial cells. For binding and invasion at least three wells/bacterial strain were
used for each experiment, and the experiment was repeated three times. Mean and SEM are
graphed for each strain. * p < 0.05, ** p < 0.01
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Figure 4: UTI89 ΔompA/pLP 4 KO has decreased membrane permeability. Outer membrane
permeability of UTI89 surA::kan, UTI89, UTI89 ΔompA, UTI89 ΔompA/pLP 3 KO, and UTI89
ΔompA/pLP 4 KO was assessed by disc diffusion using 30 µg novobiocin. The zone of inhibition
(including the disc) was measured for each strain. The experiment was repeated three times (2
discs/strain/experiment). Average and SEM are graphed for each strain.
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Figure 5: UPEC OmpT can cleave the cathelicidin LL-37. EHEC EDL 933, UTI89, UTI89
ΔompT were incubated with biotin-labelled LL-37 for up to 1 hr (0, 5, 15, 30, or 60 min samples
shown for each strain, left to right). Untreated biotin-LL-37 is shown at far left and is indicated
by black arrow. Presence of cleavage products was detected by separation on SDS-PAGE gel
and immunoblot against biotin. Cleavage products are denoted by black arrow and asterisk (*).
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Figure 6: UPEC OmpT is not required for cathelicidin resistance. UTI89 and UTI89 ΔompT
cells were incubated with 1, 5, or 20 µg/mL CRAMP in PBS for 2 hr at 37˚C. Percent survival
was determined relative to an untreated control. Mean and SEM are shown for each treatment.
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Figure 7: UTI89 ΔompT is not attenuated in a murine model of UTI. Age-matched C3H/HeN
mice were infected with UTI89 (black filled circles) or UTI89 ΔompT (open circles). Bladders
and kidneys (data not shown) were harvested 1, 6, or 24 hpi, or 2 wpi and the bacterial load was
determined by serial dilution and plating of organ homogenates. Geometric mean is indicated by
the horizontal bar and the dashed line shows the limit of detection. n = 4-10 mice/time point.
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Figure 8: OMVs can be cleanly purified from UPEC. (A) Protein profile of wild-type OMVs
on silver-stained SDS-PAGE gel after initial purification. Protein marker (M), UTI89 outer
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membrane prep (1) and UTI89 OMVs (2) are shown. (B) Negative-stained TEM image of UTI89
OMVs. (C) Density gradient fractions that contain OMVs can be identified on silver-stained
SDS-PAGE gel. Labelled lanes are: protein marker (M), OMV input, and density gradient
fractions 1-14. OMVs are concentrated in fractions 5-9. (D) Protein profile of OMVs from
UTI89 (U), degS::cat (dS; diluted 1:100), pepP::cat (pP), and yieM::cat (yM). Fold change of
vesicle production was approximated by ImageJ analysis of major outer membrane proteins.
Vesiculation (fold change) is shown relative to UTI89.
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Figure 9: OMVs from UTI89 degS::cat are more plentiful and are distinct in composition
from those of UTI89. (A) OMV-containing pellets of UTI89, UTI89 degS::cat, and UTI89
degS::cat/pDegS (left to right) vary in size. Pellets are circled in red. (B) Proteins in OMVs
isolated from UTI89, UTI89 degS::cat, and UTI89 degS::cat/pDegS were separated by SDSPAGE and silver-stained. Approximately equal amounts of protein were loaded. Lane 1 is a
protein marker, OMVs are in lanes 2-4 (UTI89 in lane 2, UTI89 degS::cat in lane 3, and UTI89
degS::cat/pDegS in lane 4). (Adapted from Figure 3 of Bradley and Danka, 2015)
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Figure 10: Deletion of degS decreases virulence of UTI89 in mice, but IBC formation is
unaffected. (A) UTI89 (circles) or UTI89 degS::cat (squares) were used to infect age-matched
C57Bl/6 mice. Bladders were harvested at 24 hpi and bacterial burdens were determined. 3
mice/strain were infected in three separate experiments. The geometric mean is indicated by the
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horizontal line. **** p < 0.0001 (B) Early (top row) and mature (bottom row) IBCs can be found
in the bladders of mice infected with UTI89/pcomGFP (left column) or UTI89 degS::cat (right
column). DNA is stained with the red dye Syto 61. IBCs are indicated with white arrows.
Representative pictures are shown. (Adapted from Figures 6 and 7 of Bradley and Danka)
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Figure 11: Binding is unaffected by degS mutation, but invasion is severely limited. (A) The
ability of UTI89, UTI89 degS::cat, UTI89 degS::cat/pDegS, or UTI89 fimH::kan (negative
control) to bind to 5637 cells was assessed in vitro. (B) The bacterial cells that invaded into the
5637 cells are shown as a percentage of bound cells. The mean and SEM are shown for each
strain. * p < 0.05 (Adapted from Figure 8 of Bradley and Danka)
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Figure 12: CRAMP-deficient mice have an unknown substance coating the uroepithelium.
Uroepithelial cells have defined borders and a wrinkled surface in C57Bl/6 mice (A, B).
CRAMP-deficient mice (C-F) have an unknown substance coating the surface of the
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uroepithelium. Cell shape is similar underneath the coating (E, F), and areas of exfoliation can be
found (D). Scale bar is 100 µM in A, D, and E; 25 µM in B, C, F.

158

References
1. Smith SG, Mahon V, Lambert MA, Fagan RP. A molecular Swiss army knife: OmpA
structure, function and expression. FEMS Microbiol Lett 2007; 273:1-11.
2. Pautsch A, Schulz GE. Structure of the outer membrane protein A transmembrane domain.
Nat Struct Biol 1998; 5:1013-7.
3. Ma Q, Wood TK. OmpA influences Escherichia coli biofilm formation by repressing cellulose
production through the CpxRA two-component system. Environ Microbiol 2009; 11:2735-46.
4. Nicholson TF, Watts KM, Hunstad DA. OmpA of uropathogenic Escherichia coli promotes
postinvasion pathogenesis of cystitis. Infect Immun 2009; 77:5245-51.
5. Prasadarao NV. Identification of Escherichia coli outer membrane protein A receptor on
human brain microvascular endothelial cells. Infect Immun 2002; 70:4556-63.
6. Prasadarao NV, Srivastava PK, Rudrabhatla RS, Kim KS, Huang SH, Sukumaran SK. Cloning
and expression of the Escherichia coli K1 outer membrane protein A receptor, a gp96
homologue. Infect Immun 2003; 71:1680-8.
7. Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev
Miobiol 2010; 8:26-38.
8. Rolhion N, Hofman P, Darfeuille-Michaud A. The endoplasmic reticulum stress response
chaperone: Gp96, a host receptor for Crohn disease-associated adherent-invasive Escherichia
coli. Gut Microbes 2011; 2:115-9.
9. Lebret T, Watson RW, Molinie V, et al. Heat shock proteins HSP27, HSP60, HSP70, and
HSP90: expression in bladder carcinoma. Cancer 2003; 98:970-7.

159

10. Mittal R, Prasadarao NV. Nitric oxide/cGMP signalling induces Escherichia coli K1 receptor
expression and modulates the permeability in human brain endothelial cell monolayers during
invasion. Cell Microbiol 2010; 12:67-83.
11. Maruvada R, Blom AM, Prasadarao NV. Effects of complement regulators bound to
Escherichia coli K1 and Group B Streptococcus on the interaction with host cells. Immunology
2008; 124:265-76.
12. Davies RL, Lee I. Sequence diversity and molecular evolution of the heat-modifiable outer
membrane protein gene (ompA) of Mannheimia (Pasteurella) haemolytica, Mannheimia
glucosida, and Pasteurella trehalosi. J Bacteriol 2004; 186:5741-52.
13. Hritonenko V, Stathopoulos C. Omptin proteins: an expanding family of outer membrane
proteases in Gram-negative Enterobacteriaceae. Mol Membr Biol 2007; 24:395-406.
14. McCarter JD, Stephens D, Shoemaker K, Rosenberg S, Kirsch JF, Georgiou G. Substrate
specificity of the Escherichia coli outer membrane protease OmpT. J Bacteriol 2004; 186:591925.
15. Thomassin JL, Brannon JR, Gibbs BF, Gruenheid S, Le Moual H. OmpT outer membrane
proteases of enterohemorrhagic and enteropathogenic Escherichia coli contribute differently to
the degradation of human LL-37. Infect Immun 2012; 80:483-92.
16. Premjani V, Tilley D, Gruenheid S, Le Moual H, Samis JA. Enterohemorrhagic Escherichia
coli OmpT regulates outer membrane vesicle biogenesis. FEMS Microbiol Lett 2014; 355:18592.
17. Lundrigan MD, Webb RM. Prevalence of ompT among Escherichia coli isolates of human
origin. FEMS Microbiol Lett 1992; 76:51-6.

160

18. Marrs CF, Zhang L, Tallman P, et al. Variations in 10 putative uropathogen virulence genes
among urinary, faecal and peri-urethral Escherichia coli. J Med Microbiol 2002; 51:138-42.
19. Kanamaru S, Kurazono H, Ishitoya S, et al. Distribution and genetic association of putative
uropathogenic virulence factors iroN, iha, kpsMT, ompT and usp in Escherichia coli isolated
from urinary tract infections in Japan. J Urol 2003; 170:2490-3.
20. Weiser JN, Gotschlich EC. Outer membrane protein A (OmpA) contributes to serum
resistance and pathogenicity of Escherichia coli K-1. Infect Immun 1991; 59:2252-8.
21. Hui CY, Guo Y, He QS, et al. Escherichia coli outer membrane protease OmpT confers
resistance to urinary cationic peptides. Microbiol Immunol 2010; 54:452-9.
22. Brannon JR, Thomassin JL, Desloges I, Gruenheid S, Le Moual H. Role of uropathogenic
Escherichia coli OmpT in the resistance against human cathelicidin LL-37. FEMS Microbiol
Lett 2013; 345:64-71.
23. He XL, Wang Q, Peng L, et al. Role of uropathogenic Escherichia coli outer membrane
protein T in pathogenesis of urinary tract infection. Pathog Dis 2015; 73.
24. Kuehn MJ, Kesty NC. Bacterial outer membrane vesicles and the host-pathogen interaction.
Genes Dev 2005; 19:2645-55.
25. Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer
membrane vesicles. Annu Rev Microbiol 2010; 64:163-84.
26. MacDonald IA, Kuehn MJ. Offense and defense: microbial membrane vesicles play both
ways. Res Microbiol 2012; 163:607-18.
27. McBroom AJ, Johnson AP, Vemulapalli S, Kuehn MJ. Outer membrane vesicle production
by Escherichia coli is independent of membrane instability. J Bacteriol 2006; 188:5385-92.

161

28. Manning AJ, Kuehn MJ. Contribution of bacterial outer membrane vesicles to innate
bacterial defense. BMC Microbiol 2011; 11:258.
29. India C. Bradley ESD. Characterization of a UPEC degS mutant in vitro and in vivo. Journal
of Emerging Investigators 2015:1-8.
30. Waller PR, Sauer RT. Characterization of degQ and degS, Escherichia coli genes encoding
homologs of the DegP protease. J Bacteriol 1996; 178:1146-53.
31. Meltzer M, Hasenbein S, Mamant N, et al. Structure, function and regulation of the
conserved serine proteases DegP and DegS of Escherichia coli. Res Microbiol 2009; 160:660-6.
32. Alba BM, Zhong HJ, Pelayo JC, Gross CA. degS (hhoB) is an essential Escherichia coli
gene whose indispensable function is to provide sigma (E) activity. Mol Microbiol 2001;
40:1323-33.
33. Zasloff M. Defending the epithelium. Nat Med 2006; 12:607-8.
34. Zasloff M. The antibacterial shield of the human urinary tract. Kidney Int 2013; 83:548-50.
35. Zasloff M. Antimicrobial peptides, innate immunity, and the normally sterile urinary tract. J
Am Soc Neph 2007; 18:2810-6.
36. Chromek M, Slamova Z, Bergman P, et al. The antimicrobial peptide cathelicidin protects
the urinary tract against invasive bacterial infection. Nat Med 2006; 12:636-41.
37. Nielsen KL, Dynesen P, Larsen P, Jakobsen L, Andersen PS, Frimodt-Moller N. Role of
Urinary Cathelicidin LL-37 and Human beta-Defensin 1 in Uncomplicated Escherichia coli
Urinary Tract Infections. Infect Immun 2014; 82:1572-8.
38. Danka ES, Hunstad DA. Cathelicidin augments epithelial receptivity and pathogenesis in
experimental Escherichia coli cystitis. J Infect Dis 2015; 211:1164-73.

162

39. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide
synthesized in the liver. J Biol Chem 2001; 276:7806-10.
40. Finberg KE. Regulation of systemic iron homeostasis. Curr Opin Hematol 2013; 20:208-14.
41. Bowdish DM, Davidson DJ, Hancock RE. A re-evaluation of the role of host defence
peptides in mammalian immunity. Current Protein Pept Sci 2005; 6:35-51.
42. Bowdish DM, Davidson DJ, Scott MG, Hancock RE. Immunomodulatory activities of small
host defense peptides. Antimicrob Agents Chemother 2005; 49:1727-32.
43. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial
peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002;
169:3883-91.

163

APPENDIX ONE
READING, WRITING, AND PRESENTING ORIGINAL SCIENTIFIC RESEARCH: A
9-WEEK COURSE IN SCIENTIFIC COMMUNICATION FOR HIGH SCHOOL STUDENTS

Elizabeth S. Danka*1,2 and Brian M. Malpede1,3

1

Young Scientist Program, 2Department of Pediatrics, 3Department of Microbiology, Washington

University in St. Louis

*Corresponding author. Email: esdanka@wustl.edu; Address: 660 S. Euclid Ave, Campus Box
8208, St. Louis, MO 63110

Modified from Danka and Malpede manuscript (accepted to Journal for Microbiology and
Biology Education for December 2015 publication).

Abstract
High school students are not often given opportunities to communicate scientific findings
with their peers, the general public, and/or people in the scientific community, and therefore they
do not develop scientific communication skills. We present a 9-week course that can be used to
teach high school students, with no previous knowledge, how to read and write primary scientific
articles, and to discuss scientific findings with a broad audience. Various forms of this course
have been taught for the past 10 years as part of an intensive summer research program for rising
high school seniors that is coordinated by the Young Scientist Program at Washington University
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in St. Louis. The format presented here includes assessments for efficacy through both rubricbased methods and student self-assessment surveys.

Introduction
The Young Scientist Program (YSP; ysp.wustl.edu) at Washington University in St.
Louis is a science education outreach program that strives to introduce high school students to
careers in STEM fields and to increase the participation of underrepresented minorities in these
fields. The Summer Focus program was established within YSP in 2001 as a paid summer
internship in which high school students would experience authentic, hands-on scientific
research [2]. Over the past two decades, Summer Focus has grown to incorporate a college
preparatory course and a scientific communication course [4]. The scientific communication
course teaches students how to find and read primary scientific literature, how to compose their
own scientific findings into a journal-style article, and how to present their findings to a broad
scientific audience. Here, we present the curriculum for this scientific communication course,
along with tools for assessing students’ learning and examples of student papers and
presentations.
We believe that the skills taught in this course should be introduced to students before
they reach the college level. Although AAAS’s Vision and Change is targeted at undergraduate
education, some of the goals laid out in the report can be addressed at the high school level [1].
For example, Vision and Change calls for students that are “competent in communication and
collaboration” and have “a certain level of quantitative competency, and a basic ability to
understand and interpret data” [1]. Skills such as data interpretation are essential for daily life,
where individuals must be able to understand and interpret data that are presented to them, and
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make decisions based on their interpretation. Furthermore, students that have mastered these
skills will likely perform better on standardized tests such as the PSAT, SAT, ACT, and certain
AP/IB tests, and should increase their chances of winning scholarships and being accepted into
college. This is particularly important for underprivileged students in St. Louis. In 2009, only
16% of St. Louis Public School students scored at or above the national average for the ACT
[10]. Through this course, we aim to improve high school students’ science communication
skills, writing skills, and ability to understand and interpret basic scientific data.

Intended audience and prerequisite knowledge
This course has been designed for rising high school seniors participating in an intensive
summer research experience through the Young Scientist Program at Washington University in
St. Louis. Students do not need to have prerequisite knowledge before completing this course, as
it is flexible enough to accommodate students with limited prior knowledge and a range of
reading and writing abilities.
A multi-step application process is used to select students for the Summer Focus
program. The Young Scientist Program has established relationships with high schools
throughout the greater St. Louis metropolitan area, which includes public and private high
schools from St. Louis city, the surrounding Missouri counties, and some schools in Illinois. As
such, the Summer Focus leadership team is able to notify schools when the application opens and
to remind them to encourage their students to apply. The application includes brief and optional
demographic data, a short essay addressing their motivation to apply for the program, and
questions about their extra-curricular activities, job experience, awards, and previous research
experience. The students also submit two letters of recommendation and an official transcript.
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Incomplete applications are not excluded. Each application is reviewed and scored by the
Summer Focus director or assistant director and at least three separate volunteers. Although a
transcript is part of the application, the student’s grade point average is not taken into account;
rather, the transcript is used to determine 1) if the student has challenged his/herself
academically, 2) the availability of advanced placement courses, and 3) regular attendance.
When evaluating applications, volunteers attempt to identify students that have limited access to
other research experiences and would therefore benefit from the program. Approximately 30-40
students are invited for a formal, on-campus interview, where they meet with three pairs of
interviewers that probe each student’s curiosity, creativity, ability to work as a team, ability to
work individually, and more. The interviewers meet as a group to discuss which students will be
given offers. Interviewers consider whether the students can commit to the full program, have
previous research experience or can pay for a separate experience, want to participate in the
program, and will benefit from participating in the program. Depending on funding,
approximately 16 students are offered positions each summer.

Learning time
As presented here, the course meets weekly for 1.5-2 hours per session, for 9 weeks
(Table 1); total in-class time is 12-16 hours. Out-of-class homework assignments (e.g., writing
drafts of various sections of the paper, creating presentations, peer review) build on the material
that was covered in class that week and prepare the students for class the following week. This
homework generally does not require more than 1-2 hours per week.
We also offer 3 optional sessions: one in which the students complete a short preassessment survey and writing assessment (Supplements 2 and 3), and two in which the
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instructors can hold individual meetings with students to discuss their progress on the final
paper. Since our program ends with a summer symposium, we ask the students to practice their
presentations as a group every day during week 9; however, this practice time could be shortened
to only occur during the scheduled class time.

Learning objectives
After completing the course, students will be able to:
1. Identify the major sections of a scientific article and describe the content that each section
should contain.
2. Write individual sections of a scientific article.
3. Analyze simple figures from scientific articles and draw conclusions from these figures.
4. Effectively peer review another student’s written work.
5. Communicate original scientific findings to an audience with a diverse knowledge
background.
6. Develop an effective presentation style.

Procedure
Materials, student instructions, faculty instructions, and sample data
It is best if class sessions are held in a room with a projector and a white/chalkboard, as
the students give multiple presentations throughout the course and the instructors often use
projected presentations to augment the lesson of the day. There are no necessary wet lab
components.
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The course is taught by two volunteer instructors to divide the workload. The instructors
typically are graduate students recruited from our YSP volunteer pool. Each instructor teaches
the course for 2 years; schedules are staggered so that there is an experienced instructor and a
new instructor each year. This course also utilizes the volunteer base of YSP in order to hold
small-group discussions with students at the end of most classes and to objectively assess
presentations throughout the course.
The syllabus distributed to the students is shown in Supplement 1. The students do not
receive credit for their participation in the course or in the summer program. However, they do
receive a stipend as part of this internship; accordingly, they are expected to attend to all class
sessions, and to actively participate in each class. Expectations for the students and the
guidelines for the final paper and presentation are included in the syllabus. We also present a
schedule with which the students can keep track of their assigned homework and due dates.
Throughout the summer, the Summer Focus leadership team stresses to the students that they are
expected to act professionally and to treat their summer experience as a job. The students are told
at the beginning of the summer that if they do not turn in the required assignments, their stipend
may be withheld until the work is completed. The students’ research mentors and tutors also
have access to the class syllabus, and encourage the students to complete their assignments
during breaks in the lab. We have had very few instances of students not completing the
assignments.
As shown in the sample syllabus (Table 1), the first class meeting is the longest and sets
the students up for a successful summer. Our students come from high schools across the St.
Louis metropolitan area, and we want them to be comfortable with each other and the instructors;
therefore, we start off the first class by playing a few ice-breaker games. Once everyone knows
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the names of their classmates, we introduce basic writing skills, the purpose of scientific writing,
examples of scientific sources, what plagiarism is and how to avoid it, and the sections of a
scientific paper. We use a previous student’s paper to ease them into reading scientific literature
and to show them what they will be able to do by the end of the summer. Many of our students
know previous participants or attend the same schools as previous participants, and showing our
students what their peers have achieved helps build self-efficacy (particularly in regard to
understanding scientific writing and their own writing skills) [11]. Outside of class, the program
has an intensive research focus, so we also walk all of the students through a literature search
using PubMed (pubmed.org), before helping them perform individual searches based on what
they will be studying. If desired, instructors can have students fill out a writing pre-assessment
(to give the instructors an idea of how much attention an individual student might need) and an
overall pre-assessment survey at this first meeting (shown in Supplements 2 and 3). Due to the
structure of our program, the students complete these assessments and other administrative
paperwork before the summer starts, but they can easily be included at the very beginning of this
first meeting.
The classes have a more defined structure for the rest of the summer. A different topic
(e.g., the format and content of a Materials and Methods section) is covered in each class, and
the instructors incorporate student discussion, questions for the students, and active learning
activities (e.g., think-pair-share) into each session [5, 6, 9]. We include examples from previous
students and current literature as often as possible. The students often complete a preparatory
reading and a worksheet before coming to class to discuss the topic in-depth with the instructors
and their classmates, and to participate in an activity. These homework assignments include
instructions at the top of each sheet, and are shown in Supplement 4.
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After the topic of the day has been covered, students divide up into small groups for the
last 10-15 minutes of class to discuss their projects with their peers and a volunteer (graduate
student, post-doc, etc.). Throughout the summer, when the students are doing group work, we
place them into groups of 3-4 students that represent many different backgrounds to encourage
discussion and collaboration among students that may not usually interact. In these discussions,
each student will describe his/her project and will answer a few questions from their peers and/or
the volunteer. These sessions informally assess the students’ understanding of their projects, and
give the students practice communicating with a low-stakes, scientific audience composed of
their peers. These sessions can also address discrete goals, such as asking the students to describe
their projects in lay terms, as if they were speaking to a family member or friend not in science,
instead of using jargon. The volunteers mediate (but do not lead) the discussion, and provide the
students with constructive feedback.
There are also multiple opportunities throughout the summer for each student to present
before a larger group. In the third week of class, students give short presentations in which they
must explain the project background, their hypothesis, and some of the methods they will learn
and employ during their time in lab. Volunteers attending this presentation assess the students’
presentation skills using a rubric (Supplement 5). Results of these assessments are not shared
with the students. Students build on this presentation over the course of the summer as they
create a final presentation on their project and the laboratory work that they completed. During
the class period in week 8, a complete final presentation is presented to their classmates,
instructors, and the same volunteer assessors from their first presentation. In our program, these
final presentations are given during an end-of-summer symposium, and the students intensely
practice and edit their presentations each day of the ninth week. The daily practice sessions are
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not required, but we find the students improve their presentations and presenting immensely over
the course of the week. In addition to feedback from the instructors, the students also take notes
and give each of their classmates’ critiques. Finally, chalk talks (oral presentations given without
supporting slides, although a chalk board may be used to draw figures or models) represent a
distinct way in which work-in-progress is communicated in science. Our students present a short
chalk talk to the class in the middle of the summer to familiarize them with this format.
As mentioned in the section on learning time, one-on-one meetings can be included in the
schedule. Each meeting is short, usually 10-15 minutes, but allots time for an instructor to meet
with a student (and their mentor and tutor, in our case) to provide feedback on his/her writing.
These meetings can also be used to assess what the student does and does not understand, and to
reinforce concepts that have been taught in class.

Suggestions for determining student learning
Our course does not provide a grade for students, but our assessments allow us to
evaluate student learning and our own teaching. Students are given assignments that support the
topics we have covered in class, and they must implement what they have learned about the
sections of a scientific paper to write a manuscript describing their own work from the summer.
Beyond the written sections of a paper that the students turn in, homework assignments help the
instructors to assess student comprehension and learning with regard to Learning Objectives 1, 2
and 4. These assignments are not graded, but help the instructors identify any weaknesses in
individual students. To help ensure that the students work on their papers throughout the
summer, they are periodically required to turn in individual sections and drafts. This gives the
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instructors an opportunity to see how much progress each student has made, and what they are
struggling with, and to provide rewriting suggestions.
In order to more formally assess student learning over the course of the summer, we have
recently added a rubric-based presentation assessment (Supplement 5). As mentioned in the
instructions above, this assessment is performed at the beginning of the summer and again at the
end of the summer by volunteers who are not otherwise connected to the course or the students.
These assessments allow us to examine the extent to which Learning Objectives 5 and 6 are
addressed.
Finally, we have recently designed rubric-based methods for assessing student gains in
figure analysis. This addition will allow us to better assess Learning Objective 3. We anticipate
presenting the results of these analysis methods in the future, after we have collected data from
multiple student cohorts. We expect our students will particularly improve with figure analysis in
their own field of study.
Of important note, our students represent a diverse range of abilities and educational
backgrounds. Most of our students come from urban schools within the St. Louis Public School
district, although a few students each year come from private schools within the city or from the
outlying areas. Our students therefore begin the course with distinct individual skills, needs, and
opportunities for improvement. We believe that this course is helpful for a diverse set of students
such as ours, and that all students benefit from participation in this course. We acknowledge that
the students spend the vast majority of their time working in the lab alongside a research mentor.
As such, these mentors influence what the students learn over the course of the summer, as well
as student performance on the final assessments. Therefore we also offer a self-assessment that
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each student can complete at the conclusion of the course, which identifies areas in which each
student thinks he/she has improved over the summer (Supplement 6).

Sample data
We have included two sample final paper and two sample final presentations to illustrate the
products the students have created by the end of this course (Supplements 7 and 8).

Safety issues
As this course does not entail wet lab work, there are no safety issues to consider when
implementing this course.

Discussion
Field testing and evidence of student learning
High school students participating in the Summer Focus program have been taught
scientific communication in a similar writing course for 10 years [2, 4]. The course is designed to
accomplish a number of learning objectives focused on teaching students how to read and write
scientific articles, and how to present original scientific data. Recently, we have implemented
straightforward analysis methods, including both student self-assessments and rubric-based
assessments, which may inform potential modifications to the class.
In addition to addressing the described learning objectives, this course brings diversity
into the classroom, provides students with opportunities to practice working in groups, and
fosters discussion among peers. For this article, we assessed two separate cohorts of students.
The first cohort comprised 14 total students, 10 girls (71.4%) and 4 boys (28.6%) (Figure 1A).
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The second cohort included 16 total students, 10 girls (62.5%) and 6 boys (37.5%); in total, we
report results from 30 students, 67% of which were girls. Of these 30 students, 14 identified their
race as Black, 9 as Caucasian, 6 as Asian, and 1 chose “I prefer not to answer” (Figure 1B).
Furthermore, the students represent a variety of socioeconomic backgrounds and attend different
types of schools throughout the St. Louis metropolitan area [9].
We used informal, pre-assessment surveys that utilize a modified Likert scale to
determine whether the students were already familiar with the concepts and skills that would be
taught in this course (Supplement 2) [8]. This scale included responses as follows: 0 represents
Strongly Disagree, 1 represents Disagree, 2 represents Neutral, 3 represents Agree, and 4
represents Strongly Agree. Therefore, survey questions with a median response greater than 2
indicate a positive response. The surveys were completed the first day of class before any
material had been covered. While 73% of students report having read a scientific paper, 40%
reported not being able to name the parts of a scientific paper, and the remaining 60% reported
that they were unsure if they could. Approximately 67% of students report that they have
previously interpreted basic scientific results, although students feel neither comfortable nor
uncomfortable doing so (Table 2). Additionally, 67% of students report that they have not
previously written a scientific paper, and feel neutral about whether they would be comfortable
writing a scientific paper. The majority of students reported having confidence in their oral
presentation skills, critical thinking skills, and ability to effectively peer review (Table 2).
Similarly, post-assessment surveys were used to monitor the students’ own impressions
of their improvement over the course of the summer (Supplement 6). The results of these surveys
indicate that students felt they made gains in a number of areas (Table 3). We found that 100%
of students were confident that they could name the parts of a scientific paper, while only 25%
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thought they could at the beginning of the summer. Although some students felt that they could
interpret basic scientific results at the beginning of the summer, the majority of students reported
that they were comfortable interpreting basic scientific results at the end of the summer (Table
3). While students report that they felt uncomfortable writing a scientific paper before the course,
they felt very comfortable writing a scientific paper after taking the course (Table 3). Based on
the surveys, students felt more confident with regard to their writing and oral presentation skills
after completing the course (Table 3). Students also indicated that they felt they had developed
critical thinking skills and could effectively review and critique a peer’s work (Table 3).
Finally, the greatest gains are seen in the final papers and presentations that the students
create by the end of the summer. We do not grade or otherwise quantitatively evaluate student
papers, so we have provided examples of students’ writing pre-assessment responses (which
correspond to Supplement 3) and their respective final papers in Supplement 7. The final papers
that the students create by the end of this course are of very high quality. Our students have won
awards in national writing competitions, had papers accepted to the Journal for Emerging
Investigators [3], and have successfully used their papers in college applications and scholarship
applications. Examples of final student presentations (including edits from a week of practice
that occurred after the assessment) can be found in Supplement 8. The students improve their
presenting “style” (including slide design, verbal delivery, and nonverbal delivery) over the
course of the 9-week program (Figure 2). Additionally, the students create clear, concise and
polished presentations that include the major sections of a formal scientific presentation
(background information, methods, results, and discussion) and generally fall between “good”
and “excellent” when assessed by rubric (Figure 3). The “final” presentation assessment was in
the second to last week of class, before the students had intensely practiced their presentations.
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We did not assess the students during the final symposium as we were interested in individual
gains without the intensive practicing of the final week, but the students continue to improve
with each practice session. Our data support the idea that students involved in summer research
programs are more confident in their abilities to perform laboratory science experiments [7].
However, we believe that the course described here can be used to augment a summer research
experience and to effectively teach diverse high school students, with widely ranging previous
experiences, how to employ the major forms of scientific communication.

Possible modifications
Although this course was designed for rising high school seniors, it could be used for
college freshmen, or adapted for use with younger students. The course could also be abbreviated
to focus on individual skills, such as writing a scientific paper or presenting scientific data to a
particular type of audience. Each of these focused topics could be presented as stand-alone
workshops. However, we do not feel that the course in its entirety could be condensed into a 1-2
day workshop, as students need time to develop ideas and to practice the skills presented in each
class session – this cannot be accomplished overnight.
Finally, this course was designed for students that are generating their own data alongside
research mentors who can help the students outside of class. However, it is feasible that students
(individually, or in pairs or groups) could write papers or create presentations discussing
methods and data from case reports, data collected from laboratory exercises done by an entire
class, or other sources.
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Supplemental materials:
Supplement 1: Student syllabus
Supplement 2: Pre-assessment questions
Supplement 3: Writing pre-assessment
Supplement 4: Homework assignments and worksheets
Supplement 5: Presentation assessment rubric
Supplement 6: Post-assessment questions
Supplement 7: Two sample student writing pre-assessment responses and corresponding final
papers*
Supplement 8: Two sample student final presentations*
*due to length, Supplements 7 and 8 are not included here (will be available online at JMBE)
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Tables and Figures:
Table 1: Example class syllabus.
Week
Pre-SF meeting
(optional)
Week 1
(3 hrs)

Week 2 (1.5 hrs)

Week 3 (1.5 hrs)

Week 4 (1.5 hrs)

Week 5 (1.5 hrs)

Week 6 (optional)
(10-15 min)

Week 6 (1.5 hrs)

Week 7
(beginning of
week)
Week 7 (1.5 hrs)

Week 8 (optional)
(10-15 min)
Week 8 (1.5 hrs)
Week 9 (2 hrs)
(Every dayoptional)

In-class
-Writing pre-assessment
-Ice breakers
-6 C’s of writing (very briefly)
-Plagiarism
-Types of science writing
-Database searches, practice (NCBI)
-Sections of a paper (with example)
-Critical reading skills
-Go over example paper (previous
student’s), discuss
-Project discussion with volunteers
-Give 5 min project presentation focusing on
background, main Q, hypothesis and
methods
-Q’s (students, teachers, volunteers)
-Format and content of Materials and
Methods using a real paper (journal club
style)
-Project discussion with volunteers
-Format and content of Results section using
same paper (from last week, journal club
style)
-Project discussion with volunteers
-One on one meetings with student, mentor,
tutor and teacher
-Discuss M&M (return edits) and grill them
for understanding
-Format and content of
Abstract/Intro/Discussion
-2 min project chalk talk and Q&A from
students, teachers, volunteers
-Return Draft #1 edits so they can be
incorporated into Draft #2
-Presentation skills (watch, critique a good
and a bad presentation)
-How to do Citations and in-text references
-Project discussion with volunteers
-One on one meetings with student, mentor,
tutor and teacher
-Discuss Draft #2 edits and discuss content
of intro and disc
-Project presentations with critiques from
classmates and teachers
-Practice presentations every morning
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Assignments due in class
-Students should know their
project topic and lab
-Worksheet with summary of
lab/project overview focusing on
main Q, hypothesis and approach

-Worksheet to prepare for critical
reading discussion

-Peer review previous year’s paper
-Prepare 5 min project
presentation for the class
-Find and read 2 papers related to
project, summary
- M&M worksheet
-M&M for their project
- Results worksheet

-Edited M&M and Results for
their project (“Draft #1)
- Ab/Intro/Dis worksheet
-Prepared chalk talk outline

-Abstract, Introduction and
Discussion for their project, plus
Draft #1 (“Draft #2)

-Prepare 5 min project
presentation
-Final paper due Thursday,
Symposium on Friday

Figure 1: Gender and race of students participating in the summer program. The selfidentified gender (A) and race (B) of our 2013 and 2014 student cohorts.
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Table 2: Results of pre-assessment survey.

Question 4: I feel comfortable interpreting basic scientific results.

Median
scorea, b
2

Question 5: I feel confident in my writing skills.
Question 7: I feel comfortable writing a scientific paper.

2
2

Question 8: I feel confident in my oral presentation skills.

3

Question 9: I have strong critical thinking skills.

3

Question 10: I can review and critique a peer’s work effectively.

a

3
Answers were ranked on a scale of 0-5, 0 representing Strongly Disagree, 1 representing

Disagree, 2 representing Neutral, 3 representing Agree, and 4 representing Strongly Agree;
b

n=15 students
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Table 3: Results of post-assessment survey.
Median
scorea, b
Question 3: Were you able to interpret basic scientific results at the
beginning of the summer?
Question 4: Do you feel comfortable interpreting basic scientific results
now?
Question 5: Did you feel comfortable writing a scientific paper before
Summer Focus?
Question 6: Do you feel comfortable writing a scientific paper after
completing Summer Focus?
Question 7: Do you feel more confident in your writing now that you
have completed the Writing Course?
Question 8: Are you more confident in your oral presentation skills now
that you have completed the Writing Course?
Question 9: Do you feel you have developed critical thinking skills?
Question 10: Do you feel you can review and critique a peer’s work
effectively?
a
Answers were ranked on a scale of 0-5, 0 representing Strongly Disagree, 1

2
4
1
3.5
3.5
3
3
3
representing

Disagree, 2 representing Neutral, 3 representing Agree, and 4 representing Strongly Agree;
b

n=28 students
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Figure 2: Results of presentation style assessment. Students demonstrated improvements in
slide design, verbal delivery, and nonverbal delivery between their first presentation and their
last presentation in class. Each student’s average score from three volunteer assessors was used
to calculate a median score (n=30 students for first presentation and n=27 students for last
presentation). Scores are converted to percentages to account for different numerical scales in the
2013 and 2014 rubrics. The requirements for each category were unchanged.
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Figure 3: Results of presentation content assessment. Students are able to create presentations
that thoroughly address important background information, methods, results, and discussion
sections. Each student’s average score from three volunteer assessors was used to calculate a
median score (n=27 students). Scores are converted to percentages to account for different
numerical scales in the 2013 and 2014 rubrics. The requirements for each category were
unchanged.
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Supplement 1: Student syllabus
Writing Course Syllabus
Course Instructors:
Name 1
Name 2

Phone number
Email address
Phone number
Email address

Goals:
While taking this course, you will:
● Recognize the style, format, and content of scientific papers.
● Understand your research and present this research to an audience.
● Understand and discuss others’ research at a basic level.
● Develop your ability to review others’ work.
● Appreciate the importance of scientific writing, speaking, and other ways
communication.
Expectations:
Skills in writing, oral presentations, and peer review are required for your success in college,
with further education, and in building and maintaining a career. This writing course is
designed to teach you about these life skills, but exactly how much you get out of the class will
depend on how much time and effort you put into it. Attendance is mandatory (unless you
have a valid reason for missing, and you inform the course instructors ahead of time). We
expect that you will arrive on time each week and be ready to participate in class, as your
participation will help you engage and actively think about the writing/editing process. The
assignments for each week will prepare you for what we will go over in class, as well as
reinforce in-class topics, so please be thorough and thoughtful when completing them. You will
receive written comments each week on your assignments from the instructors. We expect you
to use these comments to improve your writing throughout the summer. You will thank
yourself later for the effort spent on writing and editing this summer, as the paper will come in
handy when the time comes to talk about your research, provide admissions committees with a
written summary, or compete in a science competition in the future.
We hope that you have a wonderful summer experience! There is a lot to learn, but we want
you to enjoy the experience. If you have any problems with the writing course, your labs, or any
other aspects of the summer, DO NOT HESITATE to inform your instructors, the liaisons, or any
of the Summer Focus leaders.
Assignments:
The assignments for each class session are listed in your course syllabus and outline. For the
first few weeks, you will learn how to read scientific articles and their basic structural format. In
addition to reading these papers, you will learn to discuss them with other students in the
format of a journal club. In addition, you will learn to present your project to an audience early
on in the summer, so you have to become familiar with your project’s main question,
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background research, hypothesis and methods in the first few weeks. Starting in July, you will
begin writing your paper. We will guide you through each section, and each week you will write
a specific section of your paper and update any previously written sections. For example, for
class on July 3, you will write your Materials & Methods section. On July 11, you will turn in
your first draft of your Results section and improve your Materials & Methods section. You will
also be asked to discuss your project in a small group (other students and a volunteer) by
explaining your summer project and the progress you have made for that week. The instructors
will provide more detailed information on these assignments in class.
Progress charts: You will be asked to fill in a progress chart each week. In this chart, please list
the experiments you performed for the week, why you did them, and what your results from
these experiments show. Write whether you worked independently, with the help of your
mentor, or whether you watched your mentor do the experiment. We will review the charts to
ensure that you are receiving the maximum amount of time at the bench and the best
experience possible! Progress charts have been given to you and are in your binder.
Final paper: A scientific paper on your research project will be due at the end of summer. Your
paper should be at least five pages long, double-spaced, with 12-point Times New Roman font.
Formal requirements for formatting your paper will be distributed later. We encourage you to
write a longer paper if you would like to use the paper for science competitions. A rough draft
of your entire paper is due on July 18. We realize that some sections may not be complete
because you may still be working on the experiments. However, you should still have at least
begun to draft all of the sections of the paper. You will edit and improve this draft until the end
of the program. The final draft is due August 1 by 5:00pm. Throughout the editing process, we
encourage you to save each draft as a separate document (e.g. SF Paper-Draft 1, SF Paper-Draft
2) to at least two different hard drives (e.g. Desktop & USB) in case your computer crashes at
the last minute (it happens!!).
Final presentation: You will present your research to an audience of all SF students, their family
and friends, and SF volunteers at an end of SF Symposium on Friday, August 2. This
presentation will be 5-7 minutes long and will demonstrate why you did your research, what
your project was, and the main results and conclusions from your work. Your presentation will
have an outline similar to that of your final paper. We will help you prepare this presentation
and give you lots of feedback as you practice it over and over! Like your final paper, we
encourage you to save your final presentation to at least two different sources so that you do
not lose your hard work unexpectedly.
Writing Course: Detailed Course Outline
Date
June 5th
(Wed.)

In-class

Due today

-6 C’s of writing and plagiarism
-types of science writing

Due next week

-summary of
-read example paper
lab/project overview and fill out critical
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Boot
Camp

-how to do database searches,
practice
-sections of a scientific paper

(main Q, hypo,
methods)

June 13
(Thurs.)

-critical reading skills
-example paper
-discuss progress of project

-critical reading prep -find and read 2
worksheet
papers for project,
summarize
-prepare 5min PPT
presentation

June 20
(Thurs.)

-5 min project presentations
(background, main Q, hypo,
methods)

-summaries of 2
papers related to
your project
-5min presentation

June 27
(Thurs.)

-format and content of Materials and -M&M worksheet
Methods section
-presentation for
-discuss progress of project
Journal Club
discussion of format
and content of
M&M

-write M&M for your
project
-read example
Results, fill out
Results worksheet
-prepare 5min PPT
with group about
Results

July 3
(Wed.)

-format and content of Results
section
-discuss progress of project
-schedule one-on-one meetings

-M&M
-Results worksheet
-presentation for
Journal Club
discussion of format
and content of
Results

-read example
Abs/Intro/Disc, fill
out worksheet
-write Results for
your project
-chalk talk outline

July 8
(Mon.)

ONE-ON-ONE MEETINGS
(9AM-12PM Rooms TBA)
-Draft #1 (edited
M&M, Results)
-Abs/Intro/Disc
worksheet
-chalk talk outline

-Draft #2 (edited
M&M and Results,
add in Abstract,
Introduction and
Discussion)

July 11
(Thurs.)

-format and content of
Abstract/Intro/Discussion sections
-2 min project chalk talk

(continued on next page)
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reading worksheet

-read example
M&M, fill out M&M
worksheet
-prepare 5min PPT
with group about
M&M

July 18
(Thurs.)
(July 18
cont’d)

-presentation skills
-how to do Citations and in-text
references
-schedule one-on-one meetings

July 22
(Mon.)

ONE-ON-ONE MEETINGS
(9AM-12PM Rooms TBA)

-Draft #2 (edited
Draft #1 plus
Abstract, Intro and
Discussion)

-5-10min practice
PPT presentation

July 25
(Thurs.)

-project presentation to class (5-10
minutes)

-practice
presentation

-final presentation
and final paper

July 29August 2

-practice final project presentation
every morning at 9 AM

-final presentation

-continue editing
paper and
presentation

August 1
(Thurs.)

FINAL PAPER DUE BY 5 PM

August 2
(Friday)

SYMPOSIUM: PRESENTATIONS AND
BANQUET at 6 PM
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Supplement 2: Pre-assessment questions
Name:
Number:
Please read each question and circle the answer that describes your feeling most accurately.
1) Have you ever read a scientific paper?
Yes

No

Not sure

2) Can you name the parts of a scientific paper?
Yes

No

Not sure

3) Have you ever interpreted basic scientific results?
Yes

No

Not sure

4) I feel comfortable interpreting basic scientific results.
Strongly Disagree

Disagree

Neutral

Agree

Strongly agree

Neutral

Agree

Strongly agree

Agree

Strongly agree

Neutral

Agree

Strongly agree

Neutral

Agree

Strongly agree

Agree

Strongly agree

5) I feel confident in my writing skills.
Strongly Disagree

Disagree

6) Have you ever written a scientific paper before?
Yes

No

Not sure

7) I feel comfortable writing a scientific paper.
Strongly Disagree

Disagree

Neutral

8) I feel confident in my oral presentation skills.
Strongly Disagree

Disagree

9) I have strong critical thinking skills.
Strongly Disagree

Disagree

10) I can review and critique a peer's work effectively.
Strongly Disagree

Disagree

Neutral
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Supplement 3: Writing pre-assessment
Writing Course
Name: _________________________
Pre-course free write
You have 15 minutes to create a response to the following:
Think of a time when you read an article (magazine, newspaper, online source) about a science
or health topic. What did you learn from this article? Did you consider it to be a credible source
at the time? Why or why not? What do you think of this article now? If you have changed your
mind about the article, why did you change your mind?
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Supplement 4: Homework assignments
Lab summary and project overview
Name of PI:
General lab interest:

Project topic:
-why is this interesting?

Main question of project:

-why is this worth investigating?

Hypothesis:

Approach (what experimental methods will you be using to test your hypothesis? add more if
needed):
-Experiment 1:

-Experiment 2:

-Experiment 3:
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6 C’s of writing notes
Effective communication of ideas in written form is an incredibly valuable life skill. The 6 C’s
of writing provide basic guidelines to successfully present your ideas in a written document.
The 6 C’s are clarity, conciseness, credibility, completeness, consistency, and coherence. They
are not presented in a specific order. Each C is essential to the formation of a well written
composition. The 6 C’s are presented below.
1) Clarity: The goal of writing is to convey your ideas, thoughts, and conclusions to the reader.
Thus, your writing should be clear, easily understandable, and without errors that will hinder a
reader’s comprehension of your thoughts. To achieve clarity, the following are essential:
 Do the simple things right: check spelling and grammar! Proofread extensively.
 Always use citations where necessary.
 Be clear about what is fact versus what you hypothesize or present as a potential model
(especially important for scientific writing).
 Proper sentence structure is essential. Proofread each sentence individually to yourself
to assess how well the words flow and the sentence relates your intended meaning.
 Use active tense when writing (Jen is counting cells) and avoid passive tense when
possible (The cells are being counted by Jen).
 Pay attention to verb tenses: past tense for what you did, present tense for what is
currently being done, future tense for what you plan on doing
2) Conciseness: Your writing should be succinct but comprehensive. The following suggestions
will help maintain concise writing:
 Get to the point! Make sure that you are only adding important details.
 Make statements in simple terms.
 Remove any unnecessary sentences and words that do not enhance the reader’s
understanding of your thoughts.
 A sentence should not be longer than 3 lines. However, do not make sentences
incomplete when trying to be concise.
 Conciseness also applies to paragraphs and the paper as a whole: avoid being redundant
at all times. Proofread to ensure that you do not repeat yourself.
3) Credibility: Your writing must be convincing and trustworthy.
 How does your reader know that you didn’t just make this up?
 Detail and context are important. Convince your audience!
 Cite proper sources to provide the reader with all of your sources.
4) Completeness: Your writing should contain all necessary and appropriate information. To
make sure that your writing is complete, follow these guidelines:
 Introduce new information in all appropriate situations to avoid confusing the reader.
 Finish each thought or phrase in a sentence.
 Write in paragraphs that continue the flow of your writing and lead to your conclusions.
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Give reasoning for statements and justify why those statements are important and true.
Convince your audience!

5) Consistency: A writing composition should be uniform. Maintaining consistency will ensure
that the writing is understandable and does not confuse the reader.
 Check to make sure that everything in your document matches, including: noun/verb,
verb tenses, pronouns, etc.
 Introduce the reader to your topic and ideas.
 Ensure that your sentences and paragraphs flow effectively towards your conclusions.
6) Coherence: Your writing should have a logical, orderly, and consistent flow that will please
the reader. In addition, the sentences and paragraphs should be logically connected. Logical
connections and proper flow will make your writing understandable and easy to read. When
completing your document, assess the following aspects of the writing:
 Do things follow a logical order, or are you jumping around between topics and ideas?
 Does your work as a whole make sense? Reading out loud can help with this. You
shouldn’t need to backtrack and reread any sentence.
 Check that you have followed the other 6 C’s.
 Proofreading is a critical aspect of writing. Editing should be performed throughout the
writing process and multiple times before a document is considered complete.
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Sources of Scientific Information worksheet
There are many different ways for the average person to find out scientific information. You are
probably most familiar with popular science sources and textbooks right now, but there are
other sources of scientific information available. The credibility of these sources varies, and so it
is always important to evaluate the source and where the information in that source came
from. A list of some of these other sources is below.
-Pamphlets/Informative Brochures: Brochures for medications, pamphlets on disease
-Newspaper Articles/News Shows: Articles in the St. Louis Post Dispatch, segments on recent
developments in the evening news
-Popular Science Magazines or Books: Popular Science magazine, Discover magazine, Scientific
American magazine, National Geographic magazines, “Maneater: and Other True Stories of a
Life in Infectious Diseases” by Pamela Nagami, “The Immortal Life of Henrietta Lacks” by
Rebecca Skloot
-Documentaries: National Geographic documentaries, Discovery Channel documentaries, NOVA
programs
-References or Text Books: The Merck Manual, “Genes VII” by Benjamin Lewin
-Science Fiction Books or Movies: “Frankenstein” by Mary Shelley, Jurassic Park, Contagion
-Special Pieces in Non-Science Magazines: An article about reproductive health in a women’s
magazine
-Online: CDC website, TED talks, science blogs, Wikipedia, “The Onion” science page
-Experts in the field (often oral sources of information): Your PI, collaborators, your doctor
As you may know, scientific articles are the way that most scientists communicate new findings
and results within the field. In order to make sure that scientific papers are credible and
worthwhile, they are subjected to the process of peer review.
What is peer review?

Why is peer review important in science? Why is it important in writing?
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What are the guidelines for peer review?

Sample paper for practice peer review:
-use the brief paper below to fill out the table on the following page
Introduction
Blind people have cataracts. The majority of cataracts are age-related. Cataracts occur when
crystallins clump together, making the lens cloudy. This causes the light hitting by the lens to be
scattered. Cataracts can occur at birth, in childhood, or as older adults. There is increasing
evidence that age-related cataract has a strong genetic component (Hammond et al.,
2000). People with cataracts that appear at birth or in childhood usually have a mutation in
one gene. Some scientists think that studying families with early-onset cataracts will help us
understand age-related cataracts.
Methods
Our lab collected DNA from a family with an autosomal dominant inherited posterior polar
cataract. They used linkage analysis to map the family’s disease to chromosome 1p36. I looked
at the gene Q9UKB5 because it codes for hypothetical protein MOT8. MOT8 may be a member
of the aldehyde dehydrogenase family of enzymes. ALDH is similar to omega-crystallin
(Piatigorsky). We think that this gene is important for cataracts because it is similar to a protein
found in scallop’s eyes.
Results
I sequenced Q9UKB5. There are 5 exons. We did this using wild type DNA and DNA from two
affected individuals. I used the polymerase-chain reaction (PCR) to amplify the exons. I used 2
microliters of DNA and 1 microliter of primer. A gel was run to look at the polymerase chain
reaction product. It was sequenced with the ABI machine using the method. I printed out the
data and looked at it to see if there were any mutations. No one had two peaks. I screened 3
exons.
Conclusions
There aren’t any mutations. This project isn’t finished because we need to sequence the rest of
the exons.
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6C

Comment
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Solution

Plagiarism worksheet
Database searches and material given to you by your lab will provide you with lots of
background information about your project. You will likely refer back to this information as you
start to put together your paper and your presentation. When you do this, it will be important
to avoid plagiarism.
Discuss: What is plagiarism? How do we avoid plagiarizing?

When do we use citations? What sources need to be cited? Is there ever a time when we do not
need to cite information?

Like you have probably learned in your English classes, citation methods vary. There are
different formatting guidelines for citations in general writing (such as MLA, APA, CMS and IEEE)
and in science writing. Most peer-reviewed journals have specific guidelines for citations. When
we discuss how to do citations, we will give you a format to use.
Why have we gone over this? It is important for you to document your sources for when you
start to write your papers, so save papers that you need (either hard copy or electronically) or
write down details about the paper (authors, journal, title, etc.) on your notes so that you can
find the paper later!
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Peer Review Worksheet
Fill out this worksheet as you read through your HW article. It was written by a previous
student! Be sure to read slowly enough to identify the important parts that are outlined here.
Also, as you read, think about things that the author does well and things that the author could
have done better. We will discuss this paper in class on Thursday.

Title:

Just from the title, what do you think the paper will be about?

After reading the Introduction, what did you learn is the topic of the paper?

What is known about the subject? (list at least 3 things)

What is not known about the subject?
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What is the main question that the author is trying to answer?

What is the significance of the question? Are you convinced that this is an important question?

What is the author’s hypothesis?

How does the author plan on testing the hypothesis? (In other words, what methods will the
author use during their experiments?)
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What are the main results of the paper?

List 3 strengths of this paper.

List 3 weaknesses of this paper.

What 5 things do you think are the most important for you to consider when you are writing
your own paper?
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Materials and Methods
The Materials and Methods section of a scientific paper can give you lots of information that is
not available in any of the other sections of a paper. As its name implies, this section tells you
about the materials (chemicals, buffers, cells, etc.) that the authors used to do their
experiments and the methods (protocols, etc.) that the authors used to do their experiments.
You will likely find some things that you are familiar with in this section, as well as some things
that you have not yet learned about.
For next week, each group will make a presentation to give to the class in which they go
through the provided Materials and Methods section and discuss any points that they think are
particularly important. This presentation should be about 5 minutes long. A couple ideas of
things to consider discussing when making your presentations:
-What is the purpose of this section?
-What is the format of this section?
-What voice is used when writing the M&M?
-How much detail do the authors include?
-How does this section relate to the other sections of a paper?
This is not a complete list. Please be thorough when analyzing what goes into an effective
Materials and Methods section! Think about what is helpful and what the author has done well,
as well as what could be improved. Remember, you will be writing the M&M section for your
own paper soon!
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Results section homework handout
You will analyze the Results section from the old SF paper that you read last week. As you read
the Results section from that paper, please answer the questions below. Then fill out the final
question for your summer project.
What is the purpose of the Results section? What is the format of this section? Did the author
of your paper adhere to this format?

Name at least 3 things that should be included in the TEXT of the Results section.

Name at least 5 things that should be included in the FIGURES or FIGURE LEGENDS.
Distinguish between things that belong in the figure or in the figure legend.

What did the author do well in their Results section? What could they have done better?

Write out one or two subheadings that will be included in the Results section of your paper.
What kinds of figures will these subheadings describe?
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Abstract/Introduction/Discussion worksheet
Although the Abstract, Introduction and Discussion sections of a paper each have a different
purpose, they can give the reader similar pieces of information, so we will learn about these
three sections of the paper together.
Writing the Introduction:

Writing the Discussion:

Writing the Abstract:
It is often easiest to write the Abstract last, since it is a short summary of the entire paper.
However, you should be very thoughtful when writing your abstract as you have a lot of
information to convey to your reader in a short space. Readers will often use abstracts to judge
whether or not a paper is worthwhile, so your abstract should be convincing!
Where in the paper is the abstract placed? Is this important? What is the purpose of the
abstract?

How many sentences of the abstract should be devoted to each of the sections of your paper?
1. Introduction:
2. Materials and Methods:
3. Results:
4. Discussion:
5. Citations:
Write your abstract below. Remember to include all of the parts of the paper. If you want to
leave out the discussion/conclusion sentence for now, that is fine.
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Extras!
-your title should be specific and informative to give any potential readers an idea of what the
paper describes
-can be fairly long, are usually almost a complete sentence
-important to mention your specific topic (protein or gene of interest, model system,
general method used)
-the major conclusion can be included in the title
-if you choose to include an acknowledgements section, put it at the end of your paper, before
your citations
-generally these include people that helped with experimental design, brainstorming
ideas/conclusions, or paper editing, and funding sources
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Summer Project Chalk Talk worksheet
A chalk talk is a quick, informal way of presenting your research to an audience. Instead of using
a formal, lengthy Powerpoint presentation, you will instead give a much shorter presentation,
and you will use the white board to draw out concepts, models and/or important points. This
presentation will only be 3 minutes long! This presentation will include a brief introduction to
your project’s main question and hypothesis, followed by some brief results that you have
obtained, and then a summary of what these results mean and how they fit into the big picture.
You do not have to write everything you are going to say on the board. Fill out the following
outline to help you prepare for your chalk talk (and use the back of this page to practice
drawing the models or diagrams that you will show your audience!):
Introduction
-General topic of research with brief background (relevancy, short previous work):

-Main question:
-Hypothesis:

Results (can describe as many as wanted, probably little time for more than 3)
-Experiment 1:
-Methods:

-Results:

-Experiment 2:
-Methods:

-Results:

Summary
-Conclusion based on results:
-Big picture implications:
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Supplement 5: Presentation assessment rubric
Directions: Please use this rubric to rate these 7 parts of the students presentation (4 categories focused
on the parts of the presentation and the organization on the first two pages, 3 categories focused on the
presentation style on the third page). Indicate your numerical choice for each section on the
accompanying reporting sheet. You may use in-between numbers and you can write notes to clarify
decisions (or as you are listening) on the reporting sheet.
The students will not see or receive these reporting sheets, so please be honest and as critical as you
would be with any other scientific presentation.
Thank you for your help with this!!
Parts of the presentation categories (4):
Category
Backgroun
d section
(includes
title slide,
main Q and
hypo)

POOR (0 pts)
-Section (or key parts)
missing
-Main Q and
hypothesis not
presented or
nonsensical
-Excessive use of
clipart/unrelated
pictures

FAIR (1 pt)
-Section present but
has far too much or far
too little information
-Text presented as
paragraphs, no
citations
-Extra figures/clipart
are added when not
needed

Methods
section

-Section missing
-Experiments not
described or missing
key points
-Excessive text
-Too little explanation
-Student does not
understand
methods/cannot
explain properly

-Section present but
too many experiments
described/too much
detail included
-Too much text on
slides, mostly
paragraphs, no
citations
-No figures to clarify or
figures do not aid in
description
-Student present
minimal
understanding of
methods
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GOOD (2 pts)
-Section present with
close to the
appropriate amount of
material (1 extra or
too few slide)
-Clear main Q and
hypo
-Text presented as
bullet points or
complete sentences
Appropriate citations
included
-Most figures are of
value to the audience
-Section present with
close to the
appropriate amount of
material (every step
not described in
detail)
-Novel or complicated
experiments are
described, maybe with
figure
-Mostly bullet points
or complete phrases,
no paragraphs,
citations included
where needed
-Student
demonstrates solid
understanding of
methods used

EXCELLENT (3 pts)
-Section present with
appropriate amount of
information
-Main Q and
hypothesis are clear
-Slides have bullet
points with info, not
paragraphs
-Appropriate citations
included
-Relevant figures used
to illustrate key data
(from other articles or
constructed)
-Section present with
appropriate amount of
information
-Key experiments
explained
-Slides have bullet
points with info, not
paragraphs, citations
included
-Figures used to clarify
complex methods
-Student
demonstrates full
understanding of
methods used

Results
section

-Section missing
-Figures presented
without labels (axis,
samples, units)
-No accompanying
text with figures
-Significance not
indicated

Discussion
section
(includes
conclusions
and
acknowled
gements)

-Section (or key parts)
missing
-Results repeated, no
conclusions or analysis
-No future directions
-No
acknowledgements
-Student did not
understand the
purpose of their
research

-Section present with
some figures that are
mostly appropriate for
the data they are
displaying
-Too many/too few
figures
-Many labels are
missing
-Figures are
complicated or require
a lot of interpretation
-No flow/consistency
between figures
-Accompanying text
not sufficient or
significance missing
-Section present, but
missing one key part
(no conclusions or no
future directions or no
acknowledgements)
-Results repeated
without stated
conclusions
-No future directions
or no
acknowledgments
-Student
demonstrates minimal
understanding of the
broad purpose of their
research
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-Section present with
appropriate figures to
display data
-Figures are labeled
(may be missing 1 or
2)
-Figures are generally
easy to read and
interpret
-Figure style is mostly
consistent
-Accompanying text is
brief, but includes
significance

-Section present with
appropriate figures
chosen
-Figures used to
present data including
labels, titles, units and
keys
-Figures are easy to
read (size, coloring)
and style is consistent
through talk
-Accompanying text
highlights key findings
-Significance is
indicated

-Section present with
appropriate summary
of conclusions and
significance/interpreta
tion
-Results are needlessly
repeated
-At least one future
experiment described
-Lab/mentor are
acknowledged
-Student
demonstrates solid
understanding of their
research as whole

-Section present with
appropriate amount of
information
-A summary is given
with the main
conclusions and
significance
-Model presented for
clarity
-Future directions are
described
-Lab/mentor are
thanked
-Student
demonstrates
complete
understanding of their
research project

Presentation style categories (3):
Category
General
slide design

POOR (0 pts)
-Font size is too large
or small
-Font is hard to read
-Color scheme is
distracting or hard to
read, lots of distracting
animation
-Too many words and
little use of visual
cues/support on most
slides

FAIR (1 pt)
-Font size mostly okay
-Appropriate font
chosen
-Color scheme not
consistent or is
distracting at times,
animation occasionally
detracts from
presentation
-Extensive use of
words on most slides

GOOD (2 pts)
-Font size is
appropriate
-Font is easy to read
-Color scheme is easy
to read and consistent,
some animation
included in
presentation
-Predominantly
appropriate mix of
words and images on
most slides

Verbal
delivery

-Student did not plan
out what they wanted
to say
-Student was not able
to convey purpose of
presentation to
audience, may have
been confused about
the conclusions
-Many fillers used
-Thoughts left
unfinished
-Not loud enough for
audience to heard,
trails off while
speaking, minimal
enunciation
-Pitch, rate and
emphasis not varied

Nonverbal
delivery

-Back mostly to the
audience, or head
down to avoid
audience
-Reads from the board
and/or points to every
word
-Gestures are
distracting or
inappropriate

-Student had rough
outline for what they
wanted to say, used
notes whole time
-While presenting the
student was easily
distracted and prone
to tangents, hard to
follow along to
definite conclusion
-Fillers used often
-Some complete
thoughts, but some
trailing off speech
-Pitch, rate and
emphasis are
occasionally varied
-Correct pronunciation
used most of the time,
some enunciation
-Occasionally turns
back to the audience
while speaking
-Pointer not used or
used ineffectively
-Gestures are
distracting or
inappropriate

-Student planned out
what they wanted to
say, occasionally
glanced at notes
-Presentation rarely
strayed from topic,
audience understood
the conclusion
-Fillers used a few
times
-Most statements are
complete thoughts
-Voice is clear and
strong with good
enunciation and
pronunciation
-Audience is engaged
by some changes in
pitch, rate and
emphasis
-Faces the audience
for the majority of the
talk, some eye contact
-Pointer occasionally
used effectively
-Appropriate gestures
used
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EXCELLENT (3 pts)
-Font size is
appropriate
-Easy to read font
chosen
-Color scheme makes
presentation easy to
follow and is
consistent, animations
are used to emphasize
points
-Appropriate mix of
words and images on
every slide
-Student planned out
what they wanted to
say, notes were not
used
-Presentation was
focused and the
audience understood
the conclusion
-Minimal filler
-Statements delivered
as complete sentences
-Strong, loud, clear
speaking voice with
enunciation and
correct pronunciation
-Pitch, rate and
emphasis varied to
engage audience

-Faces the audience
and “interacts” via eye
contact
-Use of pointer to
emphasize material
-Appropriate gestures
while speaking

Supplement 6: Post-assessment questions
Name:
Please read each question and circle the answer that you feel is most accurate.
1) Could you name the parts of a scientific article before this summer?
Yes

No

2) Can you name the parts of a scientific paper now?
Yes

No

3) I was about to interpret basic scientific results at the beginning of the summer.
Strongly Disagree

Disagree

Neutral

Agree

Strongly Agree

Agree

Strongly agree

4) I feel comfortable interpreting basic scientific results now.
Strongly Disagree

Disagree

Neutral

5) I felt comfortable writing a scientific paper before Summer Focus.
Strongly Disagree

Disagree

Neutral

Agree

Strongly agree

6) I feel comfortable writing a scientific paper after completing Summer Focus.
Strongly Disagree

Disagree

Neutral

Agree

Strongly agree

7) I am more confident in my writing now that I have completed the Writing Course.
Strongly Disagree

Disagree

Neutral

Agree

Strongly agree

8) I am more confident in my oral presentation skills now that I have completed the Writing
Course.
Strongly Disagree

Disagree

Neutral

Agree

Strongly agree

Agree

Strongly agree

Agree

Strongly agree

9) I feel that I have developed critical thinking skills.
Strongly Disagree

Disagree

Neutral

10) I feel that I can review and critique a peer's work effectively.
Strongly Disagree

Disagree

Neutral
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APPENDIX TWO
CHARACTERIZATION OF A UPEC DEGS MUTANT IN VITRO AND IN VIVO

India C. Bradley1,2 and Elizabeth S. Danka3

1

Cardinal Ritter College Prep High School, 2 Young Scientist Program Summer Focus, 3

Division of Biology and Biomedical Sciences, Washington University in St. Louis

Modified from Bradley and Danka (2015) Journal for Emerging Investigators.

Abstract
The Escherichia coli DegS protein is an integral inner membrane protein that breaks
down incorrectly assembled proteins and helps to regulate the σE stress response pathway. When
degS is deleted, approximately 200-fold more outer membrane vesicles (OMVs) are produced.
As OMVs contain sections of the outer membrane and proteins from the periplasm, they may
play a role in the virulence of E. coli. To test whether degS or OMVs play a role in
uropathogenic E. coli virulence, we characterized a degS mutant. We found that degS mutation
did not affect the morphology of the bacterium, but did result in decreased virulence in vivo and
in vitro. When we tested our mutant in a murine model of cystitis, mice infected with degS::cat
bacteria had 100-fold decrease in bacterial titers in the bladder at 24 hours post-infection. In vitro
binding and invasion assays showed no difference in ability to bind to host cells, but a significant
decrease in the ability of mutant bacteria to invade into cells. Together, these data suggest that
degS::cat decreases the virulence of E. coli, and increased OMV production may be a detriment
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to virulence. Future studies can separate the role of degS and OMV production in UPEC
virulence.

Introduction
The bacterium Escherichia coli is widely distributed and occupies many niches, including
the intestines of humans and other animals. It is a rod-shaped, Gram-negative, and facultative
anaerobic bacterium. While most strains are harmless, some are capable of causing disease in
humans. One such species is uropathogenic E. coli (UPEC), the causative agent of over 85% of
urinary tract infections (UTIs) [1]. UTIs can affect the bladder, termed cystitis, or can spread to
cause a kidney infection, termed pyelonephritis. Some infections will affect both the bladder and
the kidneys. Over 50% of women will develop at least one UTI in their lifetime, and many of
these women will have recurrent infections that affect their quality of life [1]. While there are
likely many host factors that contribute to the occurrence of UTI, UPEC are characterized by the
expression of specific virulence factors such as type 1 pili, flagella, hemolysin and siderophores
[2, 3]. These virulence factors aid the bacteria in binding to the host bladder epithelial cells.
Bound bacteria can be internalized where they are protected from antibiotics and the immune
system [3]. Virulence factors help the bacteria acquire necessary nutrients and grow to high titers
within the cells. Some of these intracellular bacteria will remain hidden for up to 6 months
before emerging from the cells and causing a recurrent infection [3]. In addition to the
intracellular bacteria, bacteria are also able to persist in the lumen of the bladder, and can ascend
up the ureters to cause kidney infection. The discovery of additional UPEC virulence factors
could lead to strategies for prevention of UTIs in humans and the development of more effective
drugs for treatment of E. coli infections.
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degS of E. coli encodes a 355 residue protein that is a homolog of the DegP protease [4].
The DegS protein is an integral inner membrane protein with an active site in the periplasm [5].
This protein is able to detect and break down misfolded proteins in the periplasm so that they can
be cleared from the cell [5]. Additionally, DegS provides proteolytic cleavage of the RseA antisigma factor when misfolded proteins are detected to regulate σE activity in E. coli cells [5].
Activity of the σE pathway is essential under conditions of envelope stress as well as in nonstress conditions in order to maintain homeostasis within cells [6]. When degS is mutated in
bacteria, thousands of outer membrane vesicles (OMVs) are produced in what is likely a
response to the stress of accumulated misfolded proteins [7]. Previous work from the Kuehn lab,
as well as unpublished work from our lab, has shown that approximately 200-fold more OMVs
are produced in a degS::cat mutant strain [7].
OMVs are nano-sized (~10-300 nm in diameter), spherical, bilayered proteolipids that are
produced when small portions of the bacterial outer membrane bulge away from the cell, break
off, and release [8]. OMVs can present virulence factors to host cells, but it remains uncertain
whether OMVs are liberated by membrane instability or through a more directed process. The
production of OMVs has been described as a bacterial stress response, but experimental evidence
suggests that OMVs play a role in pathogenesis and are associated with virulence factors and
toxins [9, 10]. OMVs bear components that are thought to impact the course of infection and are
likely to play a significant role in the virulence of Gram-negative bacterial pathogens [9, 10].
To investigate the role that degS and OMVs have on the virulence of UPEC, we
characterized a degS::cat UPEC strain. We aimed to determine if degS mutation affects the
virulence of UPEC. We hypothesized that degS::cat would be more virulent due to the increased
production of OMVs, which can play an important role during infection. If degS::cat was more
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virulent, it would suggest that OMVs do increase virulence, but that degS is not essential for
UPEC virulence. Conversely, if the wild-type strain was more virulent, this could mean that an
increase in OMV production is detrimental to virulence, or that degS is essential for virulence in
UPEC. We used a variety of in vitro and in vivo assays to compare our strains and to test the
virulence of our mutant. Our results indicated that the mutation of degS slightly impairs growth
of the bacteria, but does not change the morphology or protein expression in the membranes.
Furthermore, degS::cat was less virulent than wild-type UPEC both in vitro and in vivo,
demonstrating that mutation of degS, accompanied by an increase in OMVs, decreases the
virulence of UPEC.

Materials and Methods
Bacterial Strains
The model uropathogenic E. coli strain UTI89 was used as the wild-type strain for all studies.
This strain was originally isolated from the urine of a patient with cystitis [11]. A degS::cat
mutant (UTI89 degS::cat) was previously made by replacing the degS with a chloramphenicol
resistance cassette using lambda red mutagenesis [12]. Strains were grown in fresh LB without
antibiotics, unless otherwise indicated.

Molecular Biology
A degS complementation plasmid was created by amplifying degS from UTI89 genomic DNA (F
primer: 5’-CCATCATGTTTGTGAAGCTCTTACGTTCCGTTGCGATTGG-3’, R primer: 5’TTAGTTGGTCGCCGGATATTCCTGAATGGTGACCTGC-3’).The product and the plasmid
vector PTRC99A were digested with XbaI and HindIII and then ligated together. The resulting
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plasmid was transformed into TOP10 cells. Colony PCR identified colonies that contained the
plasmid with the insert, and these colonies were sent for sequencing. Once the sequence was
confirmed to be correct, the plasmid was electroporated into UTI89 degS::cat cells. The
complemented mutant strain is termed UTI89/pTRC99a-degS degS::cat, and is referred to as
pdegS in this document.

Growth in Rich Media
UTI89, UTI89 degS::cat and UTI89 degS::cat/pdegS were cultured in a shaker overnight at 37°C
in 3 mL LB broth (with 100 µg/mL Amp for pdegS). The next morning, cells were sub-cultured
1:100 into fresh LB media with or without antibiotics as appropriate and grown ~2 h until the
OD600 = 1 (approximately 2 x 109 CFU/ml). The cells were diluted to 2 x 105 cells/mL.
Approximately 2000 cells were added to 200 µL of LB per well. Strains were plated in triplicate
wells in LB media with or without Amp as appropriate. Cells were grown at 37°C and the optical
density was recorded every 40 min for 12 h in a temperature controlled microplate reader
(Synergy 2, Biotek). Triplicate wells of LB and LB-Amp served as blanks and controlled for
contamination. The experiment was repeated three times.

Transmission Electron Microscopy (TEM)
UTI89 and UTI89 degS::cat cells were grown in LB overnight; replicates for each strain were
grown under shaking or static conditions. The cultures were centrifuged at 5000 x g for 2 min
and the pellets were resuspended in fresh PBS. Samples were then fixed and negative-stained
with uranyl acetate before analysis on a JEOL 1200EX transmission electron microscope (JEOL
USA, Peabody, MA) [13].
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Membrane Isolation
Overnight cultures of mutant and wild-type strains were sub-cultured and grown in LB until they
reached an OD600 = 0.8. Cells were pelleted and the pellets were stored at -20°C. The pellets
were resuspended in 10mM Tris pH 8.0 with 100mM RNase and DNase. Cells were lysed in the
Stansted Pressure Cell Homogenizer (model SPCH-10, United Kingdom). Whole cells were
removed by centrifugation at 3000 x g for 15 min at 4˚C. The cytosolic and membrane proteins
were resuspended in 50 mm Tris. Membranes and cytosol were separated by centrifugation at
82,500 x g for 80 min at 4˚C. The supernatant containing the cytosolic and periplasmic contents
was removed and saved and the pellet containing the membranes was resuspended in 50mM Tris
and centrifuged at 82,500 x g for 80 min at 4˚C. The supernatant containing the inner membrane
fraction was removed and saved, while the pellet containing the outer membrane fraction was
resuspended in 10mM Tris. All samples were stored at -20°C for use in downstream
applications.

Protein Expression Analysis
SDS-PAGE analysis was used to compare the proteins in whole bacteria, inner membrane, outer
membrane and cytosol from the wild-type and mutant strains. Approximately equivalent amounts
of protein from each sample were separated on a 12% SDS-PAGE gel. Gels containing whole
cell lysate, outer membrane, and cytosolic fractions were Coomassie-stained for 30 min and then
destained with 6:3:1 water: methanol: acetic acid until bands could clearly be seen. To visualize
the inner membrane proteins of the wild-type and mutant strain, a Pierce Silver Stain Kit was
used according to manufacturer’s instructions (Thermo Scientific).
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Bacterial Outer Membrane Vesicle Isolation and Protein Expression Analysis
Wild-type, degS::cat, and pdegS strains were grown in 100mL LB overnight, before
centrifugation for 10 min at 5000 x g at 4°C. Supernatant was filter sterilized with 0.2 µm filter
and ultracentrifuged for 2 hours at 40,000 RPM (100,000 x g). The pellet was resuspended in
200ul of Dulbecco’s phosphate buffered saline (Gibco) with 0.2M NaCl. A BCA protein assay
was performed according to manufacturer’s instructions (Pierce). The samples were separated by
SDS-PAGE and silver-stained to compare the proteins in the OMVs.

Antibiotic Susceptibility
UTI89 and UTI89 degS::cat were cultured in a shaker overnight at 37°C in 5 mL LB broth.
Strains were sub-cultured the next morning and grown to an OD600 = 1. The cells were diluted
1:10 in sterile PBS. The cultures were then spread evenly across the entire plate with a sterile
swab. Using sterile tweezers, three antibiotic-impregnated disks were placed onto each agar
surface. A single strain and antibiotic combination was used per plate. The antibiotics for each
disk were as follows: ampicillin (10 µg/disc), chloramphenicol (30 µg/disc), kanamycin (30
µg/disc), novobiocin (30 µg/disc), spectinomycin (100 µg/disc), and tetracycline (30 µg/disc).
The plates were incubated overnight at 37°C, and the zone of inhibition around the disk was
measured. The experiment was repeated three times.

Mouse Infections
C57BL/6 (Jackson Laboratories, Bar Harbor, Maine) mice were used for infections; all mice
were female and aged matched at 8-10 weeks. UTI89 and UTI89 degS::cat were grown in 20mL
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LB overnight under static conditions. Catheters were made with 30 gauge needles and 0.28mm
polyethylene tubing and sterilized with UV light in tissue culture hood overnight. Overnight
cultures were spun down at 2000 x g for 10 min, resuspended in sterile PBS to OD600 = 1.
Resuspended bacteria were diluted 1:1 with PBS for the inoculum. Under isoflurane anesthesia,
mice were infected transurethrally with 50 µL of bacteria (~1 x 107 bacteria/mouse). Bladders
were harvested 24 hours post-infection (hpi) using sterile technique, homogenized in sterile
phosphate-buffered saline (PBS) and plated on LB agar in order to enumerate colony forming
units (CFU)/bladder. The experiment was performed three times with three mice/bacterial
strain/group.

Confocal Microscopy
Mice were infected with 50µl of UTI89/pcomGFP or UTI89 degS::cat/pcomGFP (2
mice/bacterial strain) as described above. Mice were sacrificed 16 hpi and bladders were
harvested, bisected, and stretched. Bladders were fixed in 2.5% paraformaldehyde in PBS,
permeabilized with 0.1% Triton X-100 in PBS and stained with Syto 61 nucleic acid stain
(1:1000 in PBS, Life Technologies). Stained bladders were washed 3 times with PBS, mounted
on slides with ProLong Gold antifade reagent (Invitrogen) and imaged on a Zeiss LSM510
inverted confocal microscope.

Human Bladder Epithelial Cell Culture
5637 cells (ATCC HTB-9) were maintained in RPMI 1640 medium (Gibco) supplemented with
10% fetal bovine serum (FBS, Sigma). Cells were grown at 37°C in a humidified atmosphere
with 5% CO2.
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In vitro Binding and Invasion Assays
Binding and invasion assays were performed as described previously, with modifications [14].
Four strains were compared: UTI89, degS::cat, pdegS and UTI89 fimH

-

(negative control).

Overnight static cultures of each strain were centrifuged and resuspended in sterile PBS to OD 600
= 1. Binding, input, and invasion wells with confluent 5637 cells were prepared in triplicate for
each strain in 24-well tissue culture plates (TPP). Old medium was aspirated and 1 mL of fresh
medium was added to each well. The desired bacterial suspension (10 µL) was added to each
well. Plates were spun at 325 x g for 3 min at room temperature and returned to the incubator.
Binding and input wells were removed after 30 min. Supernatants were aspirated from the
binding wells and cells were washed five times with 1X PBS before lysis in 0.1% Triton X-100
(in PBS) at room temperature for 15 min. Input wells were not washed before cells were lysed
with 10uL of 10% Triton X-100. Each well was scraped and examined under the microscope to
ensure that all cells released. Lysed cells and bacteria were serially diluted and plated on LB agar
plates to enumerate CFU. The invasion plates were removed from the incubator after 60 min and
wells were washed once with 1X PBS. Gentamicin (10 mg/mL in media) was added to each well
and the plate was returned to the incubator for 90 min. After gentamicin treatment, wells were
washed three times with 1X PBS before lysis in PBS with 0.1% Triton X-100. Lysed cells and
bacteria were scraped, serially diluted, and plated. The LB agar plates were incubated overnight
at 37°C and colonies were enumerated the following day.

Statistical analysis
Significance was determined by a Student’s t test, with values less than 0.05 considered
220

significant. For the mouse infections, significance was determined by the Mann-Whitney U
statistical analysis as performed by GraphPad Prism 5 software.

Results
Wild-type, degS::cat and pdegS strains do not have significantly different growth in LB.
Growth curves of UTI89, UTI89 degS::cat and UTI89 pdegS were developed to compare
the effects that degS mutation has on bacterial growth. Cells were cultured in LB, and the optical
density was measured every 40 min for 12 h to create growth curves (Figure 1). Strains had
similar growth at all time points. Overall, the mutant cultures were less dense than the wild-type
or complemented strains at most time points; this difference was not significant.

degS::cat does not have altered morphology under aerated or nonaerated conditions.
Transmission electron microscopy was used to examine the effects that shaking and static
growth conditions have on the size, shape, and pili of bacterial cells from the wild-type strain or
degS::cat. Shaken cultures of either strain produced bacterial cells that were coccoid with few
pili (Figure 2B, D). Conversely, cells from static cultures were rod-shaped with lots of pili
(Figure 2A, C). The wild-type and mutant strains had similar morphological characteristics in
both the static and shaken cultures, indicating that degS::cat does not alter morphology under
either condition.

Protein composition of membranes and cytosol is similar between strains.
SDS-PAGE gels were used to compare the protein content of whole cell lysates of wildtype and mutant cells to see if degS mutation affects the expression of other proteins. There were
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no observable differences in the protein composition of whole cell lysates from wild-type or
mutant cells when stained with Coomassie blue (Figure 3A). Cellular fractionation and SDSPAGE gels were used to more closely examine the composition of the inner membrane, outer
membrane and cytosol of the two strains. We did not see any differences in the proteins in the
outer membranes of our two strains (Figure 3B). Surprisingly, we found that degS::cat was
missing a high molecular weight protein band that appeared in the cytosol from wild-type
bacteria; however, we were not able to identify this protein (arrow, approximately 200 kDa,
Figure 3B). Finally, silver stained SDS-PAGE gel was used to analyze the protein expression in
the inner membrane (Figure 3C). We did not note any major differences in the protein content of
the inner membrane between the two strains.

degS::cat results in increased production of outer membrane vesicles.
In order to confirm that degS::cat produces more outer membrane vesicles (OMVs) than
the wild-type strain, OMVs were isolated from overnight cultures of the wild-type, degS::cat,
and pdegS strains. Visual inspection of the pellets of the OMVs recovered after
ultracentrifugation revealed a much larger pellet in the degS::cat compared to either the wildtype or complemented strain (Figure 4A). This was confirmed by resuspending the pellets in
equal volumes and determining the protein content in each (UTI89 = 31 µg/mL, UTI89 degS::cat
= 910 µg/mL, pdegS = 51 µg/mL). TEM confirmed that these pellets contained mostly intact
OMVs, with minimal amounts of cellular debris (data not shown). A silver-stained SDS-PAGE
gel was used to analyze variations in OMV protein content in each strain. We found that OMVs
isolated from degS::cat contained many different proteins than OMVs from the wild-type or
complementated strains, and that some of the proteins that were common between strains varied
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in amount (see asterisks for examples, Figure 4B).

degS::cat does not alter antibiotic susceptibility.
An antibiotic disk diffusion assay was used to compare the antibiotic susceptibility of the
wild-type strain and the degS::cat. This method was used as a simple way to assess changes in
essential pathways (DNA replication, protein synthesis, cell wall synthesis, etc.). The assay
showed no significant differences in susceptibility to ampicillin, kanamycin, novobiocin,
spectinomycin, or tetracycline (p = 0.10, 0.09, 1.0, 0.07 and 0.34, respectively; Figure 5). We
therefore conclude that degS::cat and increased OMV production does not alter antibiotic
resistance, and that most essential pathways are intact. There was a significant difference in
susceptibility to chloramphenicol (p < 0.000001, Figure 5). As a resistance cassette for this
antibiotic was used to replace the degS in the mutant, chloramphenicol functioned as our positive
control for the assay.

degS::cat bacteria cause less severe infections in a murine cystitis model.
Female C57BL/6 mice were infected using a well-established murine model of cystitis in
order to compare the virulence of wild-type and mutant strains. Mice inoculated with degS::cat
had approximately 100-fold fewer bacteria in the bladder than mice inoculated with UTI89 by 24
hpi (p < 0.0001, Figure 6).

degS mutation does not alter intracellular growth in vivo.
Fluorescent confocal microscopy was used to examine the growth of wild-type and
mutant strains within murine bladder epithelial cells to investigate a potential cause for the
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differences in bladder titers 16 hpi. Although the importance of intracellular bacterial growth was
originally defined in a mouse model of UTI, intracellular growth and formation of intracellular
bacterial communities (IBCs) have been described in human patients with active cystitis [15].
The bladders of C57BL/6 mice were inoculated with UTI89/pcomGFP or degS::cat/pcomGFP.
Bladders were harvested 16 hpi and stained for microscopy. We found both early stage and
mature IBCs, indicating that the strains were equally capable of growth within bladder cells
(Figure 7). It should be noted that IBCs were more difficult to identify in mice infected with the
mutant strain, as all bacteria seemed to have lost the GFP-expressing plasmid for an unknown
reason.

degS::cat has decreased ability to invade host cells.
Binding and invasion assays were conducted in order to compare how well the wild-type,
degS::cat and pdegS strains bound and invaded 5637 human bladder epithelial cells in vitro. We
found that degS::cat bound to 5637 cells as well as the wild-type (p = 0.47, Figure 8A).
However, the degS::cat strain invaded into cells significantly less than the wild-type strain (p =
0.01, Figure 8B). We found that only 0.1% of the degS::cat bacteria that bound to cells actually
invaded, as compared to 0.59% of wild-type bacteria (Figure 8C). pdegS was able to bind and
invade as well as the wild-type strain (p = 0.83 and 0.58, respectively, Figure 8A, B). degS::cat
bound similarly to the complemented strain (p = 0.28, Figure 8A), but invaded significantly less
(p = 0.001, Figure 8B). A strain that is unable to produce pili (UTI89 fimH -) functioned as a
binding mutant and our negative control. As expected, UTI89 fimH - was unable to bind to host
cells, and, as a result, invaded significantly less than the wild-type strain (p = 0.04, 0.02,
respectively; Figure 8A, B).
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Discussion
To investigate the role that degS and OMVs have on the virulence of UPEC, we
characterized a degS mutant strain. This mutant has the degS gene replaced with a
chloramphenicol antibiotic resistance cassette. We predicted that degS::cat would be more
virulent because of the increased production of OMVs. OMVs have previously been shown to
contain outer membrane proteins, toxins and other factors that can be delivered to host cells,
which may in turn enhance infection [9, 10]. However, our results demonstrated that degS may
instead be necessary for virulence and that increased numbers of OMVs did not promote
infection.
Our experiments with degS::cat demonstrated that while degS mutation does not alter the
morphology of the bacteria under static or shaking growth conditions, the mutant has slightly
impaired growth in rich media in early log phase. This difference is no longer significant by midlog phase, although the mutant does grow at a slightly decreased density. Complementation of
the mutant restores the wild-type growth phenotype. These data may indicate that increased
OMV production early in growth modifies nutrient allocation and limits the speed at which
bacteria can replicate. Similarly, DegS function may be most important in early log phase, when
proteases can easily be overwhelmed by misfolded proteins that accumulate as the bacteria
rapidly synthesize proteins necessary for growth. In contrast to this idea, comparison of isolated
membranes did not reveal major changes in protein content. However, in the cytosol, a high
molecular weight protein was missing in the degS::cat which could be related to a change in
virulence.
We were able to confirm that degS mutation results in increased OMV production, and
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were able to restore wild-type production of OMVs by complementing the mutant with the wildtype gene. Interestingly, in addition to increased numbers of OMVs, the mutant also had changes
in the proteins contained within those OMVs. In line with the previous suggestion, these likely
represent misfolded proteins that have accumulated in the periplasm due to the lack of functional
DegS. This could be confirmed by isolating and comparing the periplasm of our three strains.
Interestingly, the variability in the protein content of the OMVs and the whole cells demonstrates
the efficiency for packing misfolded proteins specifically into OMVs to clear them from the
cells. However, it is possible that one or more of those proteins could be negatively affecting the
virulence of the mutant in vitro and/or in vivo. The degS::cat and wild-type strains also had
similar antibiotic susceptibility, indicating that the basic processes through which these
antibiotics function are not affected by increased OMV production or the presence of extra
misfolded proteins present in the outer membrane and periplasm due to the decreased DegS
activity.
In vitro binding and invasion assays and mouse infections showed that degS::cat is less
virulent than wild-type. The binding and invasion assays demonstrated that degS::cat cells were
able to bind to host cells just as well as the wild-type strain, indicating that degS::cat does not
alter pili production or function. This confirmed our TEM result showing no obvious change in
the number of pili produced by the mutant under static conditions. Surprisingly, degS::cat was
not able to invade into the cells. A complemented mutant strain was able to bind and invade as
well as the wild-type strain. However, the degS::cat strain bound and invaded significantly less
than its complement. This confirms that the deletion of degS specifically leads to decreased
ability to invade. These results may mean that degS is important for the invasion mechanism in
this model, or that increased production of OMVs is detrimental to mutant cells. Past research
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has shown that UPEC invade host cells via an HDAC6 modulated microtubule dependent
pathway; because degS::cat was not able to invade host cells this may mean that excess numbers
of OMVs can disrupt this pathway [16]. Alternatively, degS mutants may have limited ability to
produce important virulence factors due to energy wasted on misfolded proteins and OMV
production.
In a mouse model of cystitis, we found that mice infected with degS::cat had 100-fold
fewer bacteria in their bladders at 24 hpi. Consistent with our results, past research has also
shown that degS is necessary for virulence in a murine model of peritonitis, and that σE regulation
is essential for UTI [17, 18]. We did not find any differences in intracellular growth of the
bacteria when we assessed the bladders for IBC formation. However, IBCs seemed to occur less
frequently in mice infected with degS::cat (observation by the authors). Future experiments
could quantify IBC formation in mice infected with the wild-type and mutant strains to
determine if there is an invasion defect in vivo as well. Additional experiments could also
confirm that the complemented strain is able to rescue the infection defects.
The function of the DegS protein is relatively well understood. Previous studies have
indicated that DegS functions as a protease in vivo, contributes to the regulation of σE activity,
and clears incorrectly assembled proteins out of the periplasm of the cell [4-6]. When degS is not
present, OMV production increases, likely as a result of stress on the cell envelope [7]. In our
strain, OMV production may be using more of the available energy which could explain why
degS::cat grew a little bit slower than wild-type. Although OMVs have been shown to positively
impact infection, our results showed that knocking out degS decreased virulence [9, 10]. This
suggests that increased OMV production in UPEC could be stressing the cell instead of aiding in
infection. Alternatively, the extra vesicles present in mice infected with degS::cat could increase
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the activation of the host immune system, resulting in faster clearance of the mutant bacteria.
Finally, our experiments do not conclusively determine whether the altered virulence is a due to
greater numbers of OMVs, or to a different factor specific to the degS mutant. Further research
can be done to focus solely on the effects of OMVs in UPEC virulence. Specifically, wild-type
UPEC can be tested in vitro and in vivo with exogenous OMVs to determine whether OMVs
alter virulence.
By investigating bacterial virulence factors and important bacterial genes, we can better
understand how bacteria function. This can allow chemists to create drugs that are more effective
against specific bacteria, and help doctors determine how best to treat infections. E. coli persists
throughout our bodies and our environment, so an in-depth understanding of UPEC virulence
could aid in reducing UTI occurrence and recurrence, as well as associated healthcare costs.
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Tables and Figures

Figure 1: Growth of UTI89, degS::cat, and pdegS in LB. The OD600 was measured every 40
min during growth at 37ºC. UTI89 is shown in blue, degS::cat is shown in red and pdegs is
shown in green. LB and LB-Amp (used as blanks) are shown in purple and orange, respectively.
Error bars represent standard deviation.
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Figure 2: TEM images of UTI89 and degS::cat. Representative images from UTI89 and
degS::cat cells under shaken and static growth conditions. The scale bar represents 500 nm.
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Figure 3: Protein expression of whole cells and cellular fractions. (A) Coomassie stain was
used to show the protein expression in whole cell lysates from both strains. (B) Coomassie stain
was used to show protein content in the outer membrane and cytosol of both strains. Arrow
indicates a missing high molecular weight protein in the cytosol of degS::cat. (C) Silver stain
was used to show protein content of the inner membrane of the two strains. Marker indicates the
approximate protein size in kDa.
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Figure 4: Protein expression in isolated OMVs. (A) Pellets of OMVs after ultra-centrifugation
of sterile O/N supernatants. Pellets are circled in red. (B) A silver-stained protein gel revealed
difference in protein composition of OMVs. Examples are denoted with asterisks (*). Marker
indicates the estimated protein size in kDa.
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Figure 5: Antibiotic susceptibility. The antibiotic susceptibility of the wild-type and mutant
strains was determined by disc diffusion assay. The average zone of inhibition was graphed;
error bars show the standard deviation.
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Figure 6: Bladder bacterial titers from infected mice. Colony-forming units (CFU) recovered
from mouse bladders 24 hpi. Horizontal lines indicate the geometric mean.

234

Figure 7: Confocal microscopy images of IBCs. Bladders of mice infected with
UTI89/pcomGFP or UTI89 degS::cat were harvested at 16 hpi. IBCs in the bladders were
visualized at 63X. Nucleic acids are stained red. IBCs are indicated with an arrow.
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Figure 8: Binding and invasion into 5637 human bladder epithelial cells. (A) The average
percent of UTI89, degS::cat, pdegS or UTI89 fimH - (negative control for binding) that was able
to bind to host cells. (B) The average percent of each strain that was able to invade into the host
cells. (C) The average percent of bound bacteria that invaded into host cells. Error bars are used
to show the standard deviation; * p < 0.05, relative to UTI89.
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